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Cardiac implantable electronic devices (CIED) are an essential part of the management of 
patients with life-threatening arrhythmias. While many patient-related factors have been 
previously shown to play a role in the choice of CIED type offered to patients as well as 
outcomes of CIED implantation procedures, many patient characteristics remain 
understudied. Furthermore, little is known about the rates and causes of short-term 
readmissions after CIED implantation. 
The present thesis provides answers to some of the gaps in evidence around the relationship 
between several patient-related factors and the management as well as outcomes of CIED 
implantation as a de novo procedure. 
The first phase, presented in Chapter 4, examined patient characteristics that predict the 
choice of cardiac resynchronisation therapy (CRT) device offered to patients with severe 
left-sided heart failure. Factors such as patient sex, history of ventricular arrhythmias, 
active malignancy and renal failure were among the strongest predictors of the type of CRT 
offered to patients.  
The second phase, which is discussed in Chapters 5 to 8 of this thesis, focused on the impact 
of several patient-related factors on in-hospital outcomes after CIED implantation, 
including mortality and procedure-related complications (thoracic, cardiac and bleeding). 
Females were associated with worse in-hospital outcomes, despite adjustment for multiple 
confounders, as were patients with active cancer and intermediate to high-risk frailty. While 
the overall burden of comorbidity correlated with increased odds of in-hospital mortality 
and acute stroke, it did not confer worse procedure-related outcomes. 
The third and final phase, in Chapter 9 of the thesis, looked at the rates and causes of 30-
day readmissions after CIED implantation and showed that these were common (1 in 7 
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patients), with a significant proportion being due to cardiac and device-related causes. In 
the relevant chapter, I report several important patient characteristics that are predictive of 
30-day cardiac readmission. 
In my discussion, I reflect on the clinical implications of my findings including the need 
for risk scoring systems that incorporate the patient-related factors studies in this thesis as 
well as risk reduction technical strategies to address the inherent risk of procedural 
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Chapter 1. Introduction  
1. Overview 
My thesis focused on investigating patient-related factors influencing the choice of 
management and in-hospital outcomes of de novo cardiac implantable electronic device 
(CIED) procedures in adults (≥18 years). Overall, there were three main phases for this 
thesis (illustrated in Figure 1). The first phase focused on patient-related factors predicting 
the choice of cardiac resynchronisation therapy (CRT) device type, including CRT with 
pacemaker (CRT-P) and CRT with defibrillator (CRT-D). The second phase looked at 
patient characteristics influencing in-hospital outcomes of CIED implantation. The third 
and final phase focused on patient-related factors predicting 30-day cardiac readmission. 
Figure 1. Phases of the PhD thesis 
 
2. Objectives 
The main objectives of the present thesis were to study the following: 
• The influence of patient related factors on the choice of CRT device type amongst 
those who are eligible for such device.  
• The influence of patient-related factors, including sex and comorbidities such as 
cancer and frailty as well as overall comorbidity burden, on post-procedural 
outcomes of de novo CIED implantation. 
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• Causes of 30-day readmissions after CIED implantation and patient characteristics 
associated with 30-day readmission for cardiac and device-related causes.  
3. Thesis Chapters Layout 
a) Chapter 2 
This chapter reviews gives an overview of technical aspects of the CIED procedure as well 
as common indications. This is followed by a review of the existing evidence on patient-
related factors influencing procedural outcomes of CIED implantation as well as the gaps 
in current literature that form the basis of this thesis.  
 
b) Chapter 3 
In this chapter I provide a description of the two datasets from which the work in this PhD 
was performed: The United States National Inpatient Sample (NIS) and the Nationwide 
Readmissions Database (NRD). A comprehensive overview of data curation, including 
cohort extraction and restructure, identification of procedures and diagnoses, and handling 
of missing data. Furthermore, I discuss the statistical methodology used in my studies.  
 
c) Chapter 4 
The chapter focuses on the first objective of the thesis, the association between patient-
related factors and choice of CRT device (CRT-P vs. CRT-D) was examined. Furthermore, 
I focused on sex differences in receipt of device type and the trends of these differences 
between 2004 and 2014.  
 
d) Chapter 5 
This chapter addresses the second objective of my thesis. I discuss my study of the 
influence of sex on in-hospital outcomes of de novo CIED implantation, stratified by type 
of CIED (permanent pacemaker (PPM), CRT-P, CRT-D and implantable cardioverter 
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defibrillator (ICD)), and explore the trends of these differences over an 11-year period 
(2004 to 2014).  
 
e) Chapter 6 
This chapter also relates to the second objective of my thesis and focuses on outcomes of 
de novo CIED implantation in patients with historical and current cancer. Procedural 
outcomes were compared according to type of prevalent cancer as well as type of CIED 
device (PPM, CRT and ICD).    
 
f) Chapter 7 
This chapter relates to the second objective of my thesis. I discuss the impact of frailty risk 
(low, intermediate and high) on procedural outcomes of de novo CIED implantation using 
the Hospital Frailty Risk Score. Comparisons were made between different device types 
(PPM, CRT-P, CRT-D and ICD) for a range of in-hospital outcomes.  
 
g) Chapter 8 
This is the final chapter of my second objective of the thesis, in which I discuss the effect 
of overall comorbidity burden, objectively measured using the Charlson Comorbidity 
Index, on procedures outcomes of de novo CIED implantation. Outcomes were examined 
in the overall CIED cohort and according to CIED subtype (PPM, CRT-P, CRT-D and 
ICD). 
 
h) Chapter 9 
This is the first of two chapters looking at causes of 30-day readmissions after CIED 
implantation from the NRD database. This chapter looked at overall, cardiac and device-
related causes of 30-day readmissions, stratified by type of CIED device (PPM, CRT-P, 
CRT-D, ICD), as well as patient-related factors predictive of 30-day cardiac and device-
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related readmissions. Furthermore, I study differences in 30-day readmission rates and 
causes between sexes. 
 
i) Chapter 10 
The final chapter draws on the main conclusions of studies undertaken during my thesis, 
providing insight into their clinical implications as well as future research directions that 
would further our understanding of the impact of patient-related factors on outcomes of de 






Chapter 2. Background 
In this chapter, I provide an overview of the cardiac conduction system, cardiac rhythm 
disorders and heart failure, all of which are indications for cardiac implantable electronic 
device (CIED) implantation. Furthermore, I summarise the current evidence on CIED 
implantation outcomes and the gaps in current evidence that form the basis of my thesis.  
1. Cardiac rhythm disorders 
a) Overview of the cardiac conduction system 
It is essential to gain a conceptual understanding of the heart conduction system in order to 
identify the aetiology of different conduction disorders and abnormal heart rhythms 
(arrhythmias), which are common indications of cardiac implantable electronic device 
(CIED) implantation. An illustration of the conduction system is provided in Figure 1. The 
cardiac conduction sequence starts in the sinoatrial (SA) node, commonly known as the 
anatomical pacemaker, which releases an electrical stimulus that travels rapidly 
(conduction velocity: 0.5 m/sec) through both atria, resulting in their contraction, before 
passing through the atrioventricular (AV) node where the impulse is conducted at a much 
slower rate (0.05 m/sec). The slower rate of conduction through the AV node acts as a 
protective mechanism in the case of abnormally rapid heart rhythms (tachyarrhythmias). 
After the impulse passes through the AV node, it travels rapidly (2 m/sec) through the 
Bundle of His in to the left and right bundle branches, before reaching the network of 
Purkinjie fibres, which have the fastest conduction velocity (4 m/sec), all of which lead to 






Figure 1. Illustration of the heart conduction system 
 
SA: sinoatrial; AV: atrioventricular 
b) Types and prevalence of cardiac rhythm disorders 
Conduction disorders could arise from any of the previously described conduction 
pathways (SA node, AV node, Bundle of His, and left and right bundle branches). 
Collectively, these cause slow heart rhythms (bradyarrhythmia), although certain 
exceptions are highlighted below. In a study of more than 500,000 individuals the 
prevalence of bradyarrhythmia was reported to be 0.89 per 1000 person-years (95% CI 
0.86–0.92).1 Bradyarrhythmias are classified as follows:  
i. Sinus node dysfunction (SND) 
SND is increasingly common with advanced age due to gradual decrease in the number of 
pacemaker cells and, in turn, activity of the SA node. Several subtypes of SND exists 
including 1) inappropriate sinus bradycardia, 2) alternating sinus bradycardia and 
tachyarrhythmia (sick sinus syndrome (SSS)), 3) sinus pause or block, and 4) sinoatrial exit 
block. Although there is limited data on the prevalence of cardiac rhythm disorders, SSS is 
thought to occur in 1 in 600 cardiac patients ages above 65 years old. 2  
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ii. Atrioventricular (AV) blocks 
Progressive fibrosis of the cardiac conduction system occurs with ageing, leading to various 
types of acquired AV blocks. The three main types of AV block (Figure 2) include: 
• First degree AV block: progressive delay in atrial conduction resulting in a prolonged 
PR interval (>200 msec). The prevalence of first degree AV block is estimated to be 
found in 3-4% of healthy individuals.3 
• Second degree AV block 
-Mobitz I: progressive prolongation of the PR interval until one atrial impulse is 
eventually not conducted to the ventricle (no QRS complex). Prevalence is estimated 
to be 2.2%.4 
-Mobitz II: intermittently dropped QRS complexes, which means that an atrial 
complex was not conducted to the ventricle. There is limited data on the prevalence of 
Mobitz II AV block. This type of conduction disorder is likely to progress to asystole 
(complete heart pause/stop). 
-Third degree AV block: complete dissociation in electrical communication between 
atria and ventricles. The prevalence of third-degree AV block is estimated to be 
approximately 0.04%.5 Third degree AV block is highly likely to progress to asystole. 
Of the previously discussed conduction disorders, sick sinus syndrome and Mobitz II 
and third-degree AV blocks are the most frequent indication for permanent pacemaker 
(PPM) implantation. Overall, bradyarrhythmia forms 30-50% of all PPM indications, 
although this varies by country and type of arrhythmia. 6 However, there is limited data 
from large surveys and reports on the rate of PPM utilisation for each type of cardiac 
rhythm disorder.  
Several other arrhythmias are indications for CIED implantation and, therefore, are 
relevant to this thesis. These include ventricular tachycardia (VT) and ventricular 
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fibrillation (VF), collectively referred to as ventricular arrhythmias in this chapter. There 
are numerous aetiologies of ventricular arrhythmia including (but not restricted to) damage 
and/or scarring to the ventricle from a recent/old heart attack (myocardial infarction), 
diseases of the heart muscle (cardiomyopathy) or valves, and infection. Ventricular 
arrhythmias are the most common cause of sudden cardiac death (SCD), which is 
responsible for more than 100,000 deaths in the UK and up to 420000 deaths in the United 
States (US) every year. 4, 7  
Figure 2. Types of AV block 
 
Courtesy of Nicholas Patchett, Harvard Medical School, USA. Shared under the CC-BY-SA 4.0 licence. 
 
2. Heart failure 
Heart failure (HF) is a clinical syndrome used to describe symptoms (e.g. 
breathlessness) and/or signs (e.g. peripheral oedema) that reflect the heart’s inability to 
maintain its usual function, that being to provide a sufficient output to match the body’s 
demands.8 There are various types and stages of HF that are outside the scope of this thesis. 
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HF is one of the leading causes of morbidity worldwide, with an estimated prevalence of 
more than 37.7 million patients globally.9, 10 In the UK, it is estimated that 920,000 patients 
are living with HF, with more than 200,000 new diagnoses every year according to the 
latest British Heart Foundation (BHF) report in 2021. 11 Similarly, in the US there were 
more than 5.7 million patients living with heart failure in 2011 and more than 870,000 new 
cases every year. 12 The lifetime risk of HF is estimated to be as high as 33% in patients 
aged 55 years and over, depending on their sex.13  
There are numerous aetiologies of heart failure, including ischaemic heart disease, 
rheumatic and valvular heart disease, hypertension and several genetic and metabolic 
factors.14 The mortality from HF has stabilised and, in many countries decreased, in recent 
years, commensurate with advancements in pharmacotherapy as well as the increased 
utilisation of cardiac resynchronisation therapy (CRT) in patients with advanced HF. 8, 15-
17 The latter is a type of CIED also known as a biventricular pacemaker and sends electrical 
impulses (pacing) to both ventricles in a synchronised manner to help restore their 
synchrony, which is lost in many patients with HF. In England alone, age and sex-
standardised mortality from HF declined by 60% over a 30-year period (1981-2010).16 
Notwithstanding, there is limited information on the exact mortality of HF since it is often 
considered as a “mode of death” and the cause of death is attributed to its underlying 
aetiology (e.g., ischaemic heart disease). 17, 18  
While pharmacotherapy is the mainstay of treatment for patients with HF, the 
condition will continue to progress in a subset of patients whose quality of life significantly 
deteriorates and become at an increased risk of mortality. 8 CRT has been shown to improve 
heart function and quality of life in this group. 8, 19, 20 However, certain criteria have to be 
met for a patient to be eligible for a CRT device, including 1) advanced heart failure (New 
York Heart Association (NYHA) classes III or IV) despite optimal medical therapy ≥3 
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months, 2) evidence of severely impaired left ventricular (LV) function (ejection fraction 
(EF) ≤35%), and 3) QRS duration ≥130 msec on ECG. 
3. Overview of CIED implantation procedure  
A cardiac implantable electronic device (CIED) is an umbrella term encompassing 
a range of devices used to treat cardiac rhythm disorders, including bradyarrhythmia and 
ventricular arrhythmias. CIED systems typically consists of a pulse generator (battery and 
programmer), inserted in the pre-pectoral region of the chest (Figure 3), that is attached to 
one or more leads inserted in the heart chambers targeted for therapy. The programmer has 
built-in pacing modes to deal with any sense cardiac rhythm disorders. For access, an 
incision is made along the deltopectoral groove (Figure 3), followed by dissection until the 
cephalic vein is visualised, which is often the first choice of access to introduce the 
pacemaker lead(s) into the heart owing to the lower risk of vascular complications and 
pneumothorax with this approach. Other choices of access include axillary and subclavian 
veins. Implantation and fixation of the pacemaker leads is performed under fluoroscopic 
guidance.  
 
Figure 3. A dual chamber PPM with two leads in the RV and RA. 
 
PPM: permanent pacemaker; RA: right atrium; RV: right ventricle 
 
 11 
4. Types and indications of CIED devices 
Depending on the indication and intended therapy, CIED options include permanent 
pacemakers (PPM), cardiac resynchronisation therapy devices, with (CRT-D) or without 
(CRT-P) defibrillators, and implantable cardioverter-defibrillators (ICD). The indications 
for CIED use according to the 2013 ESC guidelines are illustrated in Figure 5. 19 
a) PPM 
A PPM is a type of CIED that sends electrical impulses to one or more heart 
chambers, from the pulse generator and through the pacing lead, allowing them to contract 
when the native conduction system of the heart fails to work properly. It is primarily 
indicated for the management of bradyarrhythmia. 8, 19, 21 The leads are inserted into the 
right ventricle (RV) and also occasionally into the right atrium (RA), depending on the type 
of rhythm requiring therapy (single chamber or dual chamber PPM). The programming of 
the pacemaker may either be synchronous (on demand if an abnormal rhythm is detected) 
or asynchronous (active at all times). There are numerous indications of PPM, however, 
summarised in Figure 5 are the most common and relevant indications to this thesis. 
b) ICD 
An ICD works in a similar mechanism to PPM, pacing the right ventricle in the 
event of a bradyarrhythmia, but has the additional feature of terminating dangerous 
ventricular arrhythmias that could lead to sudden cardiac death by delivering a shock 
through a coil in the implanted lead when it senses them, known as defibrillation, typically 
at an energy level between 20 and 35 joules. 22 ICD devices can either be implanted for 
primary prevention, in those at risk of fatal ventricular arrhythmias due to severely impaired 
LV function (EF ≤35%), or as a secondary prevention in those with a history of ventricular 
arrythmias with haemodynamic instability (severe drop in blood pressure and cardiac 




CRT devices work in a similar mechanism to pacemakers, i.e., providing pacing in 
patients with bradyarrhythmia, but also coordinate the contraction of dyssynchronous left 
and right ventricles in patients with heart failure (HF) who often have a more impaired 
contraction in the left ventricle.21 There are two types of CRT device, CRT with pacemaker 
(CRT-P) and CRT with defibrillator (CRT-D). The latter provides all the functions of a 
CRT device but also has the capabilities of a defibrillator, similar to an ICD, to terminate 
any sustained ventricular arrhythmias that may result in sudden cardiac death. The 






Figure 5. Types and indications of CIED arranged by frequency of use in real-world 
practice 
 




Despite the paucity of epidemiological data on rates and characteristics of patients 
undergoing different types of devices, there is no doubt that the global number of 
procedures has increased in the last decade in proportion to the increasingly ageing and 
comorbid population in which electrical conduction disorders are more likely to occur.6, 23-
27 Furthermore, the growing evidence supporting the use of ICD and CRT devices 
contributes to this rise in CIED implantation procedures.28-30  
a) PPM 
The rate of utilisation of PPM has increased in recent years. The European Society 
Cardiology (ESC) survey in 2017 reported a 12% increase in PPM procedures in Europe, 
including the UK, between 2007 and 2016 (788 to 886 per million inhabitants). 31 
Greenspon et al. reported a similar increase in the use of dual chamber pacemakers in the 
United States between 1993 and 2009 (29.1 to 50.4 per 100,000 population).32 
b) ICD 
Data from the ESC survey suggests that ICD implantations have risen by 42% in 
Europe between 2007 and 2016 (125 to 177 per million inhabitants). 31 Similar trends were 
observed in the US National Cardiovascular Data ICD Registry (NCDR-ICD), in which the 
number of single chamber ICD’s increased from approximately 28,000 implantations in 
2011 to 40,000 in 2014. 33   
c) CRT 
The utilisation of CRT in managing patients with advanced heart failure who fulfil 
the eligibility requirements for the device has significantly increased in the last decade. In 
Europe, the use of CRT has doubled over a decade (2007-2016: 72 to 157 per million 
inhabitants). 31 A similar trend was observed in the UK over the same period (110 to 177 
per million inhabitants). 31 Data from the National Health Insurance Service database in 
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Korea suggests a similar trend where CRT implantations have increased from 0.1 to 0.5 per 
100,000 population between 2009 and 2016.  
6. Importance of real-world evidence 
Although randomised controlled trials (RCT’s) are considered the most robust form 
of evidence, they often enrol highly selected cohorts with strict inclusion/exclusion criteria, 
meaning that their findings may not necessarily be extrapolated to the overall population 
of interest. 34-37 This has led to a growing interest in real-world outcomes research to fill a 
gap in evidence for those who may otherwise be excluded from RCT’s, including patients 
with specific comorbidities and characteristics undergoing de novo CIED implantation. 
Bodies that appraise the latest technology and pharmaceuticals prior to their use in 
healthcare systems such as the National Institute for Health and Care Excellence (NICE) 
in the United Kingdom (UK), and the Food and Drug Administration (FDA) in the US, 
have the recognised the importance of real-world evidence in guiding their assessments. 38, 
39 The present study utilised two large national datasets from the United States to study the 
relationship between patient-related factors and several real-world outcomes after CIED 
implantation with a focus on differences between types of CIED devices.  
7. Factors influencing choice of CRT device (CRT-P vs. CRT-D) 
Current guidelines do not provide clear recommendations on factors favouring 
implantation of CRT-D over CRT-P in patients eligible for CRT therapy.40 A recent 
European study was the first to examine factors affecting the choice of device (CRT-P vs. 
CRT-D) in a multicentre survey, and showed that women, elderly patients (>75 years), and 
those with non-ischaemic heart failure and atrial fibrillation were less likely to receive 
CRT-D (vs. CRT-P).41 However, their sample size was limited and it was believed that the 
survey captured no more than 11% of patients undergoing CRT therapy during that period, 
making them less generalizable to the wider CRT implantation population. The first 
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objective of my thesis aimed to address the current gap in evidence in that area by 
examining patient-related and institutional factors favouring therapy with either device.  
8. Patient-related factors influencing procedural outcomes  
a) Overview of procedural complications 
While there have been significant advances in CIED implantation techniques, 
device and lead technology, as well as increased operator proficiency through dedicated 
training programmes, 42, 43 the reported rate of procedure-related complications has 
increased in proportion to the rise in global procedural volume.44, 45  
Postprocedural complications range from 3 to 10%, 46-51 and range from minor 
complications such as pericardial effusion (fluid around the heart resulting from injury to 
heart vessels or chambers), haematoma at site of access (due to leaking vessels), 
pneumothorax (air in the chest), and venous thrombosis (clotting in the vein), to major 
complications including device-related infections, pericardial perforation (injury form the 
leads), venous tears or occlusion (during lead manipulation) and even death.52 However, 
there is significant variability in the definitions of major and minor complications between 
studies. Although major complications are uncommon, they can be potentially fatal, and 
more complex device types (CRT and ICD) carry a higher risk of complications due to 
prolonged procedure time and lead manipulation, and bulkier leads. 53, 54 
In a Danish registry of more than 5000 patients, one in ten patients (9.5%) 
experienced a complication after CIED implantation, half of which were major 
complications (5.6%) including lead reinterventions, pneumothoraces, and local and 
systemic infection. 55 Infection is one of the most feared complications as it is associated 
with high risk of mortality and is the most common indication for a total CIED system 
extraction, an even more risky procedure than CIED implantation.56 Greenspon et al. 
reported doubling of CIED-related infection rates (210% increase; 1.6% overall rate) 
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between 1993 and 2008, primarily due to increased utilisation of more complex devices 
(ICD) than pacemakers as well as rise in number of comorbidities.44 Although rare, 
mortality is a recognised complication of CIED implantations. The majority of studies have 
reported an incidence of all-cause mortality between 0.2 and 0.8%, rising up to 4% in 
patients with concomitant infection.44, 57, 58 
b) Patient-related predictors of complications 
Data from several ‘real-world’ studies suggests that complications are common 
after CIED implantation and increase with advancing age and overall patient risk profile.25, 
44-50, 55  
A summary of the major studies reporting associations between patient-related 
factors and CIED procedural outcomes to date, along with their inclusion criteria, outcomes 
and limitations, are presented in Table 2.1. The findings from these studies are summarised 
in Table 2.2.  
Age is the one of the most studied predictors of CIED procedural outcomes and has 
been shown to correlate with in-hospital mortality and overall complications as well as 1-
year mortality in some but not all studies, with variations observed between device types. 
(Table 2.2) 23, 55, 59-61 Similarly, some studies have reported an increased risk of major and 
minor postprocedural complications among females undergoing different types of CIED, 
but sex was shown to have no correlation with 1-year mortality in those undergoing ICD 
implantation (HR males 0.97 (0.84–1.12)). 23, 55, 59, 60, 62-64 Patients of black ethnicity have 
also been shown to be at an increased risk of in-hospital complications including death 
(1.14 (1.05–1.24)) but not 1-year mortality (HR 1.08 (0.85–1.36)) compared with white 
ethnicity. 59, 60 Chronic kidney disease (CKD) and advanced HF are also a risk factor for 
in-hospital adverse outcomes, including death, (CKD: OR 1.50 (1.33–1.70); NYHA class 
III and IV OR:  1.15 (1.01–1.31) and 1.38 (1.17–1.63), respectively) after implantation of 
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all device types as well as 1-year mortality (HR CKD: 1.19 (1.04-1.36); HF: 2.15 (1.56–
2.95)) after ICD implantation. 59, 60   
Some studies have reported a correlation between comorbidity burden as well 
frailty and procedural outcomes after CIED implantation, however these have been subject 
to limitations as discussed in the next section. A high comorbidity burden as measured by 
the Charlson Comorbidity index (CCI) score, was associated with increased odds of in-
hospital mortality in heart failure patients undergoing ICD and CRT devices (OR CCI ≥3 
vs. 0: ICD: 2.44 (1.47-4.05); CRT-P: 3.01 (1.17-7.77); CRT-D: 2.74 (1.62-4.65)).61 
Another study by Bhavnani et al. demonstrated a positive correlation between CCI score 
and 1-year mortality in those undergoing ICD implantations (de novo and upgrades) in a 
single tertiary centre (per unit CCI score: HR 1.40 (1.20–1.60)).65 
c) Limitations of the current evidence 
There is a lack of validated and well-established scoring systems for the risk 
assessment of patients undergoing CIED implantation, unlike with other procedures such 
as percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) 
surgery. 66-70 This stresses the importance of studying the relationship between common 
patient characteristics and procedural outcomes in this procedural group, which would 
provide operators with a thorough evidence base for risk stratification and optimisation of 
patients prior to CIED implantation. 
Although many studies have focused on associations between patient-related 
factors and outcomes of CIED implantations (Table 2.1), the majority of these have been 
subject to several limitations including 1) the focus on specific device types (e.g., ICD only) 
or patient groups (e.g. 65 years or those with heart failure only), 2) combined analysis of 
de novo as well as upgrade/replacement procedures (despite well-recognised differences in 
risks between each of these procedures), 3) the focus on single or composite outcomes (e.g. 
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death or any hospital complication) with variations in the definitions of complications in 
many studies. Furthermore, there is a significant variation in complication rates between 
different institutions, depending on their staffing level, procedural and operator volumes, 
and operator experience, stressing the importance of national level data.71 For example, 
Kirkfeldt et al reported at least 1.5-fold rise in risk of complications in patients undergoing 
CIED implantation in centres with an annual procedural volume <750 procedures (0–249 
procedures: aRR 1.6; 95% CI 1.1–2.2, 250–499: aRR 2.0; 95% CI 1.6–2.7, 500–749: aRR 
1.5; 95% CI 1.2–1.8).55 High hospital procedural volume (>190 cases per annum) was also 
shown to correlate with a lower odds of surgical complications (OR 0.64; 95% CI 0.50-
0.82) and lead dislocation (ventricular leads: OR 0.39; 95% CI 0.30-0.50; atrial leads: OR 
0.39; 95% CI 0.30-0.53) compared to hospitals with a low procedural volume (<50 cases 
per annum) in a German registry of 430,416 CIED implantations between 2007 and 2012. 
43 
The previously described limitations could easily explain the inconsistencies in the 
current literature on patient-related factors influencing procedural outcomes. For example, 
Zhan et al. reported increased odds in the composite endpoint of ‘any in-hospital 
complication’ after CIED implantation (de novo and upgrades/replacements) in females 
undergoing CRT-D, ICD and PPM implantation and lower odds in females undergoing 
CRT-P implantation. 23 However, their cohort was outdated (1997-2004) with no CRT 
cases until 2003 and so does not reflect contemporary practice, and their single composite 
endpoint does not inform operators of the role of sex in individual procedural outcomes of 
CIED implantation. In contrast, an analysis by Shakya et al. demonstrated no difference in 
the composite endpoint of ‘any hospital complication’ undergoing PPM, CRT and ICD 
implantation. 64 Similarly, a study by Tsai et al. reported an increased risk of in-hospital 
complications including death in black (vs. white) patients undergoing ICD implantation 
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for primary prevention (OR 1.14 (1.05–1.24)) whereas a study by Al-Khatib et al. 
demonstrated no difference in 1-year mortality between black and white patients 
undergoing ICD implantation (HR 1.08 (0.85–1.36)), including de novo and upgrade 
procedures.59, 60  
Most of the studies examining the role of frailty and comorbidity burden in CIED 
procedural outcomes to date have either measured frailty and/or comorbidity burden 
subjectively using age and number of comorbidities as a surrogate for these factors. 23, 61, 
65, 72-75 However, not all frail individuals are elderly or are multimorbid.76, 77 Similarly, not 
all comorbidities are similar in their prognostic impact, which is why established scoring 
systems such as the Elixhauser Comorbidity Score (ECS) and CCI are widely used as 
measures of overall comorbidity burden.78 Each of the two scores assigns different weights 
to individual comorbidities, with a total score being generated to measure the level of 
comorbidity burden of an individual. However, few studies have employed the CCI score 
to examine the association between comorbidity burden and procedural outcomes, 
however, these were subject to the limitations mentioned above (e.g., specific device types, 
combined de novo and upgrade procedures, or single outcomes). 
For studies examining the impact of CCI score on procedural outcomes, these have 
mainly focused on specific outcomes such as in-hospital or 1-year mortality, or a composite 
outcome of death and cardiac transplant. Therefore, there is limited information on the 
relationship between comorbidity burden, as measured by CCI, and post-procedural 
outcomes such as thoracic, cardiac complications and device-related complications in the 
context of de novo CIED implantation. One study by Swindle et. al. reported increased 
odds of in-hospital mortality with a high CCI score (≥3 vs. 0) in HF patients undergoing 
ICD and CRT devices.61 However, this study included specific patient groups (HF) 
receiving specific device types (ICD and CRT, including de novo and upgrades). 
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Furthermore, a significant limitation in their analysis is that CCI≥3 was compared with a 
CCI score of 0, which is very unusual since patients with heart failure should have a 
minimum score of 1 for this very condition.  
d) Gaps in the current evidence 
- Device-specific outcomes 
Despite the current evidence on factors that influence the clinical outcomes of CIED 
implantations to date, a myriad of patient-related factors remains understudied, 
especially according to the type of device. More complex devices (CRT and ICD) 
require longer procedure time and more prolonged lead manipulation, which may 
increase the risk of infection and vascular complications. 79, 80 Furthermore, patients 
undergoing more complex devices are often older and more comorbid and therefore 
more likely to experience a procedure-related complication. However, the majority 
of studies have not stratified outcomes by device type and only report outcomes of 
overall cohorts that may include a combination of PPM, CRT and ICD devices.  
- Sex-differences in procedural outcomes 
Several studies have looked at the associations between several patient 
characteristics such as sex and age, and adverse outcomes after CIED implantation. 
Notwithstanding, the studies looking at sex differences in procedural outcomes have 
been limited by the factors previously described (e.g., inclusion of specific devices 
or patient groups, combined analysis of de novo and upgrade/replacement 
procedures). Furthermore, it is unclear what trend such sex differences followed 
over the years in light of technical and technological advancements in CIED 




Outcome data in specific population groups remains lacking. For example, no study 
has looked at the effect of frailty on CIED implantations. While age is often an 
indicator of frailty, there are many patients with biological frailty who fall outside 
commonly defined elderly age groups (>65 years) as described above in detail. 76, 
77  
- Cancer patients 
Similarly, there is a lack of evidence on patients with cancer (both historical and 
current diagnoses) undergoing CIED implantation, and how their outcomes 
compare with patients without cancer.  
- Overall comorbidity burden 
Another important factor is the overall burden of comorbidities and whether this 
has a role in procedural outcomes in patients undergoing de novo CIED 
implantation. Very few studies have considered the overall burden of comorbidity 
and measured it objectively using validated measures such as the CCI score to look 
at procedural outcomes of de novo CIED implantation. 
All these gaps in evidence drive the need for outcomes data for these increasingly 
encountered risk groups, which would be of interest to patients, operators and stakeholders.   
9. Current literature on patient-related factors predicting 30-day readmissions 
a) Incidence and causes of 30-day readmission 
Although the majority of procedure-related complications occur in the peri-
procedural or immediate phase, some complications, especially device-related ones, can 
occur after discharge. 55, 81 Hospital readmissions are often seen as an indicator of the 
quality of care received in hospital and a burden for patients as well as healthcare systems, 
which led to certain countries such as the UK (since 2011) and US (since 2012) imposing 
fines or withholding payments for unplanned readmissions within 30 days. 82, 83 
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Furthermore, data on the trends and causes of 30-day readmissions can help identify 
patients at risk of readmissions who would benefit from interventions to reduce their 
readmission rates as well as closer follow-up and monitoring post-discharge. 
Studies looking at readmissions within 30 days show that this is quite common after 
CIED implantation, with the reported rates ranging between 12 and 15%. 84-88 Pasupula et 
al reported a modest decline in 30-day readmissions (14% to 13%) in patients undergoing 
CIED implantation between 2010 and 2014 in the US, with similar decline in device-related 
causes over the same period (4.5% to 3.9%).89 In a tertiary centre analysis of 229 
consecutive patients undergoing pacemaker implantation in the UK 30-day readmission 
rates were between 3.7% and 9.8% depending on discharge timing (same day vs. next 
day).88 
Overall, cardiac causes represent a significant proportion of 30-day readmissions 
after CIED implantation. In a national study by Pasupula et al, heart failure represented 
nearly 10% of 30-day readmissions throughout the study period (2010-2014). 86 In another 
study by Patel et al. heart failure accounted for 11-26% of 30-day readmissions, highest in 
patients who underwent CRT-D implantation, with arrhythmias being the second most 
common cause of 30-day readmissions (4.7-10.8%). 87 Another study by Gillam et al. from 
the Australian Government Department of Veterans' Affairs database reported 30-day 
readmission rates of 5.2% for device-related complications.85  
b) Patient-related predictors of 30-day readmission 
There are limited data on patient-related factors that predict 30-day readmission, 
particularly for cardiovascular causes and device-related complications. Only two studies 
have looked at 30-day readmissions after CIED implantation to date and these were from 
the Nationwide Readmissions Database (NRD), which I will also be using to conduct my 
studies that focus on this outcome. 84, 87 A summary of predictors of 30-day readmission in 
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presented in Table 2.2. However, both studies examined patient-related predictors of 
overall 30-day readmission, without focusing on cardiovascular-specific causes. 
Furthermore, there were conflicting data on predictors of readmission between studies, 
which is likely due to their analytical strategy as discussed in detail in the relevant chapter 
(Chapter 9).  For example, the lack of difference in 30-day readmissions in patients with 
congestive heart failure (CHF) in the study by Patel et. al (OR 1.05 (0.97-1.13)) despite it 
being associated with increased odds of readmission in the study by Ahmad et al. (OR 1.39 
(1.30, 1.48)). 84, 87 On a similar note, older age (>50 years) was associated with reduced 
odds of all-cause 30-day readmission in the study by Ahmad et al. whereas no difference 
was found for the same outcome in those aged >50 years by Patel et al. 84, 87 Female sex 
has been shown to be correlate with all-cause 30-day readmission in two studies (OR 1.07 
(1.04-1.11) and 1.09 (1.04-1.14) in two studies) as was chronic kidney disease in a study 
by Ahmad et al. (OR 1.97 (1.90-2.04)). 84, 87 
c) Gaps in evidence 
- Although there is emerging evidence on the decline of 30-day readmissions in 
patients undergoing CIED implantation in general, there is no data on device-
specific readmission rates and causes.89  
- There is currently a lack of data on predictors of cardiac and device-specific 30-day 
readmissions after de novo CIED implantation, with the majority of studies reporting 






10. Chapter Tables 
a) Table 2.1. Summary of studies reporting patient-related predictors of adverse outcomes and 30-day readmissions after CIED 
implantation (by year of publication) 
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Old cohort with virtually no CRT devices until 
2003 coinciding with FDA approval at the time. 
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prevention from the US 
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Specific device type, only focused on major and 
minor complications, regional cohort. 
Bhavnani 201365 
ICD implantation for 
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of sudden cardiac death 
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Included de novo and upgrade procedures. 
Predictors are for all-cause 30-day readmissions 
without a sub-analysis for cardiac-specific causes. 
Unusually low number of CIED procedures in 
comparison to studies from the same dataset for 
different years.  
Ahmad 201884 
All CIED implantation 












Included de novo and upgrade procedures. 
Predictors are for all-cause 30-day readmissions 
without a sub-analysis for cardiac-specific causes. 
Moore 2019 91 
All adult CIED 
procedures in Australia 













Included de novo and upgrade procedures. No 
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Specific device type and patient group (≥75 
years), de novo as well as upgrades, single 
outcome, small sample size. 
a lead dislodgment with repositioning, lead repositioning, lead replacement lead extraction, device problem—setscrew, device problem—pocket revision, myocardial 
perforation, pericardial tamponade, pneumothorax/haemothorax, pocket infection, skin erosion, pocket hematoma requiring intervention, clinical complications, pulmonary 
oedema, electrical storm, cardiogenic shock, post implant myocardial infarction, hypotension requiring resuscitation, sepsis, stroke, noncerebral embolus, death 
b coronary venous dissection, subclavian vein thrombosis, renal insufficiency, incisional infection, peripheral nerve injury, non-superficial venous thrombus, lead 
dislodgement not repositioned, diaphragmatic stimulation, site pain, lead fracture not requiring intervention, pocket hematoma 
c composite of cardiac arrest, cardiac perforation, cardiac valve injury, coronary venous dissection, haemothorax, pneumothorax, deep phlebitis, transient ischemic attack, 
stroke, myocardial infarction, pericardial tamponade, and arteriovenous fistula 
d composite of lead-related re-interventions, local infections requiring re-intervention, CIED-related systemic infections or endocarditis, pneumothorax requiring drainage, 
cardiac perforation, pocket revisions because of pain, generator-lead interface problems requiring re-intervention, haematomas requiring re-intervention, deep venous 
thrombosis, Twiddler's syndrome, wound revisions, stroke, myocardial infarctions, and procedure-related deaths 
e composite of haematomas resulting in a prolonged hospital stay, hospital re-admissions, or additional out-patient visits, wound infections treated with antibiotics, 




b) Table 2.2. Summary of patient factors associated with adverse outcomes in previous studies 
Factor Study Outcome Estimate Predictive value p-value 
Age 
Al-Khatib59 1-year mortality HR Per 5 years: 1.26 (1.20–1.33) <0.001 
Kirkfeldt55 
Major and Minor 
complications 
aRR 
Age 60-79 yrs. - reference 
0-30 yrs:      Major: 1.30 (0.70–2.20), Minor: 0.50 (0.20–1.50) 
40-59 yrs:    Major: 1.10 (0.80–1.50), Minor: 1.00 (0.70–1.50) 





Any adverse event or 
in-hospital mortality 
OR 
Age<65 yrs reference 
65-69 yrs: 1.02 (0.92-1.12) 
70-74 yrs: 1.08 (0.98-1.19) 
75-79 yrs: 1.14 (1.03-1.25) 
80-84 yrs: 1.22 (1.10-1.36) 






Swindle61 In-hospital mortality OR 
Age (≥80 vs. 19-79 yrs) 
ICD: 2.12 (1.19-3.79) 









Age 25-64 yrs reference 
65-74 yrs: 1.08 (CRT-D), 0.79 (CRT-P), 0.79 (ICD), 0.88 (PPM) 
75-84 yrs: 0.97 (CRT-D), 0.86 (CRT-P), 1.04 (ICD), 1.03 (PPM) 
85+ yrs: 1.09 (CRT-D), 0.45 (CRT-P), 1.34 (ICD), 0.86 (PPM) 
NS, NS, <0.01, NS 
NS, NS, NS, NS 





Age (<50 yrs reference) 
51-60 yrs: 0.94 (0.89-1.01) 
61-70 yrs: 0.85 (0.80-0.90) 
71-80 yrs: 0.83 (0.78-0.88) 









Age (18-50 yrs) – reference 
51-75 yrs: 0.94 (0.85-1.08) 




Al-Khatib59 1-year mortality HR Males: 0.97 (0.84–1.12) 0.67 
Lee 201090 




Major: 1.49 (1.02-2.16) 
Minor: 1.28 (0.91-1.80) 
0.037 
Moore91 









PPM: 1.06 [1.00, 1.13] 
ICD:  1.25 [1.09, 1.44] 
CRT: 1.22 [1.04, 1.43] 
0.002 
0.01 
Peterson63 Major adverse events OR Women 1.71 (1.57-1.86) - 
Kirkfeldt55 




Major: 1.40 (1.20–1.80) 








Major: 1.78 (1.24–2.58) 
Minor: 1.55 (1.09–2.20) 





Any adverse event or 
in-hospital mortality 
















OR Female: 1.09 (1.04-1.14) 0.001 
Race 
Al-Khatib59 1-year mortality HR Black: 1.08 (0.85–1.36) – reference is white 0.55 
Tsai60 
Any adverse event or 
in-hospital mortality 
OR Black: 1.14 (1.05–1.24) – reference is white <0.01 
CHF 
Al-Khatib59 1-year mortality HR 2.15 (1.56–2.95) <0.001 
Tsai60 
Any adverse event or 
in-hospital mortality 
OR 
NYHA I reference 
NYHA II: 0.92 (0.81–1.05) 
NYHA III: 1.15 (1.01–1.31) 











OR 1.05 (0.97-1.13) 0.23 




Any adverse event or 
in-hospital mortality 








OR 1.53 (1.24-1.88) <0.001 




Swindle61 In-hospital mortality OR 
Charlson comorbidity index ≥3 vs. 0 
ICD: 2.44 (1.47-4.05) 
CRT-P: 3.01 (1.17-7.77) 








Comorbid disease (0 is reference) 
1: 1.18 (CRT-D), 0.90 (CRT-P), 0.87 (ICD), 0.84 (PPM)  
2: 0.99 (CRT-D), 1.75 (CRT-P), 0.99 (ICD), 0.84 (PPM) 
≥3: 1.31 (CRT-D), 1.08 (CRT-P), 1.03 (ICD), 0.96 (PPM) 
<0.01, NS, <0.05, <0.01 
NS, <0.01, NS, <0.01 
<0.01, NS, NS, NS 
Green73 1-year mortality OR 
Frailty: ~4.00 
Frailty + Dementia: 8.68 (7.33–10.27) 
- 
- 
Poupin74 5-year mortality HR 
Univariate HR (reference CCI score 0) 
CCI score 1-3: 1.40 (0.67–2.94) 
CCI score ≥4: 3.41 (1.64–7.11) 
0.37 
0.001 
Ruwald75 All-cause mortality HR 
Reference: No comorbidity burden 
Primary prevention indication: 
Comorbidity burden=1: 2.10 (1.40-3.10) 
Comorbidity burden=2: 3.70 (2.40-5.70) 
Comorbidity burden=3: 6.60 (4.20-10.30) 
Secondary prevention indication: 
Comorbidity burden=1: 2.20 (1.60-3.00) 
Comorbidity burden=2: 3.80 (2.70-5.30) 
Comorbidity burden=3: 5.80 (4.00-8.40) 
 
<0.001 for all 
Boriani72 
Death or cardiac 
transplant 
HR 
CCI (per unit score) 
ICD patients: 1.23 (1.16, 1.30) 
CRT-D patients: 1.18 (1.11, 1.26) 
<0.0001 for both 
Bhavnani65 1-year mortality HR 
CCI (per unit score): 1.40 (1.20–1.60) 
CCI class (CCI 0 is reference): 
CCI 1: 0.97 (0.45, 2.08) 
CCI 2: 2.38 (1.15, 4.97) 
CCI 3: 4.30 (2.10, 8.93) 








Chapter 3. Methods 
In this chapter, I provide an overview of methods used for conducting the work in 
my thesis, including information on the datasets from which the study cohorts were derived, 
the analytical strategies followed, and the pre-defined outcomes for all the chapters that 
follow.  
1. Study datasets  
I undertook the work in this thesis from two datasets: The National Inpatient Sample 
(years 2004 to 2014) and the Nationwide Readmissions Database (years 2010 to 2015, and 
2015 to 2017 in one project). These years were specifically chosen owing to the availability 
of data at the time of the work since there is a two-year lag between hospitalisations in a 
calendar year and the availability of data for researchers. For example, in 2018, the latest 
available data was for 2016 hospitalizations. Another important aspect I considered was 
the difference in International Classification of Diseases (ICD) coding versions used in the 
earlier (2004 through September 2015; ICD-9) and later years (October 2015 onwards; 
ICD-10), meaning that they cannot be combined due to differences in diagnostic and 
procedural definitions between coding versions. Further information on the structure and 
content of both datasets is provided below. 
a) The National Inpatient Sample 
i. Overview 
The National Inpatient Sample (NIS) is the largest publicly available all-payer 
database of hospitalized patients in the United States and is sponsored by the Agency for 
Healthcare Research and Quality as a part of the Healthcare Cost and Utilization Project 
(HCUP). 92 It includes anonymized data on primary and secondary discharge diagnoses and 
procedures from more than 7 million hospitalizations annually. The NIS dataset was 
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designed to approximate 20% stratified sample of United States hospitals and provides 
sampling weights to calculate national estimates that represent more than 95% of the US 
population The estimates of hospital characteristics, numbers of discharges, length of stay, 
and in-hospital mortality from the HCUP Nationwide Inpatient Sample (NIS) were highly 
comparable to three related data sources in a previous analysis: the American Hospital 
Association (AHA) Annual Survey Database, the National Hospital Discharge Survey 
(NHDS) from the National Center for Health Statistics, and the MedPAR inpatient data 
from the Centers for Medicare and Medicaid Services (CMS) 93  
ii. Data structure 
Each record in NIS represents a unique hospitalization episode and there can be 
multiple episodes for each patient during the same calendar year. However, there is no way 
of tracking multiple admissions for the same patient over the year since the record number 
is unique to the hospitalization episode and not the patient. NIS contains sociodemographic 
information including patient age, sex, race, household income, hospital region, type of 
admission (elective vs emergency), day of admission (weekend vs weekday), type of 
admitting hospital (location, bed size, teaching status), in-hospital status at discharge (death 
vs no death) as well as 27 Elixhauser comorbidities (acquired immune deficiency syndrome, 
alcohol abuse, deficiency anaemia, chronic blood loss anaemia, rheumatoid 
arthritis/collagen vascular diseases, congestive heart failure, chronic pulmonary disease, 
coagulopathy, diabetes (uncomplicated), diabetes with chronic complications, drug abuse, 
hypertension, hypothyroidism, liver disease, lymphoma, fluid and electrolyte disorders, 
metastatic cancer, other neurological disorders, obesity, paralysis, peripheral vascular 
disorders, pulmonary circulation disorders, renal failure, solid tumour without metastasis, 
peptic ulcer disease excluding bleeding, valvular heart disease,  and weight loss) 
Furthermore, there are up to 30 diagnosis fields and 15 procedure fields codes using the 
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International Classification of Disease, Ninth Revision (ICD-9) and Clinical Classification 
Software (CCS) systems These fields are used to identify additional diagnoses and 
procedures in the admission episode. 
b) The Nationwide Readmissions Database  
i. Overview 
The Nationwide Readmissions Database (NRD) is a nationally representative 
sample of all-age, all-payer discharges from United States (US) non-federal hospitals 
sponsored by the Healthcare Cost and Utilization Project (HCUP) of the Agency for 
Healthcare Research and Quality (AHRQ) and is a database of inpatient stays and 
readmissions that can be used to generate national estimates of readmissions. 94 The NRD 
dataset constitutes a stratified sample from 22 states with anonymized data from more than 
17 million hospitalizations annually from 22 states and provides sampling weights to 
calculate national estimates that represent more than 50% of the US population 
(approximately 36 million hospitalizations per annum). 
ii. Data Structure 
Each individual record represents a unique hospitalization episode and there can be 
multiple episodes for each patient during the same calendar year. Unlike NIS, individual 
patient readmissions can be tracked across the calendar year in NRD and data on the ‘days 
to readmission’ between episodes is available within the dataset. However, patients may not 
be tracked across multiple years. This was not an issue for the purpose of my thesis since I 
only included patients with a de novo CIED implantation and looked at 30-day 
readmissions. Therefore, only patients admitted in December of each year were not possible 
to study in terms of 30-day readmissions. The NRD contains sociodemographic information 
including patient age, sex, race, median household income quartile, hospital region, type of 
admission (elective vs. emergency), day of admission (weekend vs. weekday), type of 
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admitting hospital (location, bed size, teaching status), in-hospital status at discharge (death 
vs no death) as well as 27 Elixhauser comorbidities (acquired immune deficiency syndrome, 
alcohol abuse, deficiency anaemia, chronic blood loss anaemia, rheumatoid 
arthritis/collagen vascular diseases, congestive heart failure, chronic pulmonary disease, 
coagulopathy, diabetes (uncomplicated), diabetes with chronic complications, drug abuse, 
hypertension, hypothyroidism, liver disease, lymphoma, fluid and electrolyte disorders, 
metastatic cancer, other neurological disorders, obesity, paralysis, peripheral vascular 
disorders, pulmonary circulation disorders, renal failure, solid tumour without metastasis, 
peptic ulcer disease excluding bleeding, valvular heart disease,  and weight loss). 
Furthermore, there are up to 30 diagnosis fields and 15 procedure fields codes using the 
International Classification of Disease, Ninth Revision (ICD-9) in the years 2010 to 2015 
(30th September) and up to 40 diagnosis fields and 25 procedure fields using ICD-10 (Tenth 
Revision) from October 2015 onwards. These fields are used to identify additional 
diagnoses and procedures during the admission episode. 
2. Data curation 
a) Cohort extraction 
Both NIS and NRD datasets are provided in separate calendar years, each formed of 
four individual files including core data (admission-related and sociodemographic 
information), diagnoses and procedure data, severity data and hospital data. Identification 
and extraction of cardiac implantable electronic device (CIED) cohorts for analysis were 
based on ICD-9 procedure codes (and ICD-10 in one study from NRD) from the diagnosis 
and procedure data: permanent pacemaker (ICD-9: PPM: [3770 or 3771 or 3772 or 3773] 
and [3780 or 3781 or 3782 or 3783]; ICD-10: Single chamber: 0JH634Z 0JH635Z 0JH604Z 
0JH605Z and Dual chamber: 0JH636Z 0JH606Z) cardiac resynchronisation therapy with 
defibrillator (CRT-D, ICD-9: 0051, ICD-10: 0JH639Z 0JH609Z), cardiac resynchronisation 
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therapy with defibrillator (CRT-P, ICD-9: 0050, ICD-10: 0JH637Z 0JH607Z) and 
implantable cardioverter defibrillator (ICD, ICD-9: 3794 or [3795+3796], ICD-10: 
0JH638Z or 0JH608Z). Following extraction of the procedure cohort for each year, all 4 
files (core, diagnoses and procedure, severity and hospital) were merged. Data for other 
comorbidities, procedures and complications were also extracted using the ICD-9 and 
Clinical Classification Software (CCS) codes listed in Table 3.1 and ICD-10 codes in Table 
3.2 for one study from NIS. ICD-9 codes for cancer diagnoses, which were used in one of 
the projects specifically, are presented in the relevant chapter (Table 6.1 in Chapter 6). A 
literature review was performed to agree on validated ICD codes that correctly identify in-
hospital outcomes and patient characteristics from both administrative datasets (NIS and 
NRD). Causes of readmission in the NRD datasets were identified using CCS codes for the 
years 2010 to 2015 (September), a full list of which is presented in the relevant chapter 
(Table 9.1 in Chapter 9). All cohort extractions and generation of variables were performed 
using STATA 14 statistical software (College Station, Texas, USA) while analyses were 
performed using STATA 14 and the Statistical Package for the Social Sciences (SPSS) 
version 26 (Armonk, NY, USA) software.  
b) Identifying de novo CIED implantations 
De novo CIED implantations were identified by excluding patients with no prior 
PPM or ICD in situ (ICD-9 diagnosis codes V4500/V4501 and V4502, respectively, and 
ICD-10 codes Z950 and Z95810, respectively) as well CIED removal or replacement 





c) Specific considerations for NRD (including 30-day readmissions) 
The primary outcome of interest in studies from NRD was 30-day readmission. After 
identification of the de novo CIED procedure for a patient, this was then considered the 
index episode. All previous episodes were excluded. I employed commands to generate a 
‘admissionnumber’ variable that represents sequential numbering of all subsequent 
episodes after the index admission (N+1, N+2, N+3, etc) based on a byte sequence that 
takes in to account the patient’s unique identifier (nrd_visitlink variable) and time to 
readmission variables. Unique identifiers with an ‘admissionnumber’ value>1 whose time 
to readmission from the index event was ≤30 days (identified in a variable labelled 
readmitted30days) were then exported to a new dataset as these represented the group of 
interest. All duplicates of these ID’s were removed in the new datasets and the unique ID’s 
were then merged back to the original dataset using a one-to-many merge command to flag 
all patient’s unique identifiers who were readmitted within 30 days (flag variable: 
thirtydayreadmissionflag). An example of this process is provided below.  
 
 
d) Missing data 
Variables with missing data included in-hospital death, length of stay, median household 
income, primary expected payer (insurance status), elective or weekend admission status, 
and hospital bed-size, location and teaching status. Data inspection showed these were all 
missing at random at rates of less than 5%, therefore unlikely to influence any statistical 
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inferences if excluded. As such, cases with missing values for these variables were 
excluded and this was guided by previous statistical literature. 95, 96 The frequency of 
missing data for each of the studies is presented in the relevant chapters.  
3. Outcomes 
The NIS dataset only captures in-hospital outcomes. The following in-hospital outcomes 
will be looked at in each study, all identified using the International Classification of 
Diseases coding system (Table 3.1, Table 3.2): 
a) Mortality: predefined in the dataset.  
b) Post-procedural haemorrhage: Defined as any procedure-related bleeding, 
excluding haematomas, as these reflect small, localised bleeding and could lead to 
overestimation of bleeding events. 
c) Thoracic complications: Composite of acute haemothorax and/or pneumothorax, 
thoracic vascular injury and chest drain insertion (for haemothorax or pneumothorax; 
to ensure full capture of both events) 
d) Cardiac complications: Composite of cardiac tamponade, pericardial effusion and 
pericardiocentesis (usually for cardiac tamponade and significant pericardial 
effusion; to ensure full capture of both events) 
e) Device-related infection.  
f) Device-related complications in readmission studies from NRD with ICD-10 
coding system: composite of device-related infection, lead revision, wound 
disruption, revision of pocket, and device-related complications.  
g) MACCE (Major adverse cardiovascular events): Composite of all-cause 
mortality, acute ischaemic stroke, thoracic and cardiac complications, and device-
related infection (or device-related complications in ICD-10 studies).  
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4. Descriptive Methods 
Continuous variables in NIS and NRD were primarily age and length of stay, both 
of which were not normally distributed. Therefore, both were summarized using medians 
and interquartile range (IQR) and were compared using the Kruskal-Wallis test. In certain 
studies, means were compared for categorical variables using the ANOVA test. Categorical 
variables were summarized as percentages and analysed using the chi squared (X2) test. 
5. Multivariable modelling 
Multivariable logistic regression modelling was performed to examine the 
association between the outcomes of interest (e.g., death, 30-day readmission) and the 
predictor variables in question (e.g., sex, type of CIED implanted). Further information on 
outcomes and predictor variables included in models for my studies are discussed in 
individual chapters. The goodness-of-fit of models was assessed using the Hosmer-





















Dyslipidaemia CCS D 53 
Smoking Status ICD-9 D V1582, 3051  
AF ICD-9 D 42731 
History of IHD ICD-9 D 41400-07, 4142-9 
Previous MI ICD-9 D 412 
Previous PCI ICD-9 D V4582  
Previous CABG ICD-9 D V4581  
Previous CVA (TIA and Stroke) ICD-9 D V1254 
PPM in situ ICD-9 D V4500 V4501 
ICD in situ ICD-9 D V4502 





43, 29410-11, 3310 
Thrombocytopenia ICD-9 D 2875,28749 









4271 (VT – paroxysmal and/or 
sustained), 42741 (VF) 
In-hospital procedures and outcomes 
PPM ICD-9 P 
[3770 or 3771 or 3772 or 
3773] + [3780 or 3781 or 3782 
or 3783] 
CRT-P ICD-9 P 0050 
CRT-D ICD-9 P 0051 
ICD ICD-9 P 3794 or (3795+3796) 
Lead revision ICD-9 P 3775 
Revision or relocation of pocket ICD-9 P 3779 
Acute ischemic stroke ICD-9 D 
43301, 43311, 43321, 43331, 
43381, 43391, 43401, 43411, 
43491, 4350-1, 4358-9, 436 
Major bleeding 
ICD-9 D 430, 431, 432*, 4590, 578*, 
7847, 7863, 99811 (procedure-
related bleeding) 
Shock during admission ICD-9 D 78551 
Hemopericardium ICD-9 D 4230 
Pericardiocentesis ICD-9 P 370 
Cardiac tamponade ICD-9 D 4233 
Pneumothorax ICD-9 D 51289, 5121, 8600-1 
Hemithorax ICD-9 D 8602-3 
Chest Drain Insertion CCS P 39 
Cardiac Arrest ICD-9 D 4275 
Device related infection ICD-9 D 99661 
Fever ICD-9 D 78060-64 
Bacteraemia/Viremia ICD-9 D 7907/7908 
Septicaemia ICD-9 D 038x 
Thoracic/Upper Limb Vascular injury ICD-9 D 901x, 9031, 9038-9, 9001 




Table 3.2 ICD-10 Search codes for procedures and diagnoses 
Variable Diagnostic (D)/ 
Procedural (P) 
Codes 
Diagnoses   
STEMI D I210* I211* I212* I213 
NSTEACS D I214 I219 I200 (UA) 
Type 2 MI  D I21A1 
CKD 3-5  D NI83 NI84 NI85 NI86  
Bradyarrhythmia D I440 I441 I442 R001 
Tachyarrhythmias D R000 I47* I4901 I4902 
Dyslipidaemia D E78* 
Smoker D Z720 
Cardiac arrest 
D 
I462 (due to cardiac condition); I468 and 
I469 (due to non-cardiac condition) 
Heart Failure  D I50* Cardiomyopathy: I42* 




VF: I4901 I4902; VT: I470 I472 
AF D I4891 I4820-21 I4811 I4819 I480 
History of IHD  
D 
I2510 I25110 I25111 I25118 I25119 I257* 
I258* I259* 
Previous MI D I252 I256  
Previous PCI D Z9861 
Previous CABG D Z951 
Previous CVA (TIA and 
Stroke) 
D 
Z8673   
PPM in situ D Z950 
ICD in situ D Z95810 
Dementia (Presenile Senile 
Vascular and Alzheimer’s) 
D 
F01* F02* F03* 
Thrombocytopenia D D694* D695* D696* 
Homelessness D Z590 
Transsexualism D F640 
Chronic renal failure D N18* 
Hypertension D I10* 
Anaemias D D62* D63* D64*  
Chronic Lung Disease 
(including bronchitis, 
COPD, asthma and 
bronchiectasis)  
D 
J41* J42* J43* J44* J45* J47* 
Diabetes D E08* E09* E10* E11* E13* 
Coagulopathies D D65 D66 D67 D68* D69* 
Liver disease 
D 
K70* K721* K729* K73* K74* K75* 
K76* K77* 
Metastatic disease D C77* C78* C79* R180* C7B* 
Cancers D C00-C96 
PVD D I70* I73* 







Acute ischemic stroke D I63* 
Major bleeding D I60* I61* I62* R58 K920 K921 K922 
Procedure-related bleeding 
D 
Complicating CA or PCI: I97410 and 
I97610; Complicating CABG: I97411 and 
I97611 
I976* I974* 
Acute Kidney Injury D N17* 
Cardiogenic shock  D R570 
Use of assist device or 
IABP 
P 
5A02110 5A0211D 5A02216 02HA3RJ 
02HA3RZ 
Hemopericardium D I312 
Pericardial effusion D I313 
Pericardiocentesis P 0W9D40Z 
Cardiac tamponade D I314 
PPM 
P 
Single chamber: 0JH634Z 0JH635Z 
0JH604Z 0JH605Z 
Dual chamber: 0JH636Z 0JH606Z 
CRT-P P 0JH637Z 0JH607Z 
CRT-D P 0JH639Z 0JH609Z 





RA: 02H63NZ  
RV: 02HK3NZ  
LV: 02HL3NZ 
Removal of pulse 
generator or lead 
(exclusion criteria to 








Wound disruption D T813* 
Mechanical complications 
of CIED implant 
D 
T821  
Pneumothorax D J93* 




Pleural effusion: J90 and J91 
Pleural drainage 
P 




Other: T8110* and T8119* Cardiogenic: 
T8111* Septic: T8112* 
Vascular complication of 
procedure 
D T817* 
Lead revision P 02WA3MZ 
Revision or relocation of 
pocket 
P 0JWT3PZ 




Chapter 4. Patient-related predictors of 
CRT device type 
The work presented in this chapter is based on the study published in the Canadian Journal 
of Cardiology (Appendix 1).98  
1. Introduction 
International societies recommend cardiac resynchronization therapy (CRT) as a class I 
recommendation for the management of patients with symptomatic heart failure (New 
York Heart Association (NYHA) class III or IV) with reduced ejection fraction (<35%) 
despite 3 months of optimal medical therapy, as well as the presence of bundle branch 
block (≥130 milliseconds).20, 21, 99-101 However, there are limited data in current guidelines 
to inform operators on the choice of device type (CRT with pacemaker or defibrillator; 
CRT-D and CRT-P, respectively) based on patient risk factors or comorbidities.40 While 
guidance is given to consider factors such as life expectancy, severe renal failure and 
patient frailty status, the decision on device type is often left to the operators’ 
judgement.21, 40 This drives the need for data on patient-related factors that are predictive 
of receipt of CRT-D vs. CRT-P in the real-world setting. 
Furthermore, limited data exist on sex differences in the rate of utilization of both CRT 
device types, and whether sex has an influence on the choice of device therapy. The 
European Society of Cardiology (ESC) CRT Survey II reported that females were more 
likely to receive a CRT-P than a CRT-D device.41 This survey was the first to examine 
predictors of receipt of CRT-P in a European cohort of approximately 11,000 patients 
undergoing CRT implantation between October 2015 and January 2017.  However, the 
survey was only representative of 11% of all CRT procedures in Europe, rendering their 
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findings less generalizable to the wider European population and other healthcare 
systems.  
2. Objectives 
My main objectives of this chapter were to study the following: 
a) Patient-related predictors of type of CRT device offered to those who qualify for this 
therapy.  
b) Whether sex differences in the choice of CRT device type exist and, if so, what trend 
has this disparity followed over the last decade.  
3.  Methods  
A full description of the methodology relating to all chapters of my thesis is provided in 
Chapter 3.  
a) Data Source 
This section of my thesis was based on a retrospective analysis of all de novo 
CRT implantation procedures between 2004 and 2014 from the United States (US) 
National Inpatient Sample (NIS) database, which is sponsored by the Agency for 
Healthcare Research and Quality as a part of the Healthcare Cost and Utilization 
Project (HCUP). 92 Further details on the structure and validation of NIS are provided 
in Chapter 3 of this thesis. Importantly, NIS contains annual hospitalisations from 
approximately 49% of community hospitals in the US but does not offer linkage of 
patients over multiple years. Furthermore, the record identifier in NIS is unique to the 
hospitalization episode and not the patient. Therefore, multiple admissions for the 
same patient cannot be identified. However, this is not a limitation in the context of de 
novo CRT procedures and would have only posed an issue if I had included upgrades 
and/or revisions.  
 
 44 
b) Study Design and Population 
All adults (aged ≥18 years) undergoing de novo CRT implantation between 
2004 and 2014 were included in my analysis, identified using the International 
Classification of Diseases, ninth revision (ICD-9) procedure codes (CRT-P 00.51; 
CRT-D 00.52), stratified in to two groups according to device type: CRT-P and CRT-
D.  I excluded CRT upgrades and records with missing data (study flow diagram for 
exact variables and frequencies: Figure 4.1). Cases excluded due to missing variables 
represented 3% (n=2601 unweighted records) of the cohort. Patient characteristics, 
comorbidities, and clinical outcomes were extracted using the ICD-9 procedure and 
diagnosis codes provided in Table 3.1 in Chapter 3. A CRT response score (range 0-
4) was also generated to assess the predicted response of patients to CRT, which may 
have influenced operators’ choice of device type.102 The 4 variables in the CRT score 
are: presence of 1) left bundle branch block (LBBB) and 2) non-ischemic 
cardiomyopathy and absence of 3) atrial fibrillation (AF) or 4) chronic kidney disease 
(CKD). 
c) Outcomes 
The primary outcome was receipt of CRT-D compared with CRT-P. Secondary 
outcomes were in-hospital adverse events, including major acute cardiovascular events 
(MACE), all-cause mortality and procedural-related complications (bleeding, thoracic 
and cardiac). In-hospital MACE was defined as a composite of all-cause mortality, 
cardiac complications, thoracic complications and device-related infection. Procedure-
related bleeding included any post-procedural haemorrhage or anaemia after 
haemorrhage, cardiac complications were a composite of cardiac tamponade, 
hemopericardium, pericardial effusion and pericardiocentesis, whereas thoracic 
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complications were defined as a composite of acute pneumothorax or haemothorax, 
with or without drainage, or thoracic vascular injury. 
Figure 4.1 Study flow diagram 
 
 
d) Statistical Analysis 
Descriptive statistics were performed as previously explained in Chapter 3. 
Sampling weights provided by the AHRQ were applied to all analyses. All statistical 
analyses were performed using SPSS version 24 (IBM Corp, Armonk, NY).  
Several multivariable logistic regression models were constructed to examine 
predictors of receipt of CRT-D (reference CRT-P) as well as the association between 
female sex and in-hospital outcomes stratified by device type. All multivariable models 
adjusted for differences in socioeconomic, clinical, and hospital-level covariates that 
may directly influence in-hospital outcomes (age, race, weekend admission, primary 
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expected payer, median household income, dyslipidaemia, smoking status, previous 
acute myocardial infarction (AMI), previous coronary artery bypass graft (CABG), 
previous percutaneous coronary intervention (PCI), previous cerebrovascular 
accidents (CVA) including stroke and transient ischemic attacks (TIA), 
thrombocytopenia, history of cardiac arrest, ventricular tachycardia (VT) and 
fibrillation (VF), left bundle branch block (LBBB), non-ischemic cardiomyopathy, and 
Elixhauser comorbidities (acquired immune deficiency syndrome, alcohol abuse, 
deficiency anaemias, chronic blood loss anaemia, rheumatoid arthritis/collagen 
vascular diseases, congestive heart failure, chronic pulmonary disease, coagulopathy, 
depression, diabetes (uncomplicated), diabetes with chronic complications, drug 
abuse, hypertension, hypothyroidism, liver disease, lymphoma, fluid and electrolyte 
disorders, metastatic cancer, other neurological disorders, obesity, peripheral vascular 
disease, pulmonary circulation disorders, renal failure, solid tumour without 
metastasis, valvular heart disease and weight loss), bed size of hospital, 
location/teaching status of hospital, hospital volume, year of admission. I included an 
interaction term between sex and time (year) to investigate potential temporal trends 
of association between sex and outcomes. All associations were expressed as odds 
ratios (ORs) with corresponding 95% confidence intervals (CIs). 
4. Results 
Of 400,823 de novo CRT implantation procedures between 2004 and 2014, 60,032 
were CRT-P procedures (15%) and 340,791 were CRT-D procedures (85%). Overall, there 
was a higher utilisation CRT-D amongst males (88%) compared with females (77%). 
Within the CRT groups, females were more prevalent in the CRT-P group than the CRT-
D group (41.5% vs. 27.8%). The percentage of females undergoing CRT-P and CRT-D 
implantations has increased over the study period, albeit more in the CRT-P group. For 
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example, the percentage of females undergoing CRT-P was 34.9% in 2004 compared with 
45.6% in 2014 (absolute difference: 10.7%). (Figure 4.2) 
Figure 4.2. Proportions of A) CRT-P and B) CRT-D procedures over the study 
period* 
 
*p<0.001 for trend; CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or - defibrillator, 
respectively 
 
Patients who underwent CRT-D implantation were primarily younger (71 (62,78) vs. 
77 (69,83) years) with a higher prevalence of in-hospital cardiac arrest (2.2 vs. 1.5%), VT 
(27.4 vs. 8.4%), VF (3.9 vs. 0.8%) and previous AMI (21.7% vs. 11.5%), PCI (12.1% vs. 
9.4%) and CABG (22.4 vs. 15.2%). (Table 4.1) However, the CRT-D group had a lower 
prevalence of renal failure (19.1 vs. 20.6%) and anaemias (9.6 vs. 12.5%). Several sex 
differences in patient characteristics were observed in both CRT groups. Females in both 
groups had significantly lower prevalence of VT, VF, renal failure and previous AMI, PCI 
and CABG but a higher prevalence of non-ischemic cardiomyopathy. (Table 4.1) 
Predictors of receipt of CRT-D 
 On multivariable analysis, several factors (patient-related and demographic) were 
predictive of receipt of CRT-D than CRT-P. (Table 4.2, Figure 4.3)  
Female sex was associated with reduced odds of receipt of CRT-D compared with 
males (OR 0.66 95%CI 0.64-0.67), and this persisted over the study period (ptrend=0.06). 
(Table 4.2, Figure 4.4). Advanced age also negatively correlated with the odds of receipt
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Table 4.1. Patient characteristics of study groups  











p-value CRT-P CRT-D 
p-
value 
Number of weighted 
discharges 
35107 24925  246015 94776  60032 340791  
Sociodemographic          
Age (years), median 
(IQR) 
77(68,83) 78(69,84) <0.001 71(62,78) 71(62,78) 0.08 77 (69,83) 71 (62,78) <0.001 
Ethnicity, %   <0.001   <0.001   <0.001 
White 84.0 81.3  79.9 72.0  83.0 78.0  
Black 6.5 9.1  9.4 15.9  7.5 11.2  
Hispanic 5.3 5.4  6.2 7.5  5.3 6.4  
Asian/Pacific Islander 1.2 1.4  1.3 1.3  1.3 1.3  
Native American 0.7 0.8  0.5 0.6  0.7 0.5  
Other 2.4 2.1  2.6 2.7  2.2 2.6  
Elective Admission, % 44.5 42.9 <0.001 50.3 50.2 0.673 43.9 50.3 <0.001 
Weekend admission, % 11.1 10.7 <0.001 9.0 8.9 0.429 10.9 9.0 <0.001 
Primary expected payer, 
% 
  <0.001   <0.001   <0.001 
Medicare 78.3 82.3  71.7 71.3  80.1 71.7  
Medicaid 3.0 3.2  4.5 6.5  3.0 5.0  
Private Insurance 15.9 12.4  20.3 19.2  14.5 20.0  
Self-pay 1.1 1.0  1.6 1.6  1.0 1.5  
No charge 0.0 0.1  0.2 0.2  0.1 0.2  
Other 1.7 0.9  1.7 1.2  1.3 1.6  
Median Household 
Income (Percentile), % 
  <0.001   <0.001   <0.001 
0-25th 23.3 27.2  25.5 29.5  24.9 26.5  
26-50th 26.2 27.2  26.3 26.9  26.6 26.5  
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p-value CRT-P CRT-D 
p-
value 
51-75th 26.7 24.8  25.3 23.5  25.9 24.8  
76-100th 23.9 20.9  22.9 20.1  22.7 22.2  
Hospital bed size, %   <0.001   <0.001   <0.001 
Small 9.4 10.8  8.5 8.1  10.0 8.4  
Medium 19.6 19.1  18.4 19.7  19.4 18.7  
Large 71.0 70.1  73.1 72.2  70.6 72.9  
Hospital Region, %   <0.001   <0.001   <0.001 
Northeast 15.8 14.3  20.7 19.6  15.0 20.4  
Midwest 28.6 29.2  25.1 25.9  29.1 25.5  
South 39.0 40.3  37.4 38.9  39.5 37.7  
West 16.6 16.2  16.9 15.6  16.3 16.3  
Location/ Teaching status, 
% 
  <0.001   <0.001   <0.001 
Rural 5.4 6.5  3.3 3.2  5.8 3.2  
Urban non-teaching 32.7 33.1  35.4 34.1  32.8 35.0  
Urban- teaching 61.9 60.4  61.4 62.7  61.4 61.8  
Comorbidities, %          
All-cause infection* 2.5 1.9 <0.001 1.8 1.6 <0.001 2.2 1.7 <0.001 
Cardiac Arrest 1.6 1.4 0.086 2.1 2.5 <0.001 1.5 2.2 <0.001 
Shock 1.7 1.5 0.032 1.9 1.6 <0.001 1.6 1.8 <0.001 
LBBB 73.3 70.4 <0.001 76.0 74.1 <0.001 74.6 72.8 <0.001 
Atrial Fibrillation 52.0 58.3 <0.001 36.7 29.2 <0.001 54.7 34.8 <0.001 
Ventricular Tachycardia 10.2 6.0 <0.001 29.3 22.1 <0.001 8.4 27.4 <0.001 
Ventricular Fibrillation 0.9 0.8 0.712 3.9 4.1 0.017 0.8 3.9 <0.001 
Anaemias 12.8 15.6 <0.001 9.2 11.7 <0.001 9.6 12.5 <0.001 
Coagulation disorders 6.2 4.1 <0.001 4.1 3.0 <0.001 4.4 3.3 <0.001 
Diabetes 29.0 27.1 0.015 33.4 34.1 0.063 32.9 32.7 0.576 
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p-value CRT-P CRT-D 
p-
value 
Hypertension 57.1 61.4 <0.001 56.3 56.4 0.696 58.9 56.4 <0.001 
Renal failure (chronic) 22.0 18.5 <0.001 20.2 15.9 <0.001 20.6 19.1 <0.001 
Peripheral vascular 
disease 
9.5 6.7 <0.001 9.7 6.7 <0.001 8.3 8.9 <0.001 
Valvular heart disease 1.1 1.4 <0.001 0.6 0.8 <0.001 1.2 0.6 <0.001 
Previous AMI 13.2 9.0 <0.001 23.9 15.5 <0.001 11.5 21.7 <0.001 
History of IHD 58.9 41.4 <0.001 72.1 52.2 <0.001 51.6 66.7 <0.001 
Previous PCI 10.2 8.1 <0.001 13.0 9.5 <0.001 9.4 12.1 <0.001 
Previous CABG 19.7 8.9 <0.001 26.1 12.6 <0.001 15.2 22.4 <0.001 
Previous CVA 4.4 5.3 <0.001 3.6 3.5 0.161 4.8 3.6 <0.001 
Dyslipidaemia 39.6 38.4 0.001 42.7 38.5 <0.001 39.2 41.6 <0.001 




22.1 21.7 0.569 21.2 22.6 <0.001 21.3 22.4 0.001 
Hypothyroidism 8.7 21.0 <0.001 7.1 15.2 <0.001 13.9 9.3 <0.001 
RA/collagen vascular 
diseases 
1.6 3.5 <0.001 1.1 2.9 <0.001 2.4 1.6 <0.001 
Liver disease 1.1 0.8 <0.001 1.1 0.8 <0.001 1.0 1.0 0.679 
Fluid and electrolyte 
disturbances 
16.2 19.1 <0.001 12.8 14.7 <0.001 17.5 13.3 <0.001 
Malignancies* 3.0 2.0 <0.001 1.5 1.3 0.066 1.7 1.3 0.017 
Dementia 1.0 1.1 0.233 0.3 0.3 0.320 1.1 0.3 <0.001 
*including haematological malignancies (e.g., lymphoma and leukaemia); CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or - defibrillator, respectively; 
IQR: interquartile range; AMI: acute myocardial infarction; IHD: ischemic heart disease; CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; 
CAD: coronary artery disease; LBBB: left bundle branch block 
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of CRT-D (age (years) 61-70: OR 0.77 95% CI 0.74, 0.80; 71-80: OR 0.52 95% CI 0.50- 
0.54; >80: OR 0.22 95% CI 0.21 - 0.23], p<0.001 for all). (Figure 4.3) 
Figure 4.3. Patient-related (A) and non-patient-related (B) predictors of receipt of 





Legend: *reference is male sex; § non-significant; † p<0.05; ‡ p<0.001; CI: confidence interval; OR: odds 
ratio; CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or - defibrillator, respectively.  
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 Comorbidities such as previous cardiovascular disease (AMI and CABG), previous 
cardiac arrest and ventricular arrhythmias (VT and VF) also favoured the receipt of CRT-
D while history of AF, anaemia (deficiency and chronic), renal failure and malignancies 
were associated with reduced odds of receipt of CRT-D. (Table 4.2, Figure 4.3). 
Furthermore, patients admitted to urban hospitals (teaching and non-teaching) and hospitals 
with a bigger bed capacity (medium and large) were more likely to receive CRT-D. 
Table 4.2. Multivariable analysis of predictors of receipt of CRT-D Device* 
Predictor OR [95% CI] p-value 
Female sex 0.66 [0.64, 0.67] <0.001 
Age (Years)   
≤60 (reference) - - 
61-70 0.77 [0.74, 0.80] <0.001 
71-80 0.52 [0.50, 0.54] <0.001 
>80 0.22 [0.21, 0.23] <0.001 
Primary payer   
Medicare (reference)  - - 
Medicaid 1.03 [0.98, 1.09] 0.304 
Private Insurance 0.94 [0.91, 0.97] <0.001 
Self-pay 0.92 [0.84, 1.00] 0.057 
No charge 1.33 [0.99, 1.78] 0.059 
Shock 1.01 [0.93, 1.08] 0.887 
Cardiac Arrest 1.09 [1.01, 1.18] 0.027 
Ventricular Tachycardia 4.09 [3.97, 4.22] <0.001 
Ventricular Fibrillation 4.37 [3.99, 4.79] <0.001 
Dyslipidaemia 1.04 [1.02, 1.06] <0.001 
Atrial Fibrillation 0.53 [0.52, 0.54] <0.001 
Thrombocytopenia 0.82 [0.74, 0.90] <0.001 
Previous AMI 1.56 [1.52, 1.61] <0.001 
Previous PCI 0.95 [0.92, 0.98] <0.001 
Previous CABG 1.21 [1.17, 1.24] <0.001 
Previous CVA 0.89 [0.85, 0.93] <0.001 
Family history of CAD 1.01 [0.95, 1.07] 0.771 
Alcohol abuse 0.97 [0.89, 1.05] 0.417 
Deficiency anaemias 0.84 [0.82, 0.87] <0.001 
Chronic blood loss anaemia 0.85 [0.76, 0.95] 0.006 
RA/collagen vascular 
diseases 
0.81 [0.76, 0.86] <0.001 
Chronic pulmonary disease 0.94 [0.91, 0.96] <0.001 
Coagulopathy 1.00 [0.92, 1.09] <0.001 
Depression 0.87 [0.83, 0.91] <0.001 
Diabetes 1.11 [1.09, 1.14] <0.001 
Diabetes with complications 1.04 [0.99, 1.09] 0.129 
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Drug abuse 1.06 [0.93, 1.20] 0.413 
Hypertension 0.94 [0.92, 0.96] <0.001 
Hypothyroidism 0.89 [0.86, 0.91] <0.001 
Liver disease 0.88 [0.80, 0.97] 0.008 
Lymphomas 0.65 [0.59, 0.72] <0.001 
Fluid and electrolyte disturbances 0.83 [0.81, 0.85] <0.001 
Metastatic cancer 0.52 [0.44, 0.62] <0.001 
Other neurological disorders 0.80 [0.76, 0.84] <0.001 
Obesity 0.91 [0.88, 0.94] <0.001 
Paralysis 0.89 [0.81, 0.99] 0.024 
Peripheral vascular disease 0.99 [0.96, 1.03] 0.726 
Psychoses 0.82 [0.75, 0.89] <0.001 
Pulmonary circulation disorder 0.54 [0.47, 0.62] <0.001 
Renal failure (chronic) 0.89 [0.85, 0.96] 0.002 
Solid tumour without metastases 0.76 [0.70, 0.83] <0.001 
Valvular heart disease 0.81 [0.74, 0.90] <0.001 
Weight loss 0.64 [0.60, 0.69] <0.001 
Dementia 0.53 [0.47, 0.60] <0.001 
Hospital bed size   
Small (reference) - - 
Medium 1.19 [1.15, 1.23] <0.001 
Large 1.26 [1.23, 1.31] <0.001 
Hospital Region   
Northeast (reference) - - 
Midwest 0.65 [0.63, 0.67] <0.001 
South 0.66 [0.64, 0.68] <0.001 
West 0.74 [0.72, 0.77] <0.001 
Location/ Teaching status   
Rural (reference) - - 
Urban non-teaching 1.96 [1.87, 2.05] <0.001 
Urban- teaching 1.72 [1.65, 1.80] <0.001 
*Indicator is receipt of CRT-P adjusting for the above variables and calendar year.  
As an example, odds ratio of 0.56 favours receipt of CRT-P over CRT-D; CI: Confidence Interval; 
OR: Odds ratio; CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or - defibrillator, 
respectively; IQR: interquartile range; AMI: acute myocardial infarction; CABG: coronary artery 










Figure 4.4. Odds ratios (OR) of receipt of CRT-D (vs. CRT-P) in females* 
 
Legend: *reference is male sex; CI: confidence interval; CRT-P & CRT-D: cardiac resynchronization 
therapy - pacemaker or - defibrillator, respectively; p>0.05 (non-significant for trend) 
 
5. Discussion 
My analysis is the first to examine patient-related predictors of the choice of CRT 
device type offered to patients undergoing de novo implantation. Among these patient 
predictors was sex, with females shown to be independently associated with increased 
likelihood of receipt of CRT-P (vs. CRT-D) as were older age (>60 years), history of 
malignancy, anaemia and renal failure. I also identify sociodemographic differences in the 
type of CRT device offered to patients, with those in certain regions (e.g., North-East of 
the US), urban and larger bed hospitals more likely to receive CRT-D than CRT-P.  
In my analysis several factors were predictive of receipt of CRT-D over CRT-P in 
a contemporary cohort of hospitalizations. Some of these showed similarity to the findings 
from the ESC Survey II which also reported factors such as male sex and admission to a 
university hospital as favouring a CRT-D device as well as AF favouring a CRT-P device. 
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8 However, their study did not examine many variables that were included in my analysis 
and was also based on a modest number of patients (approximately 11% of all European 
patients undergoing the procedure), making their findings less reflective of the wider 
practice amongst operators. Furthermore, younger patients (≤75 years) were more likely to 
receive a CRT-P device in the ESC survey, whereas my findings demonstrate that the odds 
of receipt of CRT-D decline from the age of 60 years. Several other factors were shown to 
inversely correlate with the odds of receipt of CRT-D in my analysis that were not 
systematically examined in the ESC Survey or other previous literature such as history of 
malignancy, renal failure and anaemia. I also demonstrate regional differences in the 
practice of operators in the US, where patients managed in regions other than the Northeast, 
and those admitted to smaller and rural hospitals were significantly less likely to receive 
CRT-D devices. Furthermore, my findings suggest that those privately insured were less 
likely to be offered a CRT-D device whereas no difference was found in choice between 
other primary payer groups. 
While the disparity in receipt of CRT-D between sexes has been previously reported 
in some studies, 41, 103 these were subject to certain limitations (e.g., selected population, 
unadjusted analyses) and, therefore, insufficiently powered to ascertain whether such 
differences do exist. Furthermore, it was unclear whether such differences, if any, have 
persisted over the years. The ESC Survey II reported lower utilisation of CRT-D (vs. CRT-
P) in females compared with males in their survey of more than 10000 CRT implantations 
in Europe.8 Similarly, in a study more than 300,000 CRT-D implantation procedures (2006-
2012), females were also shown to be less likely to receive CRT-D.104  However, their trend 
analysis only included crude rates without adjustment for any differences in patient or 
procedural characteristics between sexes. My study examines trends over a longer period 
(2004-2014) and demonstrates that females persistently less likely to receive a CRT-D 
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device compared to CRT-P over an eleven-year horizon, even after adjustment for baseline 
differences between the sexes. Several reasons could justify the lower rate of utilisation of 
CRT-D in females compared with males, including the overall lower rate of referral for 
CRT in females as well as their more superior response to CRT therapy with higher levels 
of reverse LV remodelling, making them at a lower risk of ventricular arrhythmias that 
would require defibrillation.105-107 Furthermore, lower utilisation of CRT-D therapy in 
females may be related to patient preference, with females more likely to be concerned 
about their body image, especially that CRT-D devices are bulkier and more obvious in the 
chest region, as well as their greater fear of shock therapy compared with males as 
demonstrated in one study.108 
Limitations 
There are several limitations to my analysis. First, the analysis was derived from a 
large administrative clinical dataset that is coded according to the ICD-9 manual. Coding 
inaccuracies are possible, although the use of ICD-9 codes have been previously shown to  
in particular has been previously validated studies in studies examining cardiovascular and 
specifically CIED cohorts.109-111 Second, I was unable to capture the following variables as 
they are coded in ICD-9: LV ejection fraction, aetiology of heart failure, and QRS duration, 
meaning that they were not adjusted for in my models. Finally, information on patient 
preference for device type as well as operator experience were not available, and these 
could have played a role in the choice of device implanted. 
6. Summary 
My analysis shows that age and female sex negatively correlate with the likelihood 
of receipt of CRT-D (vs. CRT-P). Several other patient comorbidities such as atrial 
fibrillation, malignancies, renal failure favour the receipt of CRT-P over CRT-D while a 
history of ischemic heart disease, cardiac arrest or ventricular arrhythmias favour the 
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receipt of CRT-D.  These findings inform operators of the current practice in choice of 
CRT type, as well as highlight the disparity in receipt of CRT-D between sexes in a real-
world national procedural cohort of de novo CRT implantations.
 








Chapter 5. Sex differences in de novo 
CIED implantation outcomes 
The work in this chapter relates to the second phase of my thesis and is based on my study 
published in the Canadian Journal of Cardiology (Appendix 2). 112 
1. Introduction 
There has been a growing interest in the study of sex differences in outcomes of cardiovascular 
procedures in recent years. Previous studies in procedures such as percutaneous coronary 
intervention, coronary artery bypass grafting and transcatheter aortic valve replacement have 
shown a disparity in clinical outcomes between sexes. 113-117 
Females undergoing CIED implantation are believed to be at a higher baseline risk of 
procedure-related complications, compared to males, due to anatomical differences such as 
their smaller chest wall size, smaller and thinner vasculature, thinner right ventricular walls, 
and lower body weight, all of which have been previously described as risk factors for 
procedure-related complications. 53, 118-120 However, these risks could be higher in patients 
receiving more complex devices such as cardiac resynchronisation therapy with defibrillator 
(CRT-D) or pacemaker (CRT-P) and implantable cardioverter defibrillators (ICD) than those 
receiving simple permanent pacemakers (PPM). While some previous studies have examined 
sex differences in procedural outcomes of cardiac implantable electronic device (CIED) 
implantations, their analyses lacked sufficient granularity to allow generalizability of their 
findings to the entire target population.44, 55, 63, 91, 121 For example, some studies compared 
gender outcomes in specific device cohorts (e.g., ICD only) or examined the effect of sex in 
the overall CIED implantation cohort without differentiation between CIED types despite the 
difference in risk profiles of patients undergoing each type of device. Furthermore, there has 




My main objectives of this chapter were to study the following: 
a) Sex differences in in-hospital procedural outcomes of de novo CIED implantation 
procedure stratified by type of implanted device.  
b) The trends of these sex differences over an 11-year period.  
3. Methods  
A full description of the methodology relating to all chapters of my thesis is provided in 
Chapter 3.  
a) Data Source 
The data source for this study was the National Inpatient Sample (NIS). Further 
information on its structure and validation has been provided in Chapter 3 and also 
described in Chapter 4 under the same heading.  
b) Study Design and Population 
I included all adults (≥18 years) undergoing de novo CIED implantation procedures 
between 2004 and 2014 (PPM, CRT-P, CRT-D, and ICD) in my analysis. I excluded any 
records with missing data for the following variables: age, sex, elective (vs. urgent) 
admission, primary payer, median household income, and hospital bed size/location (Flow 
diagram in Figure 5.1). Missing records that were excluded represented less than 3% 
(n=18,321) of the original dataset. The final study cohort was stratified according to sex 
and further by CIED type. 
All procedural information and patient characteristics other than Elixhauser 
comorbidities, as well as clinical outcomes were extracted using the International 
Classification of Diseases, ninth revision (ICD-9) procedure and diagnosis codes provided 








The primary outcomes were in-hospital major acute cardiovascular events 
(MACE), all-cause mortality and procedural-related complications (bleeding, thoracic and 
cardiac). MACE was defined as a composite of all-cause mortality, cardiac complications, 
thoracic complications and device-related infection. Procedure-related bleeding was 
defined as any post-procedural haemorrhage or post haemorrhagic anaemia according to 
ICD-9 diagnosis codes (998.11 and 285.1). Cardiac complications were defined as a 
composite of cardiac tamponade, hemopericardium, pericardial effusion and 
pericardiocentesis while thoracic complications included any acute pneumothorax or 
haemothorax (with or without chest drainage drainage) or thoracic vascular injury.  
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d) Statistical analysis 
Descriptive statistics were performed as previously explained in Chapter 3. 
Sampling weights provided by the AHRQ were applied to all analyses. All statistical 
analyses were performed using SPSS version 24 (IBM Corp, Armonk, NY).  
I performed trend analysis using linear regression models with the inclusion of time 
(in years) for assessing sex differences in outcomes over time. I also performed 
multivariable logistic regression modelling to examine the adjusted odds ratio (aOR [95% 
confidence interval]) of in-hospital adverse outcomes in females using males as the 
reference category, adjusting for the following variables: age, weekend admission, primary 
expected payer, median household income, dyslipidaemia, smoking status, previous acute 
myocardial infarction (AMI), previous coronary artery bypass graft (CABG), history of 
ischemic heart disease (IHD), previous percutaneous coronary intervention (PCI), previous 
cerebrovascular accidents including stroke and transient ischemic attacks (CVA), family 
history of coronary artery disease (CAD), thrombocytopenia, history of cardiac arrest, atrial 
fibrillation (AF), ventricular tachycardia and fibrillation (VF and VT respectively), all-
cause infection and Elixhauser comorbidities (acquired immune deficiency syndrome, 
alcohol abuse, deficiency anaemias, chronic blood loss anaemia, rheumatoid 
arthritis/collagen vascular diseases, congestive heart failure, chronic pulmonary disease, 
coagulopathy, depression, diabetes (uncomplicated), diabetes with chronic complications, 
drug abuse, hypertension, hypothyroidism, liver disease, lymphoma, fluid and electrolyte 
disorders, metastatic cancer, other neurological disorders, obesity, peripheral vascular 
disorders, psychoses, pulmonary circulation disorders, renal failure, solid tumour without 
metastasis, valvular heart disease, weight loss, bed size of hospital, location/teaching status 




There was a total of 2,815,613 hospitalization records for de novo CIED 
implantation in the United States between 2004 and 2014. Females represented 41.9% 
(n=1,178,492) of the cohort and their prevalence increased over the study period in all 
device groups other than PPM (PPM: 49.5% in 2004 to 50.7% in 2014). (Figure 5.2). 
Figure 5.2 Proportion of females undergoing CIED implantation procedures 
according to type of CIED (2004-2014) 
 
Legend: p-values are for trends 
 
There were several baseline differences in patient characteristics between males and 
females in the total CIED cohort (Table 5.1). Females were older (median 77 vs. 73 years), 
less likely to be admitted electively, with a lower prevalence of cardiac risk factors 
including dyslipidaemia, history of IHD, previous AMI and PCI, VF, VT, renal failure and 
shock. In contrast, males had a lower prevalence of AF, hypothyroidism, hypertension, 
previous CVA and deficiency anaemias. The pattern of differences in characteristics 
between sexes was consistent across the different device groups (PPM, CRT-P, CRT-D and 
ICD). (Tables 5.2 and 5.3) 
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Number of weighted 
discharges 
1637121 1178492 2815613 <0.001 
Type of CIED, %    <0.001 
PPM 53.2 74.7 62.2  
CRT-P 2.4 2.3 2.3  
CRT-D 16.7 8.7 13.3  
ICD 27.7 14.2 22.1  
Age (years), median (IQR) 73 (63, 81) 77 (68,84) 75 (65,82) <0.001 
Ethnicity, %    <0.001 
White 79.9 77.6 78.9  
Black 8.8 10.8 9.6  
Hispanic 6.4 6.6 6.5  
Asian/Pacific Islander 1.8 2.1 1.9  
Native American 0.5 0.5 0.5  
Other 2.6 2.3 2.5  
Elective Admission, % 33.5 26.9 30.8 <0.001 
Weekend admission, % 14.1 16.6 15.1 <0.001 
Primary expected payer, %    <0.001 
Medicare 71.2 78.6 74.3  
Medicaid 4.2 4.5 4.4  
Private Insurance 20.4 14.2 17.9  
Self-pay 1.9 1.3 1.7  
No charge 0.2 0.2 0.2  
Other 2.0 1.1 1.6  
Median Household Income 
(Percentile), % 
   <0.001 
0-25th 24.9 27.0 25.8  
26-50th 26.3 26.9 26.6  
51-75th 24.8 24.0 24.5  
76-100th 24.0 22.1 23.2  
Shock, % 1.5 1.2 1.4 <0.001 
All-cause infection, %* 2.5 2.4 2.5 0.198 
Cardiac Arrest, % 3.7 3.7 3.7 0.612 
Ventricular Tachycardia, 
% 
20.1 10.2 16.0 <0.001 
Ventricular Fibrillation, % 3.8 2.5 3.2 <0.001 
Comorbidities, %     
Dyslipidaemia 43.9 39.7 42.1 <0.001 
Smoking 8.8 5.5 7.4 <0.001 
Atrial Fibrillation 36.0 41.3 38.2 <0.001 
Thrombocytopaenia 3.7 2.8 3.3 <0.001 
Previous AMI 16.9 8.8 13.5 <0.001 
History of IHD 57.6 37.5 49.2 <0.001 









Previous CABG 18.5 7.5 13.9 <0.001 
Previous CVA 4.1 4.9 4.5 <0.001 
Family history of CAD 2.8 2.5 2.7 <0.001 
AIDS 0.1 0.0 0.1 <0.001 
Alcohol abuse 2.8 0.6 1.9 <0.001 
Deficiency anaemias 11.3 15.4 13.0 <0.001 
Chronic Blood loss anaemia 0.6 0.9 0.7 <0.001 
RA/collagen vascular 
diseases 
1.2 3.2 2.1 <0.001 
Heart Failure 46.3 40.2 43.8 <0.001 
Chronic pulmonary disease 19.1 19.1 19.1 0.103 
Coagulopathy 4.8 4.0 4.5 <0.001 
Depression 4.3 8.0 5.8 <0.001 
Diabetes 25.7 23.9 24.9 <0.001 
Diabetes with complications 4.6 4.4 4.5 <0.001 
Drug abuse 1.1 0.6 0.9 <0.001 
Hypertension 62.5 67.0 64.3 <0.001 
Hypothyroidism 7.6 20.0 12.8 <0.001 
Liver disease 1.2 1.0 1.1 <0.001 
Lymphomas 0.7 0.6 0.6 <0.001 
Fluid and electrolyte 
disturbances 
15.3 20.7 17.5 <0.001 
Metastatic cancer 0.5 0.4 0.5 <0.001 
Other neurological disorders 5.4 6.9 6.0 <0.001 
Obesity 8.2 9.4 8.7 <0.001 
Paralysis 1.5 1.6 1.5 <0.001 
Peripheral vascular disease 9.8 7.6 8.9 <0.001 
Psychoses 1.5 2.1 1.8 <0.001 
Pulmonary circulation 
disorder 
0.5 0.8 0.6 <0.001 
Renal failure (chronic) 17.0 14.7 16.0 <0.001 
Solid tumour without 
metastases 
1.5 0.9 1.2 <0.001 
Valvular heart disease 1.2 1.7 1.4 <0.001 
Weight loss 1.9 2.3 2.0 <0.001 
Dementia 1.7 2.7 2.1 <0.001 
Hospital bed size, %    <0.001 
Small 8.5 9.2 8.8  
Medium 21.3 22.6 21.8  
Large 70.2 68.2 69.4  
Hospital Region, %    <0.001 
Northeast 21.5 21.1 21.4  
Midwest 23.3 24.0 23.6  
South 37.0 37.8 37.3  









Location/ Teaching status, 
% 
   <0.001 
Rural 6.0 7.4 6.6  
Urban non-teaching 40.1 41.8 40.8  
Urban- teaching 53.9 50.8 52.6  






Table 5.2 Patient characteristics of patients undergoing permanent pacemaker (PPM) and implantable cardioverter defibrillator (ICD) 
implantation 












Number of weighted discharges 873600 881748 1755438 <0.001 452788 166801 619589 <0.001 















Ethnicity, %    <0.001    <0.001 
White 82.9 80.3 81.6  74.1 66.6 72.1  
Black 6.4 8.4 7.4  13.2 20.6 15.2  
Hispanic 6.0 6.3 6.1  7.5 7.7 7.6  
Asian/Pacific Islander 2.0 2.3 2.2  1.7 1.6 1.7  
Native American 0.4 0.5 0.5  0.6 0.5 0.6  
Other 2.3 2.1 2.2  3.0 2.9 3.0  
Elective Admission, % 25.6 22.0 23.8 <0.001 38.0 35.4 37.3 <0.001 
Weekend admission, % 16.7 18.2 17.4 <0.001 12.6 13.7 12.9 <0.001 
Primary expected payer, %    <0.001    <0.001 
Medicare 78.0 83.5 80.8  57.8 57.4 57.7  
Medicaid 2.6 3.1 2.9  7.1 10.7 8.1  
Private Insurance 16.2 11.4 13.7  29.0 26.9 28.4  
Self-pay 1.4 1.0 1.2  3.1 2.8 3.0  
No charge 0.1 0.1 0.1  0.4 0.3 0.4  
Other 1.7 0.9 1.3  2.6 1.8 2.4  
Median Household Income 
(Percentile), % 
   <0.001    <0.001 
0-25th 23.8 26.0 24.9  26.5 30.3 27.5  
26-50th 26.5 27.0 26.7  26.0 26.1 26.1  
51-75th 24.8 24.2 24.5  24.4 23.2 24.1  
76-100th 24.9 22.7 23.8  23.1 20.4 22.4  
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Shock, % 0.9 0.8 0.9 0.016 2.5 2.6 2.5 0.014 
All-cause infection, %* 2.7 2.5 2.6 <0.001 2.4 2.8 2.5 <0.001 
Cardiac Arrest, % 2.9 3.0 3.0 0.137 6.3 8.4 6.8 <0.001 
Ventricular Tachycardia, % 4.1 3.0 3.6 <0.001 46.3 41.2 44.9 <0.001 
Ventricular Fibrillation, % 0.5 0.4 0.4 <0.001 10.3 12.8 10.9 <0.001 
Comorbidities, %         
Dyslipidaemia 43.8 40.2 42.0 <0.001 45.4 38.0 43.4 <0.001 
Smoking 7.2 4.5 5.9 <0.001 12.4 10.5 11.9 <0.001 
Atrial Fibrillation 39.8 45.7 42.7 <0.001 27.2 23.2 26.2 <0.001 
Thrombocytopenia 4.1 3.0 3.5 <0.001 3.0 2.6 2.9 <0.001 
Previous AMI 9.1 6.1 7.6 <0.001 28.3 19.1 25.8 <0.001 
History of IHD 45.7 32.4 39.0 <0.001 71.9 54.5 67.2 <0.001 
Previous PCI 9.4 6.1 7.7 <0.001 15.5 10.8 14.2 <0.001 
Previous CABG 14.6 6.1 10.3 <0.001 21.6 11.7 18.9 <0.001 
Previous CVA 4.8 5.3 5.1 <0.001 3.1 3.4 3.2 <0.001 
Family history of CAD 2.5 2.4 2.4 <0.001 3.6 3.2 3.5 <0.001 
Alcohol abuse 2.4 0.5 1.4 <0.001 3.9 1.5 3.2 <0.001 
Deficiency anaemias 13.3 16.2 14.8 <0.001 8.7 13.5 10.0 <0.001 
Chronic Blood loss anaemia 0.8 0.9 0.9 <0.001 0.5 0.8 0.6 <0.001 
RA/collagen vascular 
diseases 
1.4 3.3 2.3 <0.001 1.0 3.1 1.5 <0.001 
Heart Failure 24.1 28.8 26.4 <0.001 60.0 62.8 60.8 <0.001 
Chronic pulmonary disease 18.1 17.8 17.9 <0.001 19.9 23.3 20.8 <0.001 
Coagulopathy 5.3 4.1 4.7 <0.001 4.2 3.9 4.1 <0.001 
Depression 4.8 8.2 6.5 <0.001 3.8 7.9 4.9 <0.001 
Diabetes 24.1 22.7 23.4 <0.001 26.7 26.6 26.7 0.579 
Diabetes with complications 4.9 4.3 4.6 <0.001 4.4 5.0 4.6 <0.001 
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Drug abuse 0.7 0.4 0.5 <0.001 2.0 1.7 1.9 <0.001 
Hypertension 66.6 70.3 68.5 <0.001 58.8 57.3 58.4 <0.001 
Hypothyroidism 9.0 21.9 15.5 <0.001 5.2 13.3 7.4 <0.001 
Liver disease 1.1 0.9 1.0 <0.001 1.3 1.2 1.3 <0.001 
Lymphomas 0.8 0.6 0.7 <0.001 0.5 0.6 0.5 <0.001 
Fluid and electrolyte 
disturbances 
16.5 21.7 19.1 <0.001 14.2 19.3 15.6 <0.001 
Metastatic cancer 0.7 0.5 0.6 <0.001 0.2 0.2 0.2 0.054 
Other neurological disorders 7.4 7.9 7.6 <0.001 3.5 4.5 3.8 <0.001 
Obesity 7.6 8.8 8.2 <0.001 9.1 11.9 9.9 <0.001 
Paralysis 1.9 1.8 1.9 <0.001 1.1 1.2 1.1 <0.001 
Peripheral vascular disease 10.0 7.7 8.8 <0.001 9.6 7.7 9.1 <0.001 
Psychoses 1.8 2.2 2.0 <0.001 1.3 2.3 1.6 <0.001 
Pulmonary circulation disorder 0.6 0.9 0.7 <0.001 0.3 0.5 0.4 <0.001 
Renal failure (chronic) 16.7 14.5 15.6 <0.001 15.5 14.2 15.1 <0.001 
Solid tumour without metastases 2.1 0.9 1.5 <0.001 0.9 0.7 0.8 <0.001 
Valvular heart disease 1.6 1.9 1.8 <0.001 0.8 1.2 0.9 <0.001 
Weight loss 2.2 2.4 2.3 <0.001 1.6 2.1 1.7 <0.001 
Dementia 2.9 3.4 3.2 <0.001 0.4 0.5 0.4 <0.001 
Hospital bed size, %    <0.001    <0.001 
Small 9.5 9.7 9.6  6.6 6.8 6.7  
Medium 23.4 23.7 23.6  19.2 19.6 19.3  
Large 67.1 66.6 66.9  74.2 73.6 74.1  
Hospital Region, %    <0.001    <0.001 
Northeast 21.5 21.5 21.5  22.9 21.6 22.6  
Midwest 22.7 23.5 23.1  23.5 24.6 23.8  
South 36.4 37.3 36.9  37.5 38.3 37.7  
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West 19.4 17.6 18.5  16.0 15.5 15.9  
Location/ Teaching status, %    <0.001    <0.001 
Rural 8.0 8.5 8.3  3.6 3.4 3.5  
Urban non-teaching 44.7 44.5 44.6  34.8 33.9 34.5  
Urban- teaching 47.3 47.0 47.1  61.6 62.8 61.9  















Table 5.3 Patient Characteristics of the cardiac resynchronization therapy implantation groups 












Number of weighted 
discharges 
38597 27539 66136 <0.001 272136 102404 374540 <0.001 
Age (years), median (IQR) 
77 (68, 
83) 
78 (69, 84) 
77 (69, 
83) 






Ethnicity, %    <0.001    <0.001 
White 84.1 81.5 83.0  80.2 72.3 78.0  
Black 6.4 8.9 7.4  9.3 15.8 11.1  
Hispanic 5.3 5.4 5.3  6.1 7.4 6.5  
Asian/Pacific Islander 1.2 1.4 1.3  1.3 1.3 1.3  
Native American 0.7 0.7 0.7  0.5 0.6 0.5  
Other 2.3 2.0 2.2  2.6 2.6 2.6  
Elective Admission, % 44.7 43.1 44.0 <0.001 50.4 50.3 50.4 0.718 
Weekend admission, % 11.1 10.7 10.9 0.07 9.0 8.9 9.0 0.543 
Primary expected payer, %    <0.001    <0.001 
Medicare 78.3 82.6 80.1  71.9 71.4 71.7  
Medicaid 2.9 3.1 3.0  4.4 6.5 5.0  
Private Insurance 16.0 12.3 14.5  20.3 19.3 20.1  
Self-pay 1.1 1.0 1.0  1.5 1.5 1.5  
No charge 0.0 0.1 0.1  0.2 0.2 0.2  
Other 1.6 0.9 1.3  1.7 1.2 1.5  
Median Household Income 
(Percentile), % 
   <0.001    <0.001 
0-25th 23.2 27.1 24.8  25.4 29.4 26.5  
26-50th 26.2 27.2 26.6  26.3 26.8 26.4  
51-75th 26.6 24.9 25.9  25.4 23.5 24.9  
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76-100th 24.0 20.9 22.7  23.0 20.2 22.2  
Shock, % 1.7 1.4 1.6 0.017 1.9 1.6 1.8 <0.001 
All-cause infection, %* 2.5 1.8 2.2 <0.001 1.8 1.6 1.7 <0.001 
Cardiac Arrest, % 1.6 1.4 1.5 <0.001 2.1 2.5 2.2 <0.001 
Ventricular Tachycardia, 
% 
10.2 6.0 8.4 <0.001 29.3 22.1 27.4 <0.001 
Ventricular Fibrillation, % 0.8 0.8 0.8 0.663 3.9 4.1 3.9 0.003 
Comorbidities, %         
Dyslipidaemia 39.6 38.4 39.1 0.002 42.7 38.6 41.6 <0.001 
Smoking 5.1 3.7 4.5 <0.001 7.7 6.1 7.2 <0.001 
Atrial Fibrillation 52.0 58.5 54.7 <0.001 36.8 29.4 34.8 <0.001 
Thrombocytopenia 4.9 3.1 4.1 <0.001 3.1 2.0 2.8 <0.001 
Previous AMI 13.3 9.0 11.5 <0.001 24.0 15.5 21.7 <0.001 
History of IHD 59.0 41.3 51.6 <0.001 72.2 52.2 66.7 <0.001 
Previous PCI 10.3 8.1 9.4 <0.001 13.0 9.5 12.1 <0.001 
Previous CABG 19.7 8.8 15.2 <0.001 26.2 12.5 22.4 <0.001 
Previous CVA 4.4 5.3 4.8 <0.001 3.6 3.5 3.5 0.452 
Family history of CAD 2.2 2.7 2.4 <0.001 2.7 2.9 2.7 <0.001 
Alcohol abuse 1.9 0.4 1.3 <0.001 2.2 0.6 1.7 <0.001 
Deficiency anaemias 12.6 15.0 13.6 <0.001 9.0 11.4 9.7 <0.001 
Chronic Blood loss anaemia 0.5 0.9 0.7 <0.001 0.5 0.5 0.5 0.018 
RA/collagen vascular 
diseases 
1.6 3.5 2.4 <0.001 1.1 2.9 1.6 <0.001 
Heart Failure 76.0 75.0 75.6 0.002 90.7 92.1 91.1 <0.001 
Chronic pulmonary disease 21.8 21.0 21.5 0.029 21.0 22.5 21.4 <0.001 
Coagulopathy 6.3 4.1 5.4 <0.001 4.2 3.0 3.8 <0.001 
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Depression 3.8 7.5 5.3 <0.001 3.5 6.4 4.3 <0.001 
Diabetes 24.8 23.6 24.3 <0.001 29.1 29.7 29.2 <0.001 
Diabetes with complications 4.4 3.6 4.0 0.001 4.4 4.4 4.4 0.197 
Drug abuse 0.6 0.3 0.5 <0.001 0.9 0.5 0.8 <0.001 
Hypertension 57.1 61.4 58.9 <0.001 56.3 56.4 56.4 0.600 
Hypothyroidism 8.8 21.1 13.9 <0.001 7.1 15.2 9.3 <0.001 
Liver disease 1.1 0.9 1.0 0.003 1.1 0.8 1.0 <0.001 
Lymphomas 1.1 0.8 1.0 0.001 0.5 0.6 0.6 0.025 
Fluid and electrolyte 
disturbances 
16.2 19.3 17.5 <0.001 12.8 14.6 13.3 <0.001 
Metastatic cancer 0.4 0.4 0.4 0.549 0.1 0.2 0.1 0.337 
Other neurological 
disorders 
4.0 4.1 4.0 0.368 2.5 2.8 2.5 <0.001 
Obesity 7.3 9.1 8.1 <0.001 8.3 10.5 8.9 <0.001 
Paralysis 1.0 0.8 0.9 0.001 0.8 0.9 0.8 0.012 
Peripheral vascular disease 9.5 6.7 8.3 <0.001 9.7 6.7 8.9 <0.001 
Psychoses 1.1 1.4 1.2 0.01 0.9 1.4 1.0 <0.001 
Pulmonary circulation 
disorder 
0.6 0.8 0.7 0.011 0.3 0.3 0.3 0.02 
Renal failure (chronic) 22.0 18.6 20.6 <0.001 20.3 15.9 19.1 <0.001 
Solid tumour without 
metastases 
1.4 0.8 1.2 <0.001 0.8 0.5 0.7 <0.001 
Valvular heart disease 1.1 1.4 1.2 <0.001 0.6 0.8 0.6 <0.001 
Weight loss 2.5 2.5 2.5 0.752 1.3 1.4 1.3 0.047 
Dementia 1.0 1.1 1.1 0.404 0.3 0.3 0.3 0.256 
Hospital bed size, %    <0.001    <0.001 
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Small 9.4 10.9 10.0  8.5 8.0 8.4  
Medium 19.7 19.1 19.4  18.3 19.7 18.7  
Large 70.9 70.1 70.6  73.1 72.3 72.9  
Hospital Region, %    <0.001    <0.001 
Northeast 15.7 14.2 15.1  20.8 19.7 20.5  
Midwest 28.8 29.4 29.1  25.1 25.9 25.3  
South 39.0 40.3 39.5  37.3 38.9 37.8  
West 16.5 16.2 16.4  16.7 15.5 16.4  
Location/ Teaching status, 
% 
   <0.001    <0.001 
Rural 5.3 6.4 5.8  3.2 3.2 3.2  
Urban non-teaching 32.6 33.1 32.8  35.4 34.1 35.0  
Urban- teaching 62.1 60.6 61.4  61.4 62.8 61.8  




In-hospital adverse outcomes 
Overall, the crude rates of all in-hospital adverse events were higher in females than 
males (MACE: 5.6% vs. 4.5%; all-cause mortality: 1.0% vs. 0.9%; procedure-related 
bleeding: 3.2% vs. 2.7%; thoracic complications: 3.8% vs. 2.4%; and cardiac 
complications: 0.5% vs. 0.3%) with the exception of device-related infections, which were 
higher in males (1.1% vs. 0.6%). (Table 5.4, Figure 5.3) Similar differences in outcomes 
were observed between males and females in all device subgroups, with the exception of 
certain outcomes in the CRT groups. The rates of certain adverse outcomes were lower in 
females in the CRT-P group (MACE: 6.6% vs. 7.3%, all-cause mortality: 1.0% vs. 1.6%, 
procedure-related bleeding: 3.3% vs. 3.6%) as well as in the CRT-D group (all-cause 
mortality: 0.6% vs. 0.8%). (Table 5.5, Figure 5.4) 






MACE, %* 4.5 5.6 5.0 <0.001 
All-cause mortality, % 0.9 1.0 1.0 <0.001 
Procedure-related bleeding, % 2.7 3.2 2.9 <0.001 
Thoracic complications, % 2.4 3.8 3.0 <0.001 
Cardiac complications, % 0.3 0.5 0.4 <0.001 
Device-related infection, % 1.1 0.6 0.9 <0.001 
*MACE: Composite of mortality, thoracic complications, cardiac complications, and device-
related infection.  
 
Table 5.5 In-hospital clinical Outcomes according to sex and type of CIED 
Outcome/Study Group  Male Female Total p-value 
MACE, %*     
PPM 4.6 5.8 5.2 <0.001 
CRT-P 7.3 6.6 7.0 0.001 
CRT-D 4.7 5.1 4.8 <0.001 
ICD 4.0 4.8 4.2 <0.001 
All-cause mortality, %     
PPM 1.0 1.2 1.1 <0.001 
CRT-P 1.6 1.0 1.4 <0.001 
CRT-D 0.8 0.6 0.8 <0.001 
ICD 0.6 0.7 0.6 <0.001 
Procedure-related 
bleeding, % 
    
PPM 3.3 3.4 3.4 <0.001 
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Outcome/Study Group  Male Female Total p-value 
CRT-P 3.6 3.3 3.4 0.041 
CRT-D 1.8 2.1 1.9 <0.001 
ICD 2.0 2.5 2.2 <0.001 
Thoracic complications, %     
PPM 2.6 4.0 3.3 <0.001 
CRT-P 4.1 4.4 4.2 0.090 
CRT-D 2.3 3.3 2.6 <0.001 
ICD 2.0 2.9 2.2 <0.001 
Cardiac complications, %     
PPM 0.3 0.4 0.4 <0.001 
CRT-P 0.4 0.6 0.5 0.026 
CRT-D 0.3 0.6 0.3 <0.001 
ICD 0.3 0.6 0.4 <0.001 
Device-related infection, 
%* 
    
PPM 0.9 0.5 0.7 <0.001 
CRT-P 1.8 1.1 1.5 <0.001 
CRT-D 1.6 0.9 1.4 <0.001 
ICD 1.3 0.8 1.2 <0.001 
*MACE: Composite of mortality, thoracic complications, cardiac complications and device-related 
infection; ICD: implantable cardioverter-defibrillator; CRT-P & CRT-D: cardiac resynchronization 
therapy with pacemaker or defibrillator, respectively; PPM: permanent pacemaker 
 
Figure 5.3 In-hospital outcomes of total CIED cohort according to sex 
 
Legend: p<0.001 for all outcomes; MACE: Composite of mortality, thoracic and cardiac complications, 








Figure 5.4 In-hospital outcomes of CIED subtypes according to sex 
 
Legend: § non-significant; † p<0.05; ‡ p<0.001; ICD: automated implantable cardioverter-defibrillator; 
CRT-P & CRT-D: cardiac resynchronization therapy - pacemaker or - defibrillator, respectively; MACE: 
Composite of all-cause mortality, thoracic and cardiac complications, and device-related infection; PPM: 
permanent pacemaker. 
 
After adjustment for baselines differences, females were associated with increased 
odds of MACE (1.17 [1.16, 1.19]) and procedure-related complications (bleeding: 1.13 
[1.12, 1.15], thoracic: 1.42 [1.40, 1.44] and cardiac: 1.44 [1.38, 1.50]), but no difference in 
mortality (0.96 [0.94, 1.00]). (Table 5.6, Figures 5.5 and 5.6) Within the individual device 
groups, female sex was generally associated with increased odds of MACE and procedure-
related complications (bleeding, cardiac and thoracic) but not mortality. One exception was 
the CRT-P group where females experienced reduced odds of MACE (aOR 0.91 [0.85, 
0.97]) and no statistically significant different odds of procedure-related complications 
(aOR bleeding: 1.01 [0.92, 1.11], thoracic: 1.04 [0.95, 1.12] and cardiac: 1.06 [0.84, 1.35]).  
Trend analyses demonstrated persistently increased or worsening odds of MACE 
and procedure-related complications (bleeding, thoracic and cardiac) in females compared 
with males between 2004 and 2014. (Figures 5.7 and 5.8, p<0.001) However, the odds of 
all-cause mortality remained insignificant between sexes throughout the study period. 
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Figure 5.5 Adjusted odds ratio (aOR) of major adverse cardiovascular events 
(MACE) in females (reference is males) 
 
Legend: *p<0.01; † p<0.001; ICD: automated implantable cardioverter-defibrillator; CRT-P & CRT-D: 
cardiac resynchronization therapy - pacemaker or - defibrillator, respectively; MACE: Composite of all-
























Figure 5.6 Adjusted odds ratios (aOR) of all-cause mortality and procedure-related 
complications in females (reference is males) 
 
Legend: † p<0.001; § non-significant; ICD: automated implantable cardioverter-defibrillator; CRT-P & 


























Figure 5.7 Trend of adjusted odds ratios (aOR) of MACE in females compared with 
males (2004-2014)* 
 
Legend: *p<0.001 for trend; MACE: Composite of all-cause mortality, thoracic and cardiac complications, 





















Figure 5.8 Trend of adjusted odds ratios (aOR) of all-cause mortality and 
procedure-related complications in females compared with males (2004-2014)* 
 
Legend: *p<0.001 for all trends
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Table 5.6 Adjusted odds of adverse outcomes in females  
Group/ 
Outcome 








OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 




Male** - - - - - - - - - - 




















Male** - - - - - - - - - - 




















Male** - - - - - - - - - - 

















Male** - - - - - - - - - - 




















Male** - - - - - - - - - - 



















*MACE: Composite of mortality, thoracic complications, cardiac complications and device-related infection; ICD: implantable cardioverter-defibrillator; CRT-P & CRT-




My national-level analysis of de novo CIED implantation procedures in the US is 
the largest to investigate differences in in-hospital outcomes between sexes. I conclude 
several important findings. First, I show that, overall, females are at an increased risk of 
major acute cardiovascular events as well as procedure-related complications after CIED 
implantation, including bleeding and thoracic and cardiac complications. These findings 
were observed across all device groups other than CRT-P, where the odds of MACE were 
lower in females and no difference in postprocedural complications (bleeding, thoracic and 
cardiac) was observed between sexes. Second, I found no difference in all-cause mortality 
between sexes in the overall cohort as well as in the PPM and ICD device groups, whereas 
females were at a lower risk of mortality in the CRT-P and CRT-D groups. Finally, my 
analysis demonstrates that the increased risk of procedure-related complications in females 
has persisted, or for some outcomes worsened, over the eleven-year study period.  
While previous studies have examined the risk of adverse outcomes in females 
undergoing CIED implantation, the current evidence is conflicting, with some studies 
suggesting an increased risk of adverse outcomes in females and some suggesting no 
difference between sexes.23, 55, 59, 60, 62-64, 84, 87, 90 Furthermore, these studies were limited by 
the inclusion of specific cohorts (e.g. heart failure patients) or device types (e.g. ICD only), 
or the analysis of older procedural cohorts, making them less generalisable to current 
practice. 55, 63, 122-126 Additionally, there is a significant variation in procedural outcomes 
examined in many studies with some looking at a composite of any hospital complication 
or specific complications (e.g., mortality) at various timepoints (e.g., 1 year). For example, 
an analysis of more than 77,000 CIED implantation procedures between 2010 and 2014 
from the Japanese Diagnosis Procedure Combination database showed no difference in in-
hospital complications between sexes in the overall cohort (OR 1.09 (0.99-1.21)) and those 
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undergoing non-PPM device implantations (OR 0.88 (0.63-1.23)), with a slight increase in 
the odds of any complication in those receiving PPM (OR 1.12 (1.01-1.25)). 64 However, 
their analysis did not look at individual CIED subtypes other than PPM, nor did it examine 
individual complications (e.g., thoracic or cardiac). In contrast, a study of more than 
160,000 ICD and CRT implantations between 2006 and 2007 from the US National 
Cardiovascular Data Registry (NCDR) ICD registry showed increased odds of in-hospital 
complications among females (OR 1.71 (1.57-1.86)).63 However, these conclusions were 
derived from an outdated cohort that precedes many advances in CIED implantation 
techniques. My national-level analysis of de novo CIED procedures shows an increased 
risk of MACE as well as individual complications (bleeding, thoracic and cardiac) in 
females in the overall CIED cohort. When stratified by device type, I observed similar sex 
differences in the odds of procedure-related complications except in the CRT-P group 
where there were no differences in procedure-related complications between sexes. 
Furthermore, the odds of any in-hospital complication (MACE) in that group was lower in 
females, driven by their lower rates of mortality. One possible explanation for the lack of 
sex differences in this device group is the relatively small sample size compared with other 
device groups, making it insufficiently powered to detect any obvious sex differences in 
that group, especially that there was a signal of increased odds among females for cardiac, 
thoracic and bleeding complications that did not reach statistical significance. 
A limited number of studies have systematically examined sex differences in in-
hospital mortality after CIED implantation across difference CIED groups. My study 
demonstrates no difference in mortality between sexes across all device groups except 
CRT, where females were associated with a lower risk of mortality compared with males. 
My findings confirm those in previous studies, although many of these did not stratify their 
analyses according to CIED type. In an analysis by Moore et al. no difference was observed 
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in in-hospital was observed between sexes (OR 0.99 (0.80-1.22)) in over 81,000 
procedures.91 Similarly, in a study of ~8500 patients aged >65 years undergoing ICD 
implantation from a stratified (5%) sample of the Medicare dataset showed no difference 
in the hazard ratio (HR) of 1-year mortality between sexes (0.97 (0.84–1.12)).59 However, 
this study examined mortality in a specific elderly patient group undergoing implantation 
of a specific type of CIED, making its findings less generalisable to younger patients as 
well as those undergoing implantation of different device types. It is possible that the 
reduced mortality in females undergoing CRT implantation is attributable to their 
favourable response to resynchronisation therapy as demonstrated in previous studies.127 
The lack of difference in mortality between sexes across all other device groups, despite a 
higher risk of procedure-related complications in females as shown in my analysis, suggests 
that mortality is unlikely to be related to the procedure.   
My analysis of in-hospital outcomes after CIED implantation demonstrates a rising 
trend of post-procedural complications (bleeding, thoracic and cardiac) in females over an 
11-year period, which is a finding of concern in light of the significant technical 
advancements in recent years. Several anatomical factors increase the risk of thoracic and 
cardiac complications in females including their smaller thoracic cavities and 
subclavian/axillary vein diameters compared with males, which increase the risk 
pneumothorax, as well as their thinner right ventricle walls which makes the risk of cardiac 
perforation more likely. 53, 118-120 These findings highlight the inherent risk of procedural 
complications in females that warrants further research into technical strategies to 
neutralise the risk. For example, routine ultrasound guided vascular access as well as 
cephalic vein cut down could help reduce these complications in females, as would 
fluoroscopy or ultrasound-guided true septal placement (vs. apical or coronary sinus) of 
right ventricular leads. In a select group of patients, the use of subcutaneous or intracardiac 
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pacemakers could also help reduce these risks, although these are only proposed strategies 
that require validation in future studies.  
Limitations 
The first limitation of my analysis relates to the administrative nature of the dataset 
from which it was performed, which is subject to coding inaccuracies as mentioned in the 
limitations section in Chapter 4. Second, the NIS dataset does not provide information on 
the indication for CIED implantation as well as operator experience. Furthermore, my 
findings should be interpreted as associations and not causal given the observational nature 
of this analysis. Finally, my analysis only focused on in-hospital outcomes and it is possible 
that sex differences in longer-term outcomes may be more pronounced or insignificant. 
6. Summary 
In my analysis of 2.8 million hospitalisations for de novo CIED implantations in 
the United States, I show that female sex is an independent predictor of in-hospital adverse 
outcomes, but not mortality, and that this disparity in outcomes between sexes persisted 
over an 11-year period. These findings warrant further research on new technical and 
technological approaches to mitigate the inherent risk of procedural complications in 
females undergoing de novo CIED implantation.
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Chapter 6. De novo CIED implantation 
outcomes in patients with cancer 
The work in this chapter relates to the second phase of my thesis and is based on my study 
published in Europace journal (Appendix 3).128  
1. Introduction 
The incidence of cancer remains high both in developed countries and worldwide. 
More than 360,000 new cases of cancer were diagnosed in the United Kingdom  (UK) alone 
between 2015 and 2017, making the nation’s incidence rank higher than 90% of the rest of 
the world.129 
There has been a significant evolution in cancer treatments over the years, including 
chemotherapeutics and radiotherapy, which has reflected on the rates of cancer survival. 
However, such therapies are not free from side effects, one of which is cardiotoxicity which 
results in heart failure (HF), cancer-treatment induced arrhythmias (CTIA) and myocardial 
ischaemia. 130-132 These adverse events are more likely to occur in patients with pre-existing 
cardiac disease which is a substrate for cardiotoxicity and could persist for years even after 
withdrawal of the cancer treatment. 131, 133 Although the mainstay for the management of 
CTIA and HF remains pharmacological, a number of patients will require a cardiac 
implantable electronic device (CIED) to manage their conduction system disease, 
arrhythmias or advanced heart failure. Depending on the indication, CIED options include 
permanent pacemakers (PPM), implantable cardioverter-defibrillators (ICD), and cardiac 
resynchronization therapy (CRT).134, 135 However, it is unclear the number of patients with 
previous or current cancer who require CIED implantation continues to grow over the 
years, and whether their cancer diagnosis influences their procedural outcomes. This drives 
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the need for outcomes data for this population who are often excluded from major studies 
and clinical trials.136  
2. Objectives 
My main objectives of this chapter were to study the following: 
c) The prevalence of cancer patients undergoing de novo CIED implantation from a 
national perspective over a 12-year period 
d) Compare in-hospital procedural outcomes of de novo CIED implantation procedure 
between patients with and without (historical and current) cancer, stratified by type of 
implanted device.  
3. Methods 
A full description of the methodology relating to all chapters of my thesis is provided in 
Chapter 3.  
a) Data Source 
The data source for this study was the United States (US) National Inpatient Sample 
(NIS). Further information on its structure and validation has been provided in Chapter 3 
and also described in Chapter 4 under the same heading.  
b) Study Design and Population 
I included all hospitalizations between January 2004 and September 2015 in the US 
during which de novo CIED implantation procedures were performed. I used the 
International Classification of Diseases, ninth revision (ICD-9) to extract patient diagnoses 
and procedural data as described in Chapter 3 (codes listed in Table 3.1). ICD-9 and 
Clinical Classification Software (CCS) codes were used to identify patients with a historical 
or current cancer diagnosis (Table 6.1). I excluded patients with any missing records for 
the following variables: age, sex, length of stay and mortality (total n=19,155, ~3% of 
dataset), as well as hospitalisations during which the following procedures were performed: 
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coronary angiography, percutaneous coronary intervention, and coronary artery bypass 
grafting. (see Figure 6.1 for study flow diagram) Furthermore, I excluded patients with 
more than one historical or current cancer diagnosis.  
Patients were stratified based on the presence or absence of cancer and further by 
type of prevalent cancer in to 5 groups (haematological, prostate, colon, breast and lung). 
Haematological malignancies included leukaemia, lymphoma (Hodgkin’s and non-
Hodgkin’s), and multiple myeloma. 











Cancer of head and neck CCS D 11 
History of cancer of head and 
neck 
ICD-9 D V1001 V1002 V1021 
Cancer of oesophagus CCS D 12 
History of cancer of the 
oesophagus 
ICD-9 D V1003 
Cancer of stomach CCS D 13 
History of cancer of stomach ICD-9 D V1004 
Cancer of colon CCS D 14 
History of cancer of colon ICD-9 D V1005 
Cancer of rectum and anus CCS D 15 
History of cancer of the rectum 
and anus 
ICD-9 D V1006 
Cancer of liver and intrahepatic 
bile duct 
CCS D 16 
History of cancer of the liver and 
intrahepatic bile duct 
ICD-9 D V1007 
Cancer of pancreas CCS D 17 
Cancer of other GI organs, 
peritoneum 
CCS D 18 
History of cancer of other GI 
organs, peritoneum 
ICD-9 D V1000 V1009 
Cancer of bronchus, lung CCS D 19 
History of cancer of bronchus, 
lung 
ICD-9 D V1011 
Cancer, other respiratory and 
intra thoracic 
CCS D 20 
History of cancer, other 
respiratory and intra thoracic 
ICD-9 D V1012 V1020 V1022 
Cancer of bone and connective 
tissue 
CCS D 21 
Melanomas of skin CCS D 22 
History of melanoma of skin ICD-9 D V1082 
Other non-epithelial cancer of 
skin 
CCS D 23 
Cancer of breast CCS D 24 
History of cancer of breast ICD-9 D V103 
Cancer of uterus CCS D 25 
History of cancer of uterus ICD-9 D V1042 
Cancer of cervix CCS D 26 
History of cancer of cervix ICD-9 D V1041 
Cancer of ovary CCS D 27 
History of cancer of ovary ICD-9 D V1043 
Cancer of other female genital 
organs 
CCS D 28 
History of cancer of other female 
genital organs 
ICD-9 D V1040 V1044 
Cancer of prostate CCS D 29 
History of cancer of prostate ICD-9 D V1046 
Cancer of testis CCS D 30 
History of cancer of testis ICD-9 D V1047 
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Cancer of other male genital 
organs 
CCS D 31 
History of cancer of other male 
genital organs 
ICD-9 D V1045 V1048 V1049 
Cancer of bladder CCS D 32 
History of bladder cancer ICD-9 D V1051 
Cancer of kidney and renal pelvis CCS D 33 
History of cancer of kidney and 
renal pelvis 
ICD-9 D V1052 V1053 
Cancer of other urinary organs CCS D 34 
History of cancer of other urinary 
organs 
ICD-9 D V1050 V1059 
Cancer of brain and nervous 
system 
CCS D 35 
History of cancer of brain and 
nervous system 
ICD-9 D V1085 V1086 
Cancer of thyroid CCS D 36 
History of cancer of thyroid ICD-9 D V1087 
Hodgkin’s disease CCS D 37 
History of Hodgkin’s disease ICD-9 D V1072 
Non-Hodgkin’s lymphoma CCS D 38 
History of non-Hodgkin’s 
lymphoma 
ICD-9 D V1071 V1079 
Leukaemia CCS D 39 
History of leukaemia’s ICD-9 D 
V1060 V1061 V1062 
V1063 V1069 
Multiple myeloma CCS D 40 
Cancer, other and unspecified CCS D 41 
Secondary malignancies CCS D 42 
Neoplasms of unspecified site CCS D 43 
History of cancer, other and 
unspecified 
ICD-9 D 
V1029 V1081 V1084 
V1088 V1089 V1090 
V1091 V711 
Chemotherapy ICD-9 D/P 
Diagnoses: V58.11-12, 
V66.2, or V67.2, V87.41, 
285.3 and procedures: 
99.25, 00.10 
Radiotherapy ICD-9 D/P 
Diagnoses: V58.0, V66.1 
and V67.1 and procedures: 
92.2-92.39 
CCS: Clinical classification Software; ICD-9: International Classification of Diseases, Ninth Revision 
c) Outcomes 
The main outcomes were in-hospital major acute cardiovascular events (MACE) 
all-cause mortality and procedural-related complications (major bleeding, thoracic and 
cardiac complications, and device-related infection). MACE was defined as a composite of 
mortality, thoracic complications, cardiac complications and device-related infection. All 
analyses were stratified by type of CIED that was implanted. Major bleeding was defined 
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as any intracranial, gastrointestinal or post-procedural haemorrhage. Thoracic 
complications were defined as a composite of acute pneumothorax or haemothorax, with 
or without drainage, or thoracic vascular injury whereas cardiac complications were 
defined as a composite of cardiac tamponade, hemopericardium and pericardiocentesis.  
d) Statistical Analysis 
Descriptive statistics were performed as previously explained in Chapter 3. 
Sampling weights provided by the AHRQ were applied to all analyses. All statistical 
analyses were performed using SPSS version 26 (IBM Corp, Armonk, NY).  
Multivariable logistic regression models were constructed to examine the following 
associations using the no-cancer group as the reference 1) cancer diagnosis timing groups 
(historical and current) and in-hospital outcomes, 2) prevalent current cancer types and 
each in-hospital outcome. All associations are presented as odds ratios (95% confidence 
intervals). The following variables were adjusted for in all models: age, sex, weekend 
admission, primary expected payer, median household income, dyslipidaemia, smoking 
status, cardiac previous acute myocardial infarction, previous CABG, history of ischemic 
heart disease (IHD), previous percutaneous coronary intervention (PCI), previous 
cerebrovascular accidents (CVA) including stroke or transient ischemic attacks, family 
history of CAD, bed size of hospital, region of hospital, location/teaching status of hospital, 
year of admission, history of cardiac arrest, ventricular tachycardia (VDT) and ventricular 
fibrillation (VF), atrial fibrillation (AF), cardiogenic shock and the Elixhauser 
comorbidities: acquired immune deficiency syndrome, rheumatoid arthritis/collagen 
vascular diseases, heart failure (HF), chronic pulmonary disease, coagulopathy, diabetes 
(uncomplicated), diabetes with chronic complications, hypertension, hypothyroidism, liver 
disease, metastasis status, other neurological disorders, obesity, peripheral vascular 
disorders, valvular heart disease, and weight loss.  
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Trend analyses was performed by assessing the interaction term between each 
cancer type and year in my logistic regression models.   
4. Results 
A total of 2,670,590 de novo CIED implantations were included in my analysis of 
which 187,387 (7.0%) patients had a historical cancer diagnosis and 122,620 (4.6%) 
patients had current cancer. The number of cancer patients (historical and current) 
undergoing any CIED implantation increased between 1.5 to 2-fold over the study period 
(current: 3.3% to 7.8%; historical: 5.8% to 7.8%), a pattern that was consistent across all 
device groups (Figure 6.2). The rate of utilisation of PPM compared with other CIED types 
(CRT and ICD) was higher among the cancer groups (historical: 73.6%, current: 75%) than 
the no-cancer group (62%). 
Figure 6.2. Prevalence of cancer over the study period in A) total cohort and B) 
individual CIED subgroups 
 
Legend: *2015 only includes admissions from 1st January through 30th September; ptrend <0.001 for all 
except ICD: p=0.07; ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy; 




The most prevalent current cancer types were non-epithelial and skin (19.3%), 
prostate (19.1%), haematological (Hodgkin’s and non-Hodgkin’s lymphoma, leukaemia 
and multiple myeloma, total: 17.1%), breast (10.3%), bronchus and lung (8.0%), and colon 
(4.2%) malignancies whereas the most common historical cancers. included prostate 
(29.5%), breast (25.9%), colon (15.1%), bladder (6.7%), and bronchus and lung 
malignancies (6.0). (Figure 6.3) 
Figure 6.3. Prevalence of most common cancer diagnoses 
 
Patient characteristics 
Compared to those without cancer, patients with historical and current cancer were 
older, more likely to undergo an emergent (non-elective) procedure and were more likely 
to be of white ethnic background. (Table 6.2) The highest prevalence of males was among 
those with current cancer (62.7%) followed by those without cancer (57.1%) and those with 
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historical cancer (55.9%). Overall, the prevalence of HF was lower in the cancer groups 
(historical and current) compared with the no cancer group whereas the prevalence of risk 
factors such as AF, hypertension and dyslipidaemia were higher in the cancer groups. 
Specifically, the current cancer group had the highest prevalence of comorbidities such as 
coagulopathies (including thrombocytopaenia and anaemia), renal failure, chronic 
pulmonary disease, AF, and fluid and electrolyte disturbances. 











Number of weighted discharges 2360583 187387 122620 - 
Device type, %    <0.001 
PPM 62.0 73.6 75.0  
CRT 16.4 12.7 11.8  
ICD 21.6 13.8 13.2  
Age (years), median (IQR) 75 (65,82) 79 (72,85) 78 (71,84) <0.001 
Males, % 57.1 55.9 62.7 <0.001 
Ethnicity, %    <0.001 
White 78.2 85.3 84.3  
Black 10.1 7.5 7.0  
Hispanic 6.8 3.8 4.8  
Asian/Pacific Islander 2.0 1.1 1.7  
Native American 0.5 0.4 0.2  
Other 2.4 1.8 2.1  
LOS, days (median (IQR)) 3 (1,7) 3 (2,6) 5 (2,9) <0.001 
Elective Admission, % 31.9 27.1 24.3 <0.001 
Weekend admission, % 14.7 16.1 17.5 <0.001 
Primary expected payer, %    <0.001 
Medicare 73.5 85.7 83.3  
Medicaid 4.7 1.5 2.2  
Private Insurance 18.3 11.4 12.6  
Self-pay 1.6 0.5 0.7  
No charge 0.2 0.1 0.1  
Other 1.6 0.9 1.1  
Median Household Income 
(Percentile), % 
   <0.001 
0-25th 26.2 22.1 21.8  
26-50th 26.6 25.3 25.5  
51-75th 24.5 25.2 25.2  
76-100th 22.7 27.5 27.5  
Hospital bed size, %    0.002 
Small 9.1 9.1 9.1  













Large 68.6 68.4 67.8  
Hospital Region, %    <0.001 
Northeast 21.1 25.9 20.6  
Midwest 23.5 23.6 25.1  
South 37.8 34.4 32.9  
West 17.6 16.1 21.4  
Location/ Teaching status, %    <0.001 
Rural 6.6 6.4 6.3  
Urban non-teaching 40.6 40.0 39.1  
Urban- teaching 52.8 53.6 54.6  
Shock, % 0.9 0.4 1.1 <0.001 
Cardiac Arrest, % 1.4 0.7 1.9 <0.001 
Ventricular Tachycardia, % 3.5 2.0 3.8 <0.001 
Ventricular Fibrillation, % 2.7 1.3 2.3 <0.001 
Comorbidities, %     
Dyslipidaemia 41.8 45.8 44.7 <0.001 
Smoking 15.5 20.4 15.6 <0.001 
Atrial Fibrillation 38.3 40.4 44.0 <0.001 
Thrombocytopenia 2.1 1.9 4.7 <0.001 
Previous AMI 11.0 10.6 9.5 <0.001 
History of IHD 43.9 41.0 42.3 <0.001 
Previous PCI 8.2 9.5 6.4 <0.001 
Previous CABG 12.4 12.8 9.0 <0.001 
Previous CVA 3.6 5.8 3.6 <0.001 
Family history of CAD 2.2 2.2 1.5 <0.001 
AIDS 0.1 0.0 0.1 <0.001 
Alcohol abuse 1.9 1.1 1.7 <0.001 
Anaemia 12.9 13.9 23.0 <0.001 
RA/collagen vascular 
diseases 
2.1 2.3 2.6 <0.001 
Heart Failure 43.7 34.7 39.9  
Chronic pulmonary disease 18.7 18.6 23.0 <0.001 
Coagulopathy 3.9 3.6 7.6 <0.001 
Depression 5.9 6.3 7.9 <0.001 
Diabetes 29.3 26.4 28.8 <0.001 
Drug abuse 1.0 0.3 0.6 <0.001 
Hypertension 64.2 69.5 67.2 <0.001 
Hypothyroidism 13.0 16.5 16.3 <0.001 
Liver disease 1.1 0.7 1.5 <0.001 
Fluid and electrolyte disturbances 16.8 14.0 25.2 <0.001 
Obesity 9.0 6.1 8.8 <0.001 
Peripheral vascular disease 8.4 8.0 11.0 <0.001 
Psychoses 1.9 1.3 1.9 <0.001 
Pulmonary circulation disorder 0.6 0.4 1.3 <0.001 













Valvular heart disease 1.4 1.1 3.0 <0.001 
Weight loss 1.9 1.2 4.4 <0.001 
Dementia 1.9 2.0 2.1 <0.001 




The rates of in-hospital mortality and post-procedure complications were 
significantly (1.5 to 2-fold) higher among patients with current cancer compared with those 
without cancer (MACE: 6.9% vs. 4.1%; mortality: 1.6% vs. 0.8%; major bleeding: 2.0% 
vs. 1.1%; thoracic complications: 4.5% vs. 2.4%; cardiac complications: 0.2% vs. 0.1%), 
except for device related infection which was similar in both groups (1.1 vs. 1.0%). (Figure 
6.4, Table 6.3). However, patients with a historical cancer diagnosis experienced similar 
or lower rates of adverse events to those without cancer. Similar findings were observed in 
the individual CIED groups. (Figure 6.4) 
Figure 6.4. In-hospital adverse events in A) overall cohort and B) individual CIED 








Legend: *MACE: Composite of mortality, thoracic complications, cardiac complications and device-related 
infection; **Cardiac complications occurred at a frequency less than 0.05% in the historical cancer groups; 
ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy; PPM: permanent 
pacemaker 
 
Table 6.3. In-hospital adverse event rates 
Outcome/ 










MACE, %*     
Total, % 4.1 3.4 6.9 <0.001 
PPM, % 4.2 3.3 6.8 <0.001 
CRT, % 4.6 4.6 7.9 <0.001 
ICD, % 3.6 3.3 6.3 <0.001 
All-cause mortality, %     
Total, % 0.8 0.4 1.6 <0.001 
PPM, % 0.9 0.4 1.7 <0.001 
CRT, % 0.7 0.4 1.5 <0.001 
ICD, % 0.5 0.1 0.8 <0.001 
Major bleeding, %     
Total, % 1.1 0.8 2.0 <0.001 
PPM, % 1.2 0.8 2.0 <0.001 
CRT, % 1.1 0.8 1.5 <0.001 
ICD, % 1.1 0.8 1.9 <0.001 
Thoracic complications, %     
Total, % 2.4 2.3 4.5 <0.001 
PPM, % 2.6 2.2 4.7 <0.001 
CRT, % 2.4 2.7 4.7 <0.001 
ICD, % 1.8 1.9 3.6 <0.001 














Total, % 0.1 0.0 0.2 <0.001 
PPM, % 0.1 0.0 0.2 <0.001 
CRT, % 0.1 0.0 0.1 <0.001 
ICD, % 0.1 0.0 0.2 <0.001 
Device-related infection, 
%* 
    
Total, % 1.0 0.8 1.1 <0.001 
PPM, % 0.8 0.6 0.7 0.002 
CRT, % 1.5 1.6 2.1 <0.001 
ICD, % 1.3 1.2 2.0 <0.001 
*MACE: Composite of mortality, thoracic complications, cardiac complications and device-related infection; 
**Cardiac complications occurred at a frequency less than 0.05% in the historical cancer groups; ICD: 
implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy; PPM: permanent pacemaker. 
 
After adjustment for baseline differences between the no cancer and cancer groups, 
there were no increased odds of MACE, mortality or procedure-related complications 
between patients with historical cancer and those without cancer in the total cohort (Table 
6.4, Figure 6.5).  However, patients with current cancer were association with increased 
odds of all mortality and procedure-related complications compared with patients without 
cancer. Although similar findings were observed in the individual CIED subgroups, there 
were two exceptions.  The odds of thoracic complications were increased in patients with 
historical and current cancer in the CRT group (1.16 95% CI 1.07, 1.26 and 1.34 95% CI 
1.23, 1.46, respectively), whereas mortality was similar between patients with current 
cancer and no caner in the ICD group (OR 1.01 95% CI 0.83, 1.22, p=0.922). 
Most prevalent current cancer types 
The five most prevalent cancer types among those undergoing de novo CIED 
implantation included haematological, breast, lung, colon and prostate malignancies. The 
highest rates of MACE (15.7%), all-cause mortality (3.6%) and thoracic complications 
(12.4%) were observed among lung cancer patients while the highest rates of major 
bleeding (4.0%) and cardiac complications (0.3%) were in the colon and breast cancer 
groups, respectively. (Table 6.5, Figure 6.6) These findings were similar in the individual 
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CIED subgroups, with the exception of all-cause mortality and cardiac complications in the 
CRT group, which were highest in the colon and lung cancer subgroups, respectively. 
Figure 6.5. Adjusted odds ratios (OR) of adverse events in total cohort and 
according to device subtype 
 
Figure 6.6 In-hospital adverse events according in most prevalent cancer groups 
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Table 6.4. Adjusted odds of in-hospital adverse events*  
Study Group/ 
Outcome 
MACE** Mortality Major Bleeding Thoracic Complications 
 OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 
OR (95% CI) 
p-
value 




No cancer* - - - - - - - - 
Historical cancer 0.92 [0.89, 0.94] <0.001 0.66 [0.61, 0.71] <0.001 0.81 [0.77, 0.86] <0.001 0.99 [0.96, 1.03] 0.763 
Current cancer 1.26 [1.23, 1.30] <0.001 1.43 [1.35, 1.50] <0.001 1.38 [1.32, 1.44] <0.001 1.39 [1.35, 1.43] <0.001 
PPM 
No cancer* - - - - - - - - 
Historical cancer 0.91 [0.88, 0.94] <0.001 0.70 [0.64, 0.76] <0.001 0.80 [0.76, 0.86] <0.001 0.96 [0.92, 1.00] 0.051 
Current cancer 1.28 [1.25, 1.32] <0.001 1.48 [1.40, 1.58] <0.001 1.42 [1.35, 1.50] <0.001 1.40 [1.35, 1.45] <0.001 
CRT 
No cancer* - - - - - - - - 
Historical cancer 1.05 [0.99, 1.12] 0.135 0.71 [0.57, 0.88] 0.002 0.89 [0.76, 1.03] 0.118 1.16 [1.07, 1.26] <0.001 
Current cancer 1.18 [1.10, 1.26] <0.001 1.51 [1.30, 1.76] <0.001 1.19 [1.04, 1.38] 0.014 1.34 [1.23, 1.46] <0.001 
ICD 
No cancer* - - - - - - - - 
Historical cancer 0.93 [0.86, 0.99] 0.032 0.39 [0.29, 0.54] <0.001 0.84 [0.73, 0.97] 0.016 1.09 [0.99, 1.19] 0.078 
Current cancer 1.24 [1.16, 1.33] <0.001 1.01 [0.83, 1.22] 0.922 1.26 [1.11, 1.42] <0.001 1.34 [1.23, 1.47] <0.001 
*reference group for each outcome, **MACE: Composite of mortality, thoracic and cardiac complications and device-related infection. ICD: implantable 
















Table 6.5. In-hospital crude adverse event rates in most prevalent current cancer groups 
Outcome/ 
Study Group  














MACE, %*        
Total, % 4.1 7.5 6.5 15.7 6.5 4.0 <0.001 
PPM, % 4.2 7.5 6.5 16.6 6.3 3.3 <0.001 
CRT, % 4.6 7.9 9.8 11.0 7.8 5.3 0.002 
ICD, % 3.6 7.3 3.3 12.1 6.7 6.1 <0.001 
All-cause mortality, %        
Total, % 0.8 1.7 1.2 3.6 1.8 0.7 <0.001 
PPM, % 0.9 2.1 1.4 4.2 1.7 0.6 <0.001 
CRT, % 0.7 1.5 0.8 0.6 3.3 0.5 0.022 
ICD, % 0.5 0.6 ** 1.4 1.1 1.2 <0.001 
Major bleeding, %        
Total, % 1.1 1.8 1.1 2.2 4.0 1.7 <0.001 
PPM, % 1.2 1.9 1.3 2.3 3.6 1.8 <0.001 
CRT, % 1.1 1.3 ** 1.8 5.5 1.5 <0.001 
ICD, % 1.1 1.5 1.0 1.8 5.5 1.6 <0.001 
Thoracic complications, %        
Total, % 2.4 4.9 4.7 12.4 3.7 2.5 <0.001 
PPM, % 2.6 4.9 4.8 13.2 3.8 2.2 <0.001 
CRT, % 2.4 4.8 6.2 9.8 4.7 3.3 <0.001 
ICD, % 1.8 4.9 2.3 8.0 2.3 3.0 <0.001 
Cardiac complications, %        
Total, % 0.1 0.2 0.3 0.2 0.1 0.1 <0.001 
PPM, % 0.1 0.2 0.3 0.2 0.1 0.1 <0.001 




Study Group  














ICD, % 0.1 ** 0.6 ** 0.5 0.1 <0.001 
Device-related infection, %*        
Total, % 1.0 1.3 0.8 0.7 1.2 0.9 <0.001 
PPM, % 0.8 1.0 0.5 0.5 1.0 0.6 <0.001 
CRT, % 1.5 2.0 2.8 0.6 1.3 1.6 <0.001 
ICD, % 1.3 1.9 0.7 2.7 2.7 2.0 <0.001 
*MACE: Composite of mortality, thoracic complications, cardiac complications and device-related infection; **No or fewer than 10 events occurred; ICD: 























Table 6.6. Adjusted odds of in-hospital adverse events in most prevalent current cancer groups*  
Study Group/ 
Outcome 
MACE** Mortality Major Bleeding Thoracic Complications 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Total 
No cancer* - - - - - - - - 
Haematological 1.45 [1.38, 1.53] <0.001 1.67 [1.51, 1.86] <0.001 1.22 [1.10, 1.35] <0.001 1.61 [1.51, 1.71] <0.001 
Breast 1.11 [1.03, 1.20] 0.005 1.07 [0.90, 1.27] 0.441 0.90 [0.76, 1.07] 0.229 1.17 [1.07, 1.27] <0.001 
Lung 3.05 [2.87, 3.24] <0.001 3.20 [2.83, 3.62] <0.001 1.29 [1.12, 1.49] <0.001 3.77 [3.52, 4.03] <0.001 
Colon 1.03 [0.94, 1.13] 0.529 1.19 [0.99, 1.42] 0.062 2.32 [2.06, 2.62] <0.001 0.99 [0.87, 1.11] 0.832 
Prostate 0.81 [0.76, 0.87] <0.001 0.68 [0.58, 0.80] <0.001 1.22 [1.10, 1.36] <0.001 0.98 [0.90, 1.07] 0.670 
PPM 
No cancer* - - - - - - - - 
Haematological 1.45 [1.38, 1.53] <0.001 1.83 [1.62, 2.06] <0.001 1.32 [1.17, 1.48] <0.001 1.57 [1.45, 1.69] <0.001 
Breast 1.11 [1.03, 1.20] 0.005 1.18 [0.99, 1.42] 0.068 1.03 [0.86, 1.24] 0.733 1.20 [1.09, 1.32] <0.001 
Lung 3.05 [2.87, 3.24] <0.001 3.14 [2.75, 3.59] <0.001 1.25 [1.07, 1.47] 0.005 3.82 [3.55, 4.12] <0.001 
Colon 1.03 [0.94, 1.13] 0.529 1.05 [0.85, 1.30] 0.639 2.04 [1.77, 2.35] <0.001 1.00 [0.87, 1.14] 0.992 
Prostate 0.81 [0.76, 0.87] <0.001 0.62 [0.51, 0.75] <0.001 1.24 [1.10, 1.40] <0.001 0.89 [0.80, 0.99] 0.028 
CRT 
No cancer* - - - - - - - - 
Haematological 1.31 [1.15, 1.48] <0.001 1.54 [1.17, 2.02] 0.002 0.95 [0.72, 1.27] 0.749 1.54 [1.32, 1.80] <0.001 
Breast 1.54 [1.27, 1.87] <0.001 0.86 [0.42, 1.77] 0.688 † † 1.48 [1.17, 1.89] 0.001 
Lung 1.76 [1.38, 2.23] <0.001 0.85 [0.35, 2.09] 0.730 1.61 [0.95, 2.75] 0.079 2.90 [2.25, 3.73] <0.001 
Colon 1.05 [0.80, 1.38] 0.740 2.98 [1.93, 4.62] <0.001 3.99 [2.87, 5.56] <0.001 1.18 [0.84, 1.67] 0.339 
Prostate 0.75 [0.63, 0.89] <0.001 0.41 [0.24, 0.70] 0.001 1.09 [0.80, 1.48] 0.592 1.02 [0.83, 1.26] 0.828 
ICD 
No cancer* - - - - - - - - 
Haematological 1.48 [1.30, 1.68] <0.001 0.84 [0.55, 1.27] 0.394 1.02 [0.79, 1.33] 0.859 1.91 [1.64, 2.23] <0.001 
Breast 0.61 [0.45, 0.82] 0.001 † † 0.65 [0.38, 1.12] 0.117 0.66 [0.46, 0.95] 0.023 





MACE** Mortality Major Bleeding Thoracic Complications 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Colon 1.04 [0.79, 1.38] 0.761 1.09 [0.56, 2.10] 0.806 2.84 [2.07, 3.90] <0.001 0.66 [0.42, 1.04] 0.075 
Prostate 1.22 [1.05, 1.42] 0.008 1.71 [1.23, 2.37] 0.001 1.13 [0.86, 1.50] 0.379 1.30 [1.05, 1.60] 0.014 
*reference group for each outcome, **MACE: Composite of mortality, thoracic and cardiac complications and device-related infection; ICD: implantable 
 cardioverter-defibrillator; CRT: cardiac resynchronization therapy; PPM: permanent pacemaker; †: no or fewer than 10 events occurred
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In multivariable analysis, lung cancer patients were associated with a significant 
increase in odds of MACE (OR 3.05 95% CI 2.87, 3.24), all-cause mortality (OR 3.20 95% 
CI 2.83, 3.62), thoracic complications (OR 3.77 95% CI 3.52, 4.03) and major bleeding 
(OR 1.29 95% CI 1.12, 1.49). (Table 6.6, Figure 6.7) Patients with haematological 
malignancies were at increased odds of MACE (OR 1.45 95% CI 1.38, 1.53), mortality 
(OR 1.67 95% CI 1.51, 1.86) and post-procedure complications (major bleeding: OR 1.22 
95% CI 1.10, 1.35, thoracic complications: OR 1.61 95% CI 1.51, 1.71). The only in-
hospital complication that was increased in patients with colon and prostate cancer was 
major bleeding (OR colon: 2.32 95% CI 2.06, 2.62, prostate: 1.22 95% CI 1.10, 1.36), while 
mortality and other in-hospital complications were similar to those without cancer. 
Similarly, patients with breast cancer were only associated with increased odds of thoracic 
complications (OR 1.17 95% CI 1.07, 1.27) while all other outcomes were similar to, or 
lower than, patients without cancer. 





The above findings were found to be similar in the PPM subgroup. However, in the 
CRT subgroup only patients with lung, haematological, and breast malignancies were 
associated with increased odds of MACE and thoracic complications compared to those 
without cancer. (Table 6.6, Figure 6.7) The odds of mortality were only increased in 
patients with haematological and colon malignancies, while the odds of major bleeding 
were only increased in patients with colon cancer. In patients undergoing ICD implantation, 
the odds of MACE and thoracic complications were only increased in patients with 
haematological, lung and prostate malignancies. Only patients with lung and prostate 
malignancy were associated with increased odds of mortality while colon cancer patients 
were the only subgroup associated with increased odds of bleeding. 
5. Discussion 
My national-level analysis is the first to systematically examine in-hospital 
outcomes of patients with cancer undergoing de novo CIED implantation according to 
cancer timing (current or historical) and CIED type. I demonstrate several important 
findings. First, I show that the prevalence of patients with current and historical cancers has 
significantly increased among those undergoing CIED implantation over a 12-year period 
and are more likely to undergo implantation of PPM than CRT or ICD. Second, I show that 
patients with current cancer were associated with an increased risk of in-hospital mortality 
and adverse outcomes after CIED implantation compared to those without cancer, a finding 
that was consistent across individual CIED subtypes, while no risk of complications was 
observed in those with historical cancer except thoracic complications in patients 
undergoing CRT implantation. Furthermore, I report differences in outcomes between 
patients with prevalent current cancer types, with lung and haematological malignancies 
being associated with the highest risk of mortality and thoracic complications while 
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prostate and colon cancers had the highest odds of major bleeding compared to those 
without cancer.   
Cancer survival has increased over the past two decades, commensurate with 
advancements in cancer therapeutics (e.g. anthracyclines, anti-HER2 and anti-VEGF 
agents as well as radiotherapy). 137 However, such therapies, as well as other factors such 
as direct metastases to the heart (including the conduction tissue) and the fluid/electrolyte 
abnormalities in cancer patients are also associated with cardiotoxicity in the form of 
conduction system disease, CTIA as well as heart failure, which may require CIED 
implantation as part of their management.131, 138 Furthermore, cancer patients often have 
significant comorbidities at baseline.139, 140 While there have been many studies examining 
the impact of comorbidities on CIED procedural outcomes, there has been limited evidence 
for cancer patients who are often excluded from clinical trials despite their high prevalence 
as demonstrated in my current study.141 Furthermore, there have been no studies looking 
comparing outcomes according to device type. This drives the need for outcomes data for 
this frequently encountered population in clinical practice to inform operators and patients 
of procedural outcomes in this high-risk patient group and guide operators’ decision 
making when choosing the type of CIED offered to patients with specific cancer types.  
My findings suggest that the prevalence of (historical and current) cancer patients 
is high among those undergoing CIED implantation, representing one in six patients in 
2015, which is commensurate with the overall increase in cancer survivors reported in 
national surveys. 137, 142, 143 Moreover, the most prevalent cancer types in those undergoing 
CIED implantation are similar to those of the background population (non-melanoma skin 
cancers, bronchus, lung and bronchus, breast, colon, prostate and haematological 
malignancies).142, 143  
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In my analysis patients with current cancer were associated with worse outcomes 
after de novo CIED implantation (MACE, mortality and procedure-related complications) 
in patients with current cancer compared with those without cancer, even after adjustment 
for baseline differences between the groups, while patients with historical cancer 
experienced a similar risk of mortality and complications. These findings were generally 
consistent across individual CIED types despite variations in their procedural complexity. 
One exception was the increased risk of thoracic complications in historical cancer patients 
in the CRT group, which could possibly be explained by their susceptibility to vascular 
injuries due to previous radiation and central venous access for chemotherapy.  
Further differences were noted between current cancer patients according to the 
type of cancer; patients with lung and haematological malignancies were associated with 
the highest odds of MACE and mortality whereas colon and prostate cancers groups were 
associated with increased odds of major bleeding but not MACE or mortality. Similar 
differences were observed within the individual CIED subgroups. Despite the limited 
evidence to date, I postulate several reasons that may lead to worse outcomes in cancer 
patients and specifically in those with prevalent cancer types. The most obvious cause of 
mortality and major bleeding in those with current cancer is likely due to their primary 
cancer (e.g. metastases, tumour angiogenesis, cancer-associated coagulopathies) or even 
the associated cancer therapies (including chemotherapeutic agents and anticoagulation).144 
145 Furthermore, direct tumour invasion as well as chest irradiation may increase the 
incidence of thoracic and vascular complications.  
While CIED implantation may be unavoidable and lifesaving in many cancer 
patients, several strategies may be employed to help neutralise the inherent risk of 
complications in these patients. For example, the use of ultrasound-guided venous access 
and cephalic vein approach, as well as echocardiography guided septal-pacing may help 
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minimise their risks.  Furthermore, there may be a role for intracardiac (leadless) or 
subcutaneous pacemakers in patients who are in need of PPM or ICD therapy, respectively, 
and who are at a high-risk of complications after a standard transvenous CIED 
implantation. Additionally, the use of antimicrobial envelopes routinely in cancer patients 
may minimise their risk of device-related infection, to which they may be more prone due 
to their impaired immunity and delayed tissue healing. 146 
Limitations 
There are several limitations to my study. As mentioned in previous chapters, the 
NIS is an administrative dataset that is coded according to the ICD-9 manual and the quality 
of coding is reliant on those managing the dataset. Second, the NIS does not include 
information on pharmacotherapy (e.g., cancer therapeutics and anticoagulation) as well as 
indication of CIED implantation and type of PPM device (e.g., VVI or DDD) and, 
therefore, these were not adjusted for in my analysis. Furthermore, the NIS only captures 
in-hospital outcomes and does not specify the exact cause of death, although a previous 
national study has shown that the majority of procedure-related complications have been 
shown to occur in the peri-procedural phase and the majority of deaths in the context of 
CIED implantation were not procedure-related. 55 Finally, the severity and extent of active 
malignancy was only judged based on metastases and it is possible that certain 
unmeasurable markers of overall frailty in cancer patients would have led to them being 
offered specific device types (e.g., PPM or ICD only), with only the healthier cancer offered 
more complex device groups.  
6. Summary 
 My national analysis of de novo CIED implantation procedures in the United States 
demonstrates an increased risk of mortality and procedure-related complications among 
those with a current cancer diagnosis, especially lung, haematological and colon subtypes. 
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Furthermore, a historical diagnosis of cancer was not associated with worse outcomes in 
my study.  My findings add to the body of literature on outcomes of cancer patients 
undergoing CIED implantation, who have become increasingly encountered over a 12-year 
study period and identify specific cancer subtypes that are associated with an increased risk 
of mortality and procedural outcomes.  




Chapter 7. The impact of frailty on de 
novo CIED procedural outcomes 
The work in this chapter relates to the second phase of my thesis and is based on my study 
published in the Canadian Journal of Cardiology (Appendix 4).147  
1. Introduction 
Frailty is defined as “a clinically recognizable state of increased vulnerability 
resulting from aging-associated decline in reserve and function across multiple physiologic 
systems such that the ability to cope with every day or acute stressors is compromised”.148 
While frailty is often used to describe older adults or those with multiple comorbidities, 
patients with neither characteristic could still be considered biologically frail as 
demonstrated in previous studies. 76, 77, 149 Although frailty has been shown to be a marker 
of adverse cardiovascular outcomes in previous studies, the prevalence and outcomes of 
frail patients undergoing de novo implantation of different CIED types has not been 
systematically examined. 150-152 Many of these patients have significant comorbidities 
which excludes them from randomised trials. Very few studies have examined the 
relationship between frailty and CIED implantation outcomes, they used non-objective 
measures as a surrogate of frailty such as number of comorbidities and old age, excluding 
younger biologically frail patients. 149, 152, 153  
Although several scoring systems for frailty have been previously described, none 
is considered to be a gold standard.154 One recently described score is the Hospital Frailty 
Risk Score (HFRS) which is derived from electronic health records and based on 
International Classification of Diseases, Tenth Revision (ICD-10) codes. 155 The HFRS was 
validated against two well-established scores: The Fried Frailty Phenotype score and the 




My main objectives of this chapter were to study the following: 
a) The distribution of frailty amongst patients undergoing de novo CIED implantation. 
b) The relationship between frailty and in-hospital procedural outcomes of CIED 
implantation, stratified by CIED type. 
3. Methods 
A full description of the methodology relating to all chapters of my thesis is provided in 
Chapter 3.  
a) Data Source 
The data source for this study was the United States (US) National Inpatient Sample (NIS). 
Further information on its structure and validation has been provided in Chapter 3 and also 
described in Chapter 4 under the same heading.  
b) Study Design and Population 
All de novo CIED implantation procedures in the US NIS between 2004 and 2014 
were included in my analysis, including permanent pacemakers (PPM), implantable 
cardioverter-defibrillators (ICD), and cardiac resynchronization therapy (CRT) with 
pacemaker (CRT-P) or defibrillator (CRT-D). All procedures, patient characteristics and 
clinical outcomes other than death were extracted using the International Classification of 
Diseases, ninth revision (ICD-9) procedure and diagnosis codes provided in Table 3.1 in 
Chapter 3. Furthermore, ICD-9 equivalents of the ICD-10 codes in the HFRS were used to 
calculate the overall frailty score (full list in Table 7.1). Patients were groups in to 3 groups 
based on their frailty score: Low-Risk Frailty (LRF; <5), Intermediate-Risk Frailty (IRF; 
5-15) and High-Risk Frailty (HRF; >15). Records with missing data for the following 
variables were excluded (total n=18,321, 3% of dataset): age, gender, admission or 
discharge date, length of stay and mortality. Furthermore, procedures for device upgrades 
 
 113 
or generator replacements were excluded so as to only include de novo procedures. (see 
Figure 7.1 for study flow diagram) 
Figure 7.1. Flow chart of cohort selection 
 
Table 7.1. List of Hospital Frailty Score ICD-10 variables and their ICD-9 conversions  
ICD-10 Weight ICD-9 equivalent 
F00 7.1 331.0 
G81 4.4 342* 
G30 4 331.0 
I69 3.7 438.9, 438.89, 438.82, 438.81, 438.1* 
R29 3.6 781.9*,7817,7816,7961,71965,7814,71960,71961,71962,71963
,71964,71966,71967, 71968,71969,72989  
N39 3.2 599* except 599.0 and 599.7* 
F05 3.2 293.0 290.41 293.89 290.11 290.3 293.1  
W19 3.2 E888* 
S00 3.2 910.0, 910.1, 910.8 910.9 918.0 920 910.2 910.6 
R31 3 599.7* 
B96 2.9 041* 
R41 2.7 799.5* 
780.93 
781.8 
R26 2.6 781.2 
719.7 
I67 2.6 437* 
436 
R56 2.6 780.3*  
R40 2.5 780.0* 
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T83 2.4 997.70 
S06 2.4 850* 851* 852* 853* 854* 80010 80011 80019 80060 80061 
80069 80110 80111 80119 80160 80161 80169 80310 80311 
80319 80360 80361 80369 80410 80411 80419 80460 80461  
S42 2.3 810 811 812 
E87 2.3 276* except 276.5 
M25 2.3 719* 
E86 2.3 276.5 
R54 2.2 797 
Z50 2.1 V57 
F03 2.1 294.2 
290.0* 290.1* 290.2* 290.3* 290.8* 290.9* 
W18 2.1 E885 E886 
E917.7 E917.8 
E884.6 
Z75 2 V63.2 V63.8 V63.9 
Actually V63* and V60.5 
F01 2 290.4* 
S80 2 916* 
L03 2 681* 682* 
H54 1.9 369* 
E53 1.9 266* 
Z60 1.8 V62.9 
G20 1.8 332* 
R55 1.8 780.2 
S22 1.8 807.0* 807.1* 807.2 807.3 807.4 805.2 805.4 
K59 1.8 564.89 
N17 1.8 584 
L89 1.7 707.0* 
Z22 1.7 V02* 
B95 1.7 041.0* and 041.1* 
L97 1.6 707.10 
R44 1.6 781.1 782.0 
K26 1.6 532* 
I95 1.6 458* 
N19 1.6 586 
A41 1.6 038.9 
Z87 1.5 V12.60 V12.69 V1260 V1269 V137 V139 V219 V470 V499 
V1582 V1261 V1260 V1269 V1271 V1270 V1279 V133 
V1351 V1352 V134 V1359 V1322 V1323 V1324 V1329 
V1302 V1303 V1301 V1300 V1309 V1321 V131 V1329 
V1361 V1362 V1364 V1363 V1364 V1367 V1365 V1366 
V1368 V1369 V1551 
J96 1.5 518.81 518.84 518.51 518.83 
X59 1.5 E928.9 
M19 1.5 715* 
G40 1.4 345* 
M81 1.4 733.0* 
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S72 1.4 820* 821* 
S32 1.4 805.4 805.5 808* 806.4 806.5 
E16 1.4 251* 
R94 1.4 794* 
N18 1.4 585* 
R33 1.3 788.2* 
R69 1.3 799.9 
N28 1.3 593* 
R32 1.2 788.30 
G31 1.2 331.11 331.19 331.2 330.8 331.82 331.83 331.6 331.89 331.9 
Y95 1.2 136.9 
S09 1.2 959.01 
R45 1.2 308.0 
G45 1.2 435* 
Z74 1.1 V60.9 
M79 1.1 729.99 
W06 1.1 E884.4 
S01 1.1 870* 871* 872* 873* 
8541* 8531*8525*8523*8521* 8519 8517* 8515* 8513* 
8511* 
A04 1.1 008.43, 008.0*, 0081, 0082, 0083, 00841, 00842, 
00846,00847,00849, 0085, 008.44, 008.45  
A09 1.1 009.3 
J18 1.1 486*, 485*, 514, 481 
J69 1 507.0 
R47 1 784.59 
E55 1 268* 
Z93 1 V44 
R02 1 785.4 
R63 0.9 783.9 
H91 0.9 389.9 
W10 0.9 E880.9 
W01 0.9 E885 
E05 0.9 242* 
M41 0.9 737.3* 
R13 0.8 787.2 
Z99 0.8 V46 
U80 0.8 V09.1 
M80 0.8 733.0* AND 733.1 V13.51 
K92 0.8 570 579* 
I63 0.8 434.91 434.11 434.01 V12.54 997.02 
N20 0.7 592* 
F10 0.7 291* 303* 
Y84 0.7 E878 E879 
R00 0.7 785.1 
J22 0.7 519.8 
Z73 0.6 V695 V4985 
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R79 0.6 790.6 
Z91 0.5 V15* 
S51 0.5 881.00 
R32 0.5 296.20/296.26 296.30/296.36  
M48 0.5 724.0* 723.0 
E83 0.4 275 
M15 0.4 716.5* 
D64 0.4 285.8 285.9 
L08 0.4 686 
R11 0.3 787.0* 
K52 0.3 558* 
R50 0.1 780.60 
c) Outcomes 
The primary outcome measures were in-hospital major acute cardiovascular events 
(MACE), all-cause mortality and procedural-related complications (bleeding, thoracic and 
cardiac complications).  In-hospital MACE was a composite of all-cause mortality, thoracic 
and cardiac complications, device-related infection and reoperation. Procedure-related 
bleeding was defined as any post-procedural haemorrhage. Thoracic complications 
included any acute pneumothorax or haemothorax, with or without drainage, or thoracic 
vascular injury, while cardiac complications were defined as a composite of cardiac 
tamponade, hemopericardium, pericardiocentesis.  
d) Statistical Analysis 
Descriptive statistics were performed as previously explained in Chapter 3. 
Exploratory analyses were performed to compare the rates of in-hospital complications 
between the frailty groups. Sampling weights provided by the AHRQ were applied to all 
analyses. All statistical analyses were performed using SPSS version 26 (IBM Corp, 
Armonk, NY).  
Multivariable logistic regression modelling was employed, using maximum 
likelihood estimation, to examine the association between frailty and in-hospital outcome 
in the higher risk frailty groups (IRF and HRF) using the low-risk category (LRF) as the 
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reference. All associations are expressed as odds ratios with corresponding 95% confidence 
intervals (CI). To account for baseline differences between the groups, I adjusted for all 
variables that were not part of HFRS (to avoid collinearity), including age, sex, weekend 
admission, primary expected payer, median household income, dyslipidaemia, smoking 
status, previous acute myocardial infarction, previous CABG, history of ischemic heart 
disease (IHD), previous percutaneous coronary intervention (PCI), previous 
cerebrovascular accidents (CVA) including stroke or transient ischemic attacks, family 
history of CAD, bed size of hospital, region of hospital, location/teaching status of hospital, 
history of cardiac arrest, ventricular tachycardia and ventricular fibrillation, acquired 
immune deficiency syndrome, rheumatoid arthritis/collagen vascular diseases, congestive 
heart failure, chronic pulmonary disease, coagulopathy, diabetes, hypertension, 
hypothyroidism, liver disease, lymphoma, metastatic cancer, other neurological disorders, 
obesity, peripheral vascular disorders, solid tumour without metastasis, valvular heart 
disease, weight loss and year of admission. 
4. Results 
The total number of de novo CIED implantations between 2004 and 2014 were 
2,902,721 hospitalizations, of which the proportion of patients with low, intermediate and 
high frailty risk were 77.6%, 21.2% and 1.2%, respectively. The prevalence of patients with 
intermediate and high-risk frailty has risen between 2004 and 2014 (IRF: 14.3% to 32.5% 
and HRF: 0.2% to 3.3%). (Figure 7.2) This pattern was consistent across all the CIED 
groups. (Figure 7.3) More complex device implantations (CRT and ICD) were implanted 






Figure 7.2. Prevalence of frailty amongst patients undergoing CIED implantations 
(2004-2014) 
 
Legend: HRF: High-risk frailty; IRF: Intermediate-risk frailty; LRF: Low-risk frailty 
 
Figure 7.3. Prevalence of frailty according to type of CIED 
 






Figure 7.4. Proportion of CIED types among frailty risk groups 
 
Legend: HRF: High-risk frailty; IRF: Intermediate-risk frailty; LRF: Low-risk frailty 
 
Overall, there was a linear relationship between frailty risk and age as well as sex, 
with higher frailty groups more likely to be older, females and of non-white ethnic 
background.  (Table 7.2) Patients with higher frailty risk (IRF and HRF) also had a higher 
prevalence of arrhythmias (ventricular and atrial fibrillation), history of cardiac arrest, 
diabetes with complications, previous cerebrovascular accidents (including stroke and 
transient ischaemic attacks), hypertension and valvular heart disease. However, they also 
had a lower prevalence of previous AMI or coronary revascularisation (percutaneous 
coronary intervention or coronary artery bypass grafting). 
Table 7.2. Patient characteristics according to frailty risk group 








Number of weighted 
discharges 
2252144 614774 35804  
PPM, % 59.9 69.5 78.0 - 
CRT-P, % 2.4 2.2 2.6 - 
CRT-D, % 14.4 10.0 5.8 - 
ICD, % 23.3 18.3 13.6 - 
Age (years), median (IQR) 74 (64,82) 78 (68,84) 80 (71,86) <0.001 
Males, % 60.3 51.7 43.0 <0.001 
Ethnicity, %    <0.001 
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White 79.7 76.3 75.1  
Black 9.1 11.3 11.6  
Hispanic 6.3 7.0 7.8  
Asian/Pacific Islander 1.8 2.2 2.6  
Native American 0.5 0.5 0.4  
Other 2.5 2.6 2.4  
Elective Admission, % 36.0 13.0 7.3 <0.001 
Weekend admission, % 13.2 21.7 23.6 <0.001 
Primary expected payer, %    <0.001 
Medicare 72.7 79.6 83.1  
Medicaid 4.3 4.6 4.7  
Private Insurance 19.4 12.7 9.6  
Self-pay 1.7 1.6 1.4  
No charge 0.2 0.2 0.1  
Other 1.7 1.5 1.2  
Median Household Income 
(Percentile), % 
   <0.001 
0-25th 72.7 79.6 83.1  
26-50th 4.3 4.6 4.7  
51-75th 19.4 12.7 9.6  
76-100th 1.7 1.6 1.4  
Shock, % 0.6 4.0 5.6 <0.001 
All-cause infection, %* 0.8 7.5 21.5 <0.001 
Cardiac Arrest, % 2.5 7.5 11.4 <0.001 
Ventricular Tachycardia, % 16.0 15.9 13.6 <0.001 
Ventricular Fibrillation, % 2.7 5.1 5.6 <0.001 
Comorbidities, %     
Dyslipidaemia 43.2 38.6 37.8 <0.001 
Smoking 7.7 6.4 5.1 <0.001 
Atrial Fibrillation 36.9 42.5 46.5 <0.001 
Thrombocytopenia 2.3 6.7 10.4 <0.001 
Previous AMI 14.6 10.0 8.4 <0.001 
History of IHD 50.1 46.5 41.8 <0.001 
Previous PCI 10.5 7.2 5.4 <0.001 
Previous CABG 15.0 10.3 7.7 <0.001 
Previous CVA 3.8 6.4 9.7 <0.001 
Family history of CAD 2.9 1.9 1.0 <0.001 
AIDS 0.1 0.1 0.0 <0.001 
Alcohol abuse 1.6 2.6 2.8 <0.001 
Deficiency anaemias 9.1 25.7 39.9 <0.001 
Chronic Blood loss anaemia 0.5 1.4 1.5 <0.001 
RA/collagen vascular 
diseases 1.9 2.6 3.2 
<0.001 
Heart Failure 41.5 51.6 52.7 <0.001 
Chronic pulmonary disease 17.8 23.4 24.4 <0.001 
Coagulopathy 3.0 9.2 13.8 <0.001 
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Depression 5.2 7.7 10.3 <0.001 
Diabetes 24.6 25.8 26.5 <0.001 
Diabetes with complications 3.2 8.9 10.4 <0.001 
Drug abuse 0.8 1.2 1.1 <0.001 
Hypertension 63.3 67.8 71.5 <0.001 
Hypothyroidism 11.9 15.6 19.8 <0.001 
Liver disease 0.9 1.8 2.0 <0.001 
Lymphomas 0.6 0.9 1.0 <0.001 
Fluid and electrolyte 
disturbances 8.9 45.5 77.8 
<0.001 
Metastatic cancer 0.4 0.7 0.8 <0.001 
Other neurological disorders 3.0 15.8 25.3 <0.001 
Obesity 8.1 10.4 13.4 <0.001 
Paralysis 0.8 3.7 9.4 <0.001 
Peripheral vascular disease 8.1 11.4 12.9 <0.001 
Psychoses 1.4 3.0 4.8 <0.001 
Pulmonary circulation 
disorder 0.3 1.6 3.7 
<0.001 
Renal failure (chronic) 10.2 35.5 48.4 <0.001 
Solid tumour without 
metastases 1.2 1.6 1.7 
<0.001 
Valvular heart disease 0.8 3.2 5.6 <0.001 
Weight loss 0.9 5.4 12.5 <0.001 
Dementia 0.7 6.4 15.4 <0.001 
Hospital bed size, %    <0.001 
Small 8.8 8.7 9.0  
Medium 21.6 22.4 24.1  
Large 69.5 68.9 66.9  
Hospital Region, %    <0.001 
Northeast 21.7 20.5 16.3  
Midwest 23.5 23.9 23.7  
South 37.4 37.0 38.8  
West 17.5 18.5 21.2  
Location/ Teaching status, %    <0.001 
Rural 6.7 6.2 5.2  
Urban non-teaching 40.9 40.4 42.5  
Urban- teaching 52.4 53.4 52.4  
*All-cause infection: Composite of septicaemia, viremia and bacteraemia; HRF: High-risk frailty; IRF: 
Intermediate-risk frailty; LRF: Low-risk frailty. 
 
In-hospital adverse outcomes 
 There was a positive correlation between frailty risk and the rates of MACE, all-
cause mortality, thoracic complications and procedure-related bleeding (LRF vs. IRF vs. 
HRF; MACE: 3.5% vs. 9.9% vs. 13.9%; mortality: 0.4% vs. 2.9% vs. 5.3%; thoracic 
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complications: 2.3% vs. 5.2% vs. 7.5%; bleeding: 2.0% vs. 6.0% vs. 8.7%). (Table 7.3, 
Figure 7.5) Similar findings were observed in the individual CIED groups, with the highest 
rate of MACE in the CRT-P and CRT-D groups, especially in those with HRF (18.8% and 
16.4%, respectively), driven by their high rates of procedure-relating bleeding and thoracic 
complications. (Table 7.4, Figure 7.6) Device-related infection and cardiac complications 
were also more than 2-fold higher in the IRF and HRF groups compared with LRF group 
in the total cohort as well as in the individual CIED subgroups. 
Table 7.3. In-hospital clinical outcomes of total cohort according to frailty risk group 
Variable/Frailty Risk 








MACE, % 3.5 9.9 13.9 <0.001 
All-cause mortality, % 0.4 2.9 5.3 <0.001 
Procedure-related 
bleeding, % 
2.0 6.0 8.7 <0.001 
Thoracic 
complications, % 
2.3 5.2 7.5 <0.001 
Cardiac complications, 
% 
0.3 0.7 0.7 <0.001 
Device-related 
infection, %* 
0.6 2.0 1.9 <0.001 
Lead revision, % 1.6 1.5 1.4 0.003 
Pocket revision, % 1.0 1.5 1.6 <0.001 
 
Figure 7.5. In-hospital adverse events of frailty groups in total cohort 
 
Legend: *Comp: complications; p<0.001 for all outcomes; MACE: Composite of mortality, thoracic and 
cardiac complications, device-related infection and reoperation. 
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LRF IRF HRF p-value 
MACE, %*     
PPM, % 3.7 9.4 13.5 <0.001 
CRT-P, % 4.6 15.8 18.8 <0.001 
CRT-D, % 3.3 12.5 16.4 <0.001 
ICD, % 2.9 9.7 14.4 <0.001 
All-cause mortality, %     
PPM, % 0.4 3.0 5.7 <0.001 
CRT-P, % 0.6 4.3 5.4 <0.001 
CRT-D, % 0.3 3.1 4.1 <0.001 
ICD, % 0.2 2.1 3.7 <0.001 
Procedure-related 
bleeding, % 
    
PPM, % 2.4 6.1 9.1 <0.001 
CRT-P, % 2.3 7.7 12.2 <0.001 
CRT-D, % 1.2 5.4 6.6 <0.001 
ICD, % 1.4 5.5 7.1 <0.001 
Thoracic 
complications, % 
    
PPM, % 2.6 5.1 7.4 <0.001 
CRT-P, % 3.0 8.4 10.3 <0.001 
CRT-D, % 2.0 5.6 7.0 <0.001 
ICD, % 1.6 4.8 8.0 <0.001 
Cardiac complications, 
% 
    
PPM, % 0.3 0.7 0.7 <0.001 
CRT-P, % 0.3 1.1 1.0 <0.001 
CRT-D, % 0.3 0.7 0.9 <0.001 
ICD, % 0.3 0.8 0.5 <0.001 
Device-related 
infection, %* 
    
PPM, % 0.5 1.4 1.4 <0.001 
CRT-P, % 0.9 3.8 3.7 <0.001 
CRT-D, % 0.9 4.1 5.3 <0.001 
ICD, % 0.8 2.6 3.0 <0.001 
Length of stay (days), 
median (IQR) 
    
PPM 3 (2,6) 7 (4,11) 10 (6,17) <0.001 
CRT-P 2 (1,6) 9 (6,14) 13 (8,19) <0.001 
CRT-D 2 (1,5) 9 (6,15) 15 (9,21) <0.001 
ICD 3 (1,6) 10 (6,15) 15 (9,23) <0.001 
MACE: Composite of mortality, thoracic and cardiac complications, device-related infection and 
reoperation; LRF: Low-risk frailty; ICD: automated implantable cardioverter-defibrillator; CRT-P & CRT-






Figure 7.6. In-hospital adverse events in frailty groups according to type of CIED 
 
 
Figure 7.7. Adjusted relative risk (RR) and 95% confident intervals of adverse 
outcomes according to frailty risk group and type of CIED (reference is low-frailty 
risk group) 
 
Legend: *p>0.05 (p<0.001 otherwise)
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In multivariable analysis, the odds of MACE, all-cause mortality and complications 
(bleeding, thoracic and cardiac) were significantly increased (up to 8-fold) with higher 
frailty risk (IRF and HRF) in the overall cohort, compared to the LRF group. (Table 7.5) 
The highest odds were those of all-cause mortality which were 5 to 8-fold higher in the IRF 
and HRF groups, respectively (OR IRF: 5.01 [4.85, 5.18]; HRF: 8.32 [7.82, 8.84]).  While 
this pattern was consistent across the device groups, the odds of cardiac complications were 
insignificant for HRF patients undergoing CRT-D and ICD compared with LRF patients in 
those device groups. (Figure 7.7) 
5. Discussion 
 My national analysis of more than 2.9 million CIED implantation procedures in the 
US demonstrates a rise in the prevalence of frailty amongst those undergoing CIED 
implantation over an 11-year period, across all CIED subtypes, with patients classed as 
intermediate or high-risk frailty more than doubling during that period. My analysis also 
shows an incremental rise in the risk of mortality and procedural complications (bleeding, 
thoracic and cardiac, device-related infection) with increasing frailty risk, regardless of the 
type of CIED implanted. The odds of in-hospital mortality were as greater than 7-fold in 
patients with high-risk frailty in the overall cohort as well as in individual CIED groups.  
There are limited data on the prevalence of frailty among those undergoing CIED 
implantation. Furthermore, the studies that have examined frailty used non-objective 
measures of frailty such as age or comorbidity burden, despite previous studies showing 
little correlation between the age and number of comorbidities and frailty. 76, 77, 149 My study 
is the first to examine the distribution of frailty risk (low, intermediate and high) in patients 
undergoing CIED implantation nationally and shows that one in three patients classed as 
intermediate or high-risk frailty in 2015, more than a two-fold over the 11-year study 
period. This is significantly higher than figures reported from several small studies, 
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although these were largely limited by their measures for frailty assessment and sample 
size. For example, a recent multicentre survey from 14 countries performed by the 
European Heart Rhythm Association (EHRA) reported that less than 10% of patients 
undergoing CIED implantations in Europe are classed as prefrail or frail, although the 
assessment of frailty was not objective and was based on the physicians’ judgements. 156 
Similarly, the prevalence of frailty was 12.8% in a single-centre study of 219 CIED 
implantations in the United States. 157 However, their analysis only included less than 50% 
of all their procedures during their 2-month study coverage.  
My analysis shows a positive correlation between frailty risk and in-hospital 
mortality as well as procedure-related complications after CIED implantation, irrespective 
of the type of CIED and patients’ comorbidities and age. The odds of mortality were 
increased by almost 5-fold in patients with intermediate-risk frailty and up to 9-fold in those 
with high-risk frailty, depending on the type of CIED, while the risk of other complications 
was between 50% and 200% higher in those with intermediate and high-risk frailty 
compared with low-risk frailty patients. Although few studies have looked at the impact of 
frailty on mortality and complications of CIED implantation, a study of 83,792 elderly 
patients (≥65 years) with heart failure undergoing de novo ICD implantation in the United 
States demonstrated higher mortality at one-year in those with frailty, as measured by the 
ACG System frailty marker, compared with this those without any conditions other than 
heart failure. 152  However, their analysis only included a specific cohort (elderly with heart 
failure) undergoing a specific device implantation (ICD), making their findings less 
generalisable to the overall CIED population. Another analysis of CIED procedures in the 
US between 1997 and 2004 demonstrated higher rates of in-hospital mortality and ‘any 
complication’ in frail patients, although this was judged by the authors according to age, 
comorbidity burden and urgency of admission, none of which are reliable surrogates of 
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frailty. 23 My study demonstrated that the impact of frailty risk on clinical outcomes is 
similar across the different device groups. The latter finding has important clinical 
implications as it may encourage operators to offer more complex devices (e.g., ICD or 
CRT) who may have been denied such therapy due to fears of worse complications rates. 
The lower utilisation of complex devices in frail patients has been previously demonstrated 
in a recent EHRA survey.156  
The higher rates of device-related infection in patients with intermediate and high-
risk frailty in my analysis, especially in those in receipt of complex devices (ICD and CRT) 
are unsurprising. Several reasons could explain these findings including the reduced 
immunity in frail patients who are often older and have reduced hose defence response. 158, 
159 Furthermore, complex devices require a longer time to implant with more lead 
manipulation, all of which increase the likelihood of secondary inflammation and 
infection.79, 80  I believe that my findings in the present study highlight the importance of 
an objective assessment of patient frailty status prior to cardiac device implantation to 
identify patients at a higher risk of adverse outcomes as well as explore strategies that may 
mitigate these risks including pre-habilitation prior to the procedure, shorter procedure 
time, operation by more skilled (non-trainee) implanters as well as the use of antimicrobial 
envelopes in more frailty patients and those receiving complex devices in view of the 
significant clinical and economic consequences of device-related infections.160, 161  
Limitations 
As mentioned in my previous Chapters (4 to 6), one of the inherent limitations of 
NIS is the reliance on coding according to the ICD-9 system which is subject to 
inaccuracies based on the technical abilities of those managing the dataset. However, 
administrative datasets such as NIS have been previously shown to have comparable 
capture of demographics and procedural information compared with electronic health 
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records of multistate registries in previous studies. 162 Another limitation previously 
mentioned in preceding chapters is the lack of capture of certain information relating to 
pharmacotherapy and device indication, meaning that these variables were not adjusted for 
in the present analysis. Nevertheless, the large sample size and extensive capture of many 
demographics may mitigate some of these limitations since the patterns of my findings 
were observed in a national procedural cohort. Finally, since my dataset only captures in-
hospital outcomes, it is possible that the observed differences between frailty risk groups 
may become more pronounced on longer follow-up.   
6. Summary 
My analysis shows a rise in the number of frail patients undergoing de novo CIED 
implantation over an 11-year period in the United States, with many intermediate and high-
risk frailty patients receiving more complex devices. A higher frailty risk as measured by 
the Hospital Frailty Risk Score is associated with higher rates of in-hospital mortality and 
worse procedural outcomes, irrespective of the type of CIED implanted as demonstrated in 
my study. My findings emphasise the need for the assessment of frailty in patients 
undergoing CIED implantation using objective scoring systems such as the HFRS to 
identify those at a high risk of postoperative mortality and adverse outcomes who may 
benefit from pre-habilitation prior to the procedure. 
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Chapter 8. Impact of comorbidity burden 
on de novo CIED procedural outcomes 
The work in this chapter is based on a study I have conducted that has been accepted for 
publication in the Mayo Clinic Proceedings journal (currently in press).  
1. Introduction 
The overall rate utilisation of cardiac implantable electronic devices (CIED), 
including permanent pacemakers (PPM), implantable cardioverter defibrillators (ICD) and 
cardiac resynchronization therapy (CRT), has significantly increased in recent years on a 
global level, largely due to an increasingly ageing population who are more likely to 
experience conduction system disease and heart failure (HF). 6, 23-30  However, advancing 
age is also commensurate with comorbidities, meaning that patients undergoing CIED 
implantation are often multi-morbid. While the impact of many individual comorbidities 
on CIED procedural outcomes has previously been studied, many of these conditions co-
exist, rendering the need for assessment of the impact of overall burden of comorbidities 
on CIED procedural outcomes as important as that of individual conditions. 163-168 
 Several measures of comorbidity burden have been previously described, among 
which is the Charlson Comorbidity Index (CCI), utilises 17 conditions to measure 
comorbidity through a score based on the number as well as specific impact of each 
condition. 78, 169 The impact of CCI on outcomes such as mortality and hospital 
readmissions has been examined in many cardiovascular cohorts. 78, 165, 167 However, the 
few studies that have looked at the impact of comorbidity on procedural outcomes of CIED 
implantations have been subject to certain limitations including, but not limited to, the 
analysis of specific devices (e.g. ICD), small cohorts that are insufficiently powered to 
detect differences between difference comorbidity classes, as well as the inclusion of 
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upgrade/replacement as well as de novo procedures despite differences in the procedural 
complexity and risks of each.23, 61, 65, 72-75 As such, there is limited data on the distribution 
and procedural outcomes of different comorbidity burden levels, as measured by validated 
comorbidity measures such as CCI, after CIED implantation, and whether differences in 
these outcomes are observed between CIED subtypes.  
2. Objectives 
My main objectives in this chapter were to study the following: 
a) The distribution of comorbidity burden among different device procedural groups 
(PPM, CRT-P, CRT-D and ICD). 
b) The association between comorbidity burden, as measured by CCI score, and de 
novo CIED procedural outcomes, with a comparison between different device 
types. 
3. Methods 
A full description of the methodology relating to all chapters of my thesis is provided in 
Chapter 3.  
a) Data Source 
The data source for this study was the National Inpatient Sample (NIS). Further 
information on its structure and validation has been provided in Chapter 3 and also 
described in Chapter 4 under the same heading.  
b) Study Design and Population 
All de novo CIED implantations from September 2015 through December 2018 
were retrospectively analysed.  CIED procedures (Single and Dual Chamber PPM, CRT-
P, CRT-D, and ICD), patient characteristics, comorbidities other than those in the CCI 
 
 131 
score as well as data for other procedures, diagnoses and clinical outcomes were extracted 
from NIS using the International Classification of Diseases, tenth revision (ICD-10) 
procedure and diagnosis codes provided in Chapter 3 (Table 3.2). Missing records (n=328, 
0.3% of dataset) for age, sex, procedure urgency (elective vs. urgent), length of stay and 
mortality were excluded from the analysis, as were any cases of device upgrades or 
generator replacements and patients undergoing multiple CIED procedures or PCI or 
CABG during the same admission. (Study flow diagram in Figure 8.1)  
Figure 8.1. Study Flow Diagram 
 
All 17 variables in the CCI score are listed in Table 8.1 along with their assigned 
weights used to calculate the CCI score. All variables were extracted using the Charlson 





Table 8.1. Distribution of Charlson Comorbidity Index (CCI) components in the total 
cohort and individual CIED groups 






















1 53.2 32.5 83.1 96.8 81.6 48.8 
Renal Disease 2 33.9 26.2 35.9 38.1 28.1 28.5 
Diabetes 
(uncomplicated) 
1 22 23.9 24.3 28.6 25.9 24.4 
Chronic obstructive 
pulmonary disease 
1 24.3 21.1 28.8 27.5 25.1 22.8 
Previous Myocardial 
infarction 




2 14.7 13.7 16.4 20.1 15.2 14.7 
Peripheral vascular 
disease 




1 10.4 8.4 7.2 5.7 6.2 8 




2 4.3 3.6 3.8 2.7 2.5 3.5 
Rheumatologic 
disease 
1 3.2 3.1 3.1 2.3 2.1 2.9 
Mild liver disease 1 2.2 2 2.3 2.5 3.2 2.2 
Hemiplegia or 
paraplegia 
2 1.9 1.3 1.1 0.7 1 1.3 
Peptic ulcer 1 1.3 0.8 0.8 0.8 0.9 0.9 
Metastatic solid 
tumour 
6 1.1 0.7 0.6 0.3 0.4 0.7 
Moderate or severe 
liver disease 
3 0.7 0.4 0.4 0.5 0.5 0.4 
AIDS 6 0 0.1 0 0.1 0.3 0.1 
 
CIED: cardiac implantable electronic device; CRT: cardiac resynchronization therapy with defibrillator 




The primary outcome measures were in-hospital all-cause mortality, major acute 
cardiovascular and cerebrovascular events (MACCE), and procedure-related complications 
(thoracic, cardiac and device-related). In-hospital MACCE was defined as a composite of 
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all-cause mortality, thoracic, cardiac and device-related complications. Thoracic 
complications were defined as a composite of pneumothorax, pleural drainage and thoracic 
vascular laceration while cardiac complications were a composite of hemopericardium, 
pericardial effusion or pericardiocentesis, cardiac tamponade, and cardiac laceration. 
Device-related complications were defined as a composite of wound disruption, device 
infection, lead revision and mechanical device complications. 
d) Statistical Analysis 
Descriptive statistics were performed as previously explained in Chapter 3. Data 
extraction and cleaning was performed using Stata 16 MP (College Station, TX, USA) 
while statistical analysis was performed using SPSS version 26 (IBM Corp, Armonk, NY). 
Sampling weights provided by the AHRQ were applied to all analyses. For exploratory 
analysis, the CCI groups were stratified into the following categories: CCI 0 (no 
comorbidity burden), CCI 1 (mild), CCI 2 (moderate) and CCI ≥3 (severe).  
Multivariable logistic regression models were performed to examine the association 
between CCI (as a continuous scale) and in-hospital outcomes (MACCE, all-cause 
mortality and individual complications), expressed as odds ratios (OR) with corresponding 
95% confidence intervals (CI), adjusting for covariates that were not part of CCI. The 
following variables were adjusted for: type of device, age, sex, elective admission, weekend 
admission, primary expected payer, median household income, hospital bed size, location 
and teaching status, pre-procedure cardiogenic shock, ventricular tachycardia and 
fibrillation, atrial fibrillation, dyslipidaemia, smoking status, thrombocytopenia, history of 
percutaneous coronary intervention and/or coronary artery bypass surgery, anaemias and 




 A total of 474,475 de novo CIED implantation procedures were included my 
analysis. Dual chamber PPM was the most frequently implanted device (n=305,705, 
64.4%), followed by ICD (n=75,055, 15.8%), single chamber PPM (n=40,575, 8.6%), 
CRT-D (n=35,990, 7.6%) and CRT-P (n=17,150, 3.6%). The distribution of CCI score in 
the overall cohort was as follows: CCI 0 (no comorbidity burden: 17.7%), CCI 1 (mild: 
21.8%), CCI 2 (moderate: 18.7%), CCI ≥3 (severe: 41.8%). Patients with higher CCI class 
were more likely to undergo ICD and CRT-D implantation instead of a dual chamber PPM. 
(Table 8.2) 
Table 8.2. Sociodemographic and patient characteristics of the study groups 










Number of weighted discharges 84205 103470 88545 198255 
Type of CIED, %     
Single Chamber PPM 6.2 8.0 8.8 9.6 
Dual Chamber PPM 84.6 67.9 60.4 55.2 
CRT-P 1.2 3.2 3.9 4.7 
CRT-D 0.6 6.2 8.1 11.0 
ICD 7.2 14.3 18.4 18.9 
Sociodemographic     
Age (years), median (IQR) 74 (64,82) 75 (65,83) 76 (66,83) 76 (67,83) 
Males, % 49.9 52.1 55.4 59.6 
Elective Admission, % 16.3 17.3 16.6 14.8 
Weekend admission, % 19.2 19.1 19.8 20.0 
Ethnicity, %     
White 82.2 78.7 78.2 73.5 
Black 6.4 9.2 10.0 14.2 
Hispanic 6.2 7.1 6.7 7.4 
Asian/Pacific Islander 2.3 2.2 2.2 2.1 
Native American 0.2 0.3 0.4 0.5 
Other 2.7 2.5 2.4 2.4 
Primary expected payer, %     
Medicare 68.2 71.2 75.0 80.8 
Medicaid 5.7 6.5 6.2 5.5 
Private Insurance 22.2 18.3 15.1 10.8 
Self-pay 1.7 1.7 1.5 1.0 
No charge 0.1 0.2 0.2 0.1 
Other 2.0 2.1 2.0 1.7 
Median Household Income 
(Percentile), % 
    
0-25th 23.3 25.7 27.4 29.4 
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26-50th 26.3 26.4 26.4 26.7 
51-75th 26.2 25.2 24.7 24.0 
76-100th 24.3 22.7 21.5 19.9 
Hospital bed size, %     
Small 14.6 14.0 13.5 13.2 
Medium 29.6 28.9 28.5 28.5 
Large 55.8 57.1 58.0 58.3 
Hospital Region, %     
Northeast 22.8 23.1 23.4 21.0 
Midwest 23.5 23.6 23.9 26.6 
South 39.0 39.1 39.0 38.7 
West 14.8 14.2 13.6 13.7 
Location/ Teaching status, %     
Rural 5.5 5.0 5.2 4.7 
Urban non-teaching 23.6 22.9 21.7 20.6 
Urban- teaching 70.9 72.1 73.0 74.8 
Comorbidities, %     
Pre-procedure cardiogenic shock 0.9 2.4 3.1 4.2 
IABP or LV assist device 0.0 0.1 0.2 0.2 
Cardiac Arrest 5.3 5.9 6.0 5.8 
Ventricular Tachycardia 6.6 12.0 14.4 15.7 
Ventricular Fibrillation 3.1 4.6 4.7 3.9 
Atrial Fibrillation 27.3 30.2 31.7 34.5 
AIDS 0.0 0.0 0.0 0.2 
Dyslipidaemia 44.8 52.8 58.6 63.4 
Smoking 0.7 0.9 1.0 0.7 
Thrombocytopenia 3.6 5.4 6.3 8.7 
Previous AMI 0.0 6.6 19.4 29.4 
Previous PCI 5.0 9.2 14.7 17.9 
Previous CABG 8.6 14.9 22.3 29.3 
Previous CVA 0.0 4.5 7.8 13.2 
Anaemias 8.7 12.7 17.3 29.7 
Congestive heart failure 0.0 37.3 55.2 72.6 
Chronic obstructive pulmonary 
disease 
0.0 13.5 26.5 35.6 
Coagulopathy 4.7 6.8 7.9 10.7 
Diabetes without complications 0.0 22.1 31.0 33.2 
Diabetes with complications 0.0 0.0 2.7 33.8 
Hypertension 65.3 60.1 45.8 18.0 
Liver disease (mild) 0.0 1.0 2.1 3.9 
Liver disease (moderate or severe) 0.0 0.0 0.0 1.1 
Rheumatologic disease 0.0 2.1 3.2 4.5 
Peptic Ulcer 0.0 0.4 0.8 1.5 
Hemiplegia/hemiparesis 0.0 0.0 0.6 2.7 
Any malignancy including 
leukaemia and lymphoma 
0.0 0.0 2.2 7.2 
Metastatic cancer 0.0 0.0 0.0 1.6 
Peripheral vascular disease 0.0 5.0 10.3 18.7 
Renal failure (chronic) 0.0 0.0 11.8 62.8 
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Valvular heart disease 11.2 15.7 17.2 18.7 
Dementia 0.0 7.5 9.2 11.2 
 
AMI: acute myocardial infarction; CABG: coronary artery bypass graft surgery; CCI: Charlson Comorbidity 
Index; CIED: cardiac implantable electronic device; CRT: cardiac resynchronization therapy with 
defibrillator (CRT-D) or pacemaker (CRT-P), CVA: cerebrovascular accident (stroke or transient ischemic 
attack); IABP: intra-aortic balloon pump; ICD: implantable cardioverter defibrillator; IQR: interquartile 
range; PCI: percutaneous coronary intervention; LV: left ventricular; PPM: permanent pacemaker. 
 
 Overall, the most common CCI comorbidities in the total CIED cohort were 
congestive heart failure (48.8%), followed by renal failure (28.5%), diabetes without 
complications (24.4%) chronic obstructive pulmonary disease (22.8%) and previous 
myocardial infarction (17.3%). (Table 8.1, Figure 8.2) This pattern was observed across 
CIED types. 
 
Figure 8.2. Prevalence of individual CCI comorbidities 
 
Legend: AMI: acute myocardial infarction; CHF: congestive heart failure, CRT: cardiac resynchronization 
therapy with defibrillator (CRT-D) or pacemaker (CRT-P); CVA: cerebrovascular accident (stroke or 
transient ischemic attack); ICD: implantable cardioverter defibrillator; PPM: permanent pacemaker; PVD: 





Patient characteristics  
 In the total cohort, patients with a higher CCI class were older, more likely to be 
male, Black, admitted urgently (vs. elective), and admitted to urban teaching hospitals. As 
CCI class increased, there was an increase in the prevalence of in-hospital cardiac arrest 
and pre-procedure cardiogenic shock; a greater prevalence of ventricular tachycardia, atrial 
fibrillation, dyslipidaemia, previous PCI, anaemias (deficiency and chronic disease), and 
valvular heart disease (Table 8.2).  
In-hospital outcomes  
 The crude rates of MACCE, primarily driven by all-cause mortality and acute 
ischemic stroke, as well as thoracic and cardiac complications, length of stay and total 
hospitalization costs in the total cohort increased in line with higher CCI class. (Table 8.3, 
Figure 8.3, p<0.001 for all) Whilst there was no difference in the total rate of device-related 
complications between CCI classes, the rates of device-related infection and wound 
disruption were marginally higher in those with CCI ≥3 (0.2% for both) compared with all 
other classes (0.1% for CCI 0, 1 and 2 of both outcomes). 
 




Figure 8.3. Unadjusted rates of in-hospital adverse outcomes 
 
 
The rates of MACCE, all-cause mortality and acute ischemic stroke were higher with more 
advanced CCI class in all CIED types, except for MACCE in the CRT-P group which was 
similar across CCI classes. (Table 8.4, Figure 8.3) Although the rates of other adverse 
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outcomes (thoracic, cardiac, and device-related complications) were generally higher in 
patients with CCI class>0 for most device types, there were differences between specific 
outcomes. 
Table 8.4. In-hospital clinical outcomes according to CIED subtype and CCI class 
CCI class/Outcome 0 1 2 ≥3 p-value 
MACCE 
Single Chamber PPM 5.8 8.0 8.4 11.8 <0.001 
Dual Chamber PPM 5.5 6.9 7.8 10.8 <0.001 
CRT-P 9.5 10.3 11.7 10.6 0.129 
CRT-D 4.9 11.6 11.3 10.3 <0.001 
ICD 5.6 6.9 7.3 9.5 <0.001 
All-cause mortality 
Single Chamber PPM 0.9 1.4 1.3 3.2 <0.001 
Dual Chamber PPM 0.1 0.5 0.6 1.5 <0.001 
CRT-P 0.5 0.4 1.2 1.5 <0.001 
CRT-D 0.0 0.5 0.6 1.6 <0.001 
ICD 0.3 0.2 0.4 1.0 <0.001 
Acute ischemic stroke 
Single Chamber PPM 0.0 1.8 1.9 4.1 <0.001 
Dual Chamber PPM 0.0 1.1 1.6 3.9 <0.001 
CRT-P 0.0 0.3 1.7 2.6 <0.001 
CRT-D 0.0 0.1 0.6 1.6 <0.001 
ICD 0.0 0.3 1.0 2.6 <0.001 
Thoracic complications 
Single Chamber PPM 1.2 1.8 2.2 2.4 <0.001 
Dual Chamber PPM 1.9 2.2 2.2 2.2 <0.001 
CRT-P 4.5 3.1 4.0 2.5 <0.001 
CRT-D 2.9 2.9 2.6 1.9 <0.001 
ICD 1.5 2.0 1.7 2.0 <0.001 
Cardiac complications 
Single Chamber PPM 2 1.2 1.6 1.4 0.008 
Dual Chamber PPM 1.1 1.4 1.8 1.8 <0.001 
CRT-P 0.0 3.0 2.0 2.5 <0.001 
CRT-D 0.0 3.1 2.2 1.9 <0.001 
ICD 1.3 1.7 1.6 1.8 0.043 
Total device-related complications 
Single Chamber PPM 2.9 2.3 2.0 1.9 <0.001 
Dual Chamber PPM 2.7 2.4 2.3 2.5 0.001 
CRT-P 5.5 3.9 3.7 2.5 <0.001 
CRT-D 2.0 6.0 6.4 4.2 <0.001 
ICD 3.1 3.5 3.1 2.9 0.003 
Device-related infection 
Single Chamber PPM 0.3 0.2 0.0 0.2 <0.001 
Dual Chamber PPM 0.1 0.1 0.1 0.2 <0.001 
CRT-P 0.0 0.1 0.4 0.1 <0.001 
CRT-D 0.0 0.1 0.1 0.1 0.626 




Single Chamber PPM 1.2 0.5 0.6 0.6 <0.001 
Dual Chamber PPM 1.3 1.1 1.1 1.2 <0.001 
CRT-P 0.5 1.0 0.7 0.9 0.305 
CRT-D 0.0 2.0 1.9 1.0 <0.001 
ICD 0.7 0.7 0.8 0.7 0.759 
Wound disruption 
Single Chamber PPM 0.2 0.2 0.1 0.2 0.765 
Dual Chamber PPM 0.1 0.1 0.1 0.2 <0.001 
CRT-P 0.5 0.4 0.0 0.3 0.001 
CRT-D 0.0 0.2 0.4 0.2 <0.001 
ICD 0.1 0.2 0.2 0.2 0.313 
Device mechanical complications 
Single Chamber PPM 2.1 1.7 1.7 1.3 <0.001 
Dual Chamber PPM 2.2 1.9 1.8 1.8 0.001 
CRT-P 5.0 3.0 3.0 1.9 <0.001 
CRT-D 2.0 5.2 5.3 3.7 <0.001 
ICD 2.6 3.0 2.6 2.3 0.003 
 
 After adjustment for all baseline differences, each unit CCI score was associated 
with an increase in odds of MACCE (OR 1.10; 95% CI 1.09, 1.11), all-cause mortality (OR 
1.23; 95% CI 1.21, 1.25) and acute stroke (OR 1.45; 95% CI 1.44, 1.46). (Table 8.5, Figure 
8.4, p<0.001 for all) These findings were consistent across CIED subtypes, although there 
was no difference in odds of mortality with increasing CCI score in the CRT-P and CRT-
D groups. Increasing CCI score was associated with reduced odds of thoracic (OR 0.95 
95% CI 0.94, 0.96), cardiac (OR 0.95 95% CI 0.94, 0.96) and device-related (OR 0.96 95% 
CI 0.95, 0.97) complications in the overall cohort, a pattern that was also observed in 
majority of individual device groups. 
 
Table 8.5. Odds ratios (OR) of adverse outcomes per unit of CCI score 
Outcome OR (95% CI) p-value 
MACCE 
Total 1.10 [1.09, 1.11] <0.001 
Single Chamber PPM 1.11 [1.10, 1.13] <0.001 
Dual Chamber PPM 1.11 [1.10, 1.12] <0.001 
CRT-P 1.03 [0.99, 1.06] 0.064 
CRT-D 1.01 [0.99, 1.03] 0.451 
ICD 1.08 [1.07, 1.10] <0.001 
All-cause mortality 
Total 1.23 [1.21, 1.25] <0.001 
Single Chamber PPM 1.23 [1.19, 1.27] <0.001 
Dual Chamber PPM 1.24 [1.22, 1.26] <0.001 
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CRT-P 1.15 [1.07, 1.25] <0.001 
CRT-D 1.27 [1.22, 1.34] <0.001 
ICD 1.16 [1.11, 1.22] <0.001 
Acute ischemic stroke 
Total 1.45 [1.44, 1.46] <0.001 
Single Chamber PPM 1.36 [1.33, 1.40] <0.001 
Dual Chamber PPM 1.47 [1.45, 1.49] <0.001 
CRT-P 1.48 [1.41, 1.57] <0.001 
CRT-D 1.54 [1.47, 1.60] <0.001 
ICD 1.49 [1.45, 1.52] <0.001 
Thoracic complications 
Total 0.95 [0.94, 0.96] <0.001 
Single Chamber PPM 0.99 [0.95, 1.03] 0.520 
Dual Chamber PPM 0.93 [0.92, 0.94] <0.001 
CRT-P 0.93 [0.88, 0.98] 0.007 
CRT-D 0.89 [0.85, 0.93] <0.001 
ICD 1.00 [0.97, 1.03] 0.804 
Cardiac complications 
Total 0.95 [0.94, 0.96] 0.012 
Single Chamber PPM 1.01 [0.97, 1.06] 0.580 
Dual Chamber PPM 1.00 [0.98, 1.01] 0.540 
CRT-P 1.00 [0.94, 1.06] 0.915 
CRT-D 0.92 [0.88, 0.96] <0.001 
ICD 0.94 [0.91, 0.97] <0.001 
Device related complications 
Total 0.96 [0.95, 0.97] <0.001 
Single Chamber PPM 0.88 [0.85, 0.92] <0.001 
Dual Chamber PPM 0.99 [0.97, 0.998] 0.020 
CRT-P 0.85 [0.81, 0.90] <0.001 
CRT-D 0.91 [0.88, 0.93] <0.001 
ICD 0.94 [0.92, 0.97] <0.001 
*Adjusted for the following: type of device, age, sex, elective admission, weekend admission, primary 
expected payer, median household income, hospital bed size, location and teaching status, pre-procedure 
cardiogenic shock, ventricular tachycardia and fibrillation, atrial fibrillation, dyslipidaemia, smoking status, 
thrombocytopenia, history of percutaneous coronary intervention and coronary artery bypass surgery, 
















My analysis of more than 470,000 de novo CIED procedures is the largest to study 
the relationship between comorbidity burden and in-hospital procedural outcomes across 
all device types and concludes several significant findings. I show that patients undergoing 
CIED are often multi-morbid, with more than 4 out of every 10 patients classed as having 
a severe comorbidity burden (CCI score ≥3), especially in those undergoing CRT-D and 
ICD implantation. Furthermore, I find that patients with a high comorbidity burden are 
more critically unwell during their admission as evidenced by their higher rates of pre-
procedure cardiogenic shock, cardiac arrest during admission, and ventricular tachycardia. 
However, despite adjustments for patient characteristics between comorbidity burden 
groups, CCI score correlated with worse MACCE, driven by higher all-cause mortality and 
acute stroke, while there was no positive relationship between CCI score and risk of 
thoracic, cardiac or device-related complications after implantation.  
 While individual patient comorbidities (e.g., diabetes, heart failure, chronic kidney 
disease, cancer) have been shown to impact CIED procedural outcomes, these often co-
exist.32, 55, 59, 128, 147, 170 Therefore, the overall burden of comorbidity is of equal importance 
when assessing the procedural risk of patients undergoing CIED implantation. Only few 
studies have examined the relationship between comorbidity burden and CIED procedural 
outcomes, although these were subject to certain limitations.23, 61, 65, 72-75 For example, some 
studies have used the number of comorbidities as a surrogate of comorbidity burden instead 
of established comorbidity measures such as CCI that considers differences in the impact 
of each type of comorbidity.23, 75 Certain studies focused on specific subtypes of cardiac 
devices (e.g. PPM or ICD only) or combined de novo and upgrade procedures, despite the 
differences in procedural complexity between device and procedure types, or examined 
composite outcomes (e.g. any in-hospital complication), leaving a gap in knowledge about 
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the impact of comorbidity burden, as measured by the CCI score, on a variety of 
postprocedural outcomes after CIED implantation.61, 65, 72-74  
In my analysis, a significant number of patients undergoing CIED implantation 
were severely comorbid (CCI score ≥3), the least being those dual chamber PPM (36%) 
and the highest being those in receipt of CRT-D (60.8%). Although there was a positive 
relationship between comorbidity burden and the odds of all-cause mortality (16-27% 
increase per unit score of CCI) and acute stroke (36-54% per unit score), a higher 
comorbidity score was not associated with increased odds of procedure-related 
complications. These findings were generally consistent across device subtypes. My study 
is the first to assess the impact of comorbidity burden, measured objectively using the CCI 
score, on a range of in-hospital procedural outcomes after de novo CIED implantation. A 
previous study by Swindle et al., severe comorbidity (CCI≥3) was associated with a 
significant increase in odds of in-hospital mortality (OR ICD: 2.44 (1.47-4.05); CRT-P: 
3.01 (1.17-7.77); CRT-D: 2.74 (1.62-4.65)) among heart failure patients (n=26,887) 
undergoing ICD and CRT implantation.61 While this is consistent with my findings, their 
study included de novo and upgrade/revision procedures. Furthermore, all patients in that 
study had a minimum CCI of 1, which is the allocated score for congestive heart failure.  
Another study of 1,062 ICD and CRT-D procedures reported an increased hazard of 1-year 
mortality (HR 1.40 (1.20-1.60)) per additional CCI score. However, their cohort only 
included specific device subtypes, including upgrade and de novo CIED procedures.65 
While no study has previously examined the impact of comorbidity burden on 
procedural outcomes, including cardiac, thoracic, and device-related complications, an 
analysis by Zhan et al. showed no increase in odds of ‘any in-hospital complication’ in  
patients with  ≥3 comorbidities undergoing implantation of all CIED subtypes other than 
CRT-D. 23 However, their study does not provide insight into the relationship between 
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comorbidity burden and important procedural outcomes since their composite outcome was 
very broad (at least 7 individual outcomes), and they measured comorbidity burden 
subjectively, according to the number of comorbidities, ignoring the prognostic impact of 
each type of comorbidity.  
Based on my study findings, a higher comorbidity burden does not pose a risk for 
complications after CIED implantation. However, it is possible that an element of selection 
bias exists, where healthier implanted are more likely to be selected for more complex 
devices such as CRT.  
Limitations 
The limitations of the present study pertain to the type and capture of the dataset 
(e.g., susceptibility to coding errors, limited information on pharmacotherapy and 
procedure indication) and are identical to those acknowledged in Chapters 4 to 7. However, 
these limitations are expected to be similar across different comorbidity groups and are not 
expected to influence the validity of these findings.   
6. Summary 
My analysis demonstrates a significant proportion of patients undergoing de novo 
CIED implantation are comorbid, with 4 out of 10 patients considered to have a severe 
comorbidity burden. Although increasing CCI score correlated with a higher risk of in-
hospital all-cause mortality and acute ischemic stroke in my analysis, patients with a higher 
CCI score were at no increased risk of thoracic, cardiac, or device-related complications. 
These findings emphasise the need for assessing the overall comorbidity burden of patients 
undergoing CIED implantation based on objective scoring methods for reliable 
prognostication of mortality and stroke complications.
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Chapter 9. Causes and predictors of 30-
day hospital readmissions after de novo 
CIED implantation 
Part of the work in this chapter is based on my study that was published in the International 
Journal of Cardiology (Appendix 5). 170  
1.  Introduction 
Permanent pacemakers (PPM) and implantable cardioverter-defibrillators (ICD) 
play a key role in the management of many serious cardiac rhythm disorders. Furthermore, 
cardiac resynchronisation therapy (CRT) has been shown to improve the quality of life and 
survival of patients with severe left ventricular failure who meet the eligibility criteria for 
these devices. Collectively, these are known as cardiac implantable electronic devices 
(CIED) and their utilisation has significantly increased in the last two decades.44, 45 While 
the majority of complications after CIED implantation occur in the peri-procedural or post-
procedural phase, a proportion of these can occur after the hospitalization episode.55, 81 
Unplanned readmissions after a hospitalization episode are seen as a metric of the 
quality of care provided and represent a burden to patients as well as healthcare institutions 
from an economic and resource perspective. As such, many countries such as the United 
Kingdom (UK) and the United States (US) have introduced fines or penalties for 
institutions if patients are readmitted within 30 days.82, 83 Only few studies have looked at 
the rates, causes and predictors of 30-day readmissions after CIED implantation and these 
were subject to several limitations, including the focus on all-cause readmissions only, 
without the analysis of cardiac-specific causes, or the lack of comparison between CIED 
types.84-88 Consequently, there is limited data on the trend of 30-day readmissions after 
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CIED implantation over time, which is of great importance to cardiologists and other 
stakeholders when restructuring services and planning health policies. Furthermore, 
adequate knowledge on what proportion of these admissions is due to cardiac causes, and 
whether there are certain predictors of such events, is necessary to identify patients who 
require further optimisation or closer follow-up at discharge.  
Sex has been shown to correlate with all-cause readmission, with females more 
likely to be readmitted within 30 days in two previous studies. 84, 87 However, it is unclear 
whether females are more likely to be readmitted due to cardiac and device-related causes 
than males and if any sex differences have persisted in recent years.  
2.  Objectives 
The main objectives of this chapter included the following:  
a) To examine the rates and causes of 30-day readmissions after CIED implantation 
from a national perspective. 
b) Compare the rates and causes of 30-day readmissions between sexes as well as 
CIED types (PPM, CRT and ICD).  
c) Study the trend of 30-day readmissions between 2010 and 2015 including 
differences in these trends between sexes. 
3. Methods 
A full description of the methodology relating to all chapters of my thesis is provided in 
Chapter 3.  
a) Data Source 
The data source for this study was the United States (US) Nationwide Readmissions 




b) Study Design and Population 
My cohort included all ‘index’ hospitalisations during which adults (≥18 years) 
underwent de novo CIED implantation between January and November for the years 2010 
to 2014, and January to August in 2015, as well as all readmissions within 30 days from 
the date of discharge from the index hospitalisation. The final month in each study year 
was excluded as no 30-day follow-up would have captured for these procedures given that 
patients’ hospitalizations cannot be tracked over multiple calendar years. I extracted all 
patient and procedural characteristics using the International Classification of Diseases, 
ninth revision (ICD-9) diagnosis and procedural codes provided in the supplements (Table 
3.1). I identified primary causes of readmission according to the Clinical Classification 
Software (CCS) codes provided in Table 9.1. Records with missing data as well as those 
where patients had a missing length of stay and death information were excluded (n=1170, 
0.14% of the original dataset). (see Figure 9.1 for flow diagram).  






Table 9.1 Clinical Classification Software search codes 
Category Codes 
Respiratory 127 128 130 131 132 133 134 221 
Infection 1 2 3 4 5 6 7 8 9 76 77 78 90 122 123 124 125 126 129 
135 197 201 
Bleeding 60 153 182 
Peripheral vascular disease 114 115 116 117 118 119 
Genitourinary 159 160 161 162 163 164 165 166 170 175 215 
Renal disease 156 157 158 
Gastrointestinal 138-152, 154, 155, 214, 222, 250, 251 
TIA/stroke 109-113 
Trauma 207, 225-236, 239, 244, 260 
Endocrine/metabolic 48-51, 53, 58, 186 
Neuropsychiatric 650-663, 670, 79-85, 95, 216,  
Haematological/neoplastic 11-47, 59, 61-64 
Rheumatology  54 
ENT 92-94 
Non-specific chest pain 102 
Oral health problem 136, 137 
Obstetric 174, 176-181, 184, 185, 187-196, 218-220, 223, 224 
Dermatology  198-200 
Poisoning 241-243 
Syncope  245 
Other non-cardiac 10 45 52 55 56 57 120 121 167 168 169 172 173 202 
203 204 205 206 208 209 210 211 212 217 237 238 240 
246 247 248 252 253 254 255 256 257 258 259 
Heart failure 108 
Arrhythmia 106-107 
Conduction disorder 105 
Valve disorders 96 
Pericarditis 97 
Coronary artery disease 
including angina 
101 
Acute myocardial infarction 100 
Hyper/hypotension 98, 99, 183, 249 
Other cardiac 103, 104, 213 
c) Outcomes 
The primary outcome measures were 30-day all-cause and cardiac readmissions. 
Secondary outcomes included in-hospital mortality, acute stroke or transient ischemic 
attack (TIA), acute kidney injury (AKI), bleeding, device-related infection and device 
revision or removal during the readmission episode.  
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d) Statistical Analysis 
Descriptive statistics were performed as previously explained in Chapter 3. I 
performed an exploratory analysis of 30-day all-cause and cardiac readmission rates, 
stratified by sex and further by CIED types. Sampling weights provided by the AHRQ were 
applied to all analyses. Trend analysis was performed by including time (years) as a 
covariate in linear regression models where the outcome was the variable of interest (e.g., 
30-day all-cause readmission or 30-day device-related cause readmission). 
I performed multivariable logistic regression modelling to identify predictors of 30-
day cardiac readmission as well as to examine the odds of 30-day cardiac and device-related 
readmissions in females, with male sex being the reference category.  All associations are 
expressed as odds ratios (OR) along with 95% confidence interval (CI), adjusting for the 
following covariates in addition to sex, admission year and CIED type: age, weekend 
admission, primary expected payer, median household income, atrial fibrillation (AF), 
thrombocytopenia, ventricular tachycardia (VT) and fibrillation (VF), dyslipidaemia, 
smoking status, previous AMI, previous coronary artery bypass graft (CABG), previous 
PCI, previous cerebrovascular accidents (CVA) including stroke and TIA, family history 
of coronary artery disease (CAD), bed size of hospital, year of admission, Elixhauser 
comorbidities (acquired immune deficiency syndrome (AIDS), deficiency anaemias, 
chronic blood loss anaemia, rheumatoid arthritis/collagen vascular diseases, congestive 
heart failure, chronic pulmonary disease, coagulopathy, depression, diabetes 
(uncomplicated), diabetes with chronic complications, drug abuse, hypertension, 
hypothyroidism, liver disease, lymphoma, fluid and electrolyte disorders, metastatic 
cancer, other neurological disorders, obesity, peripheral vascular disorders (PVD), 
psychoses, pulmonary circulation disorders, chronic renal failure, solid tumour without 
metastasis, peptic ulcer disease excluding bleeding, valvular heart disease, and weight loss), 
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and complications during index admission (acute stroke or TIA, AKI, procedure-related 
bleeding, thoracic and cardiac complications). Thoracic complications were defined as a 
composite of acute pneumothorax or haemothorax, with or without drainage, or thoracic 
vascular injury whereas cardiac complications were defined as a composite of cardiac 
tamponade, hemopericardium, pericardiocentesis.  
4.  Results 
A total 1,155,992 index hospitalisations for de novo CIED implantation were 
recorded between January 2010 and August 2015.  Overall, the rate of 30-day all-cause 
readmission was 14% (n=187,913) and this was higher in females (14.4%) than males 
(13.6%).  The rate of 30-day all-cause readmission declined between 2010 and 2015 (14.5% 
to 13.5%, p<0.001), and this was evident in both sexes (males: 14.1% vs. 13.4%; females: 
15% to 13.7%). (Figure 9.2) 
Figure 9.2. Trends of all-cause, cardiac, non-cardiac and device-related 30-day 
readmissions 
 
p<0.001 for trend; *2015: January to August only 
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Table 9.2. Patient characteristics of study groups 












Number of weighted 
discharges 
660430 495562 1155992 104359 83554 187913 
Type of CIED, %       
PPM 59.5 78.1 67.4 54.0 74.4 63.0 
CRT-P 2.6 2.5 2.5 2.8 2.9 2.9 
CRT-D 14.3 7.5 11.4 17.2 8.4 13.3 
ICD 23.6 11.9 18.6 25.9 14.4 20.8 
Age (years), median (IQR) 73 (64, 81) 77 (68,84) 75 (65,83) 74 (64,82) 78 (68,85) 76 (66,83) 
Weekend admission, % 16.6 18.4 17.4 18.3 19.9 19.0 
Primary expected payer, %       
Medicare 71.2 79.3 74.6 76.5 83.1 79.4 
Medicaid 4.6 4.4 4.5 6.3 5.6 6.0 
Private Insurance 19.4 13.7 17.0 13.4 9.3 11.6 
Self-pay 1.9 1.2 1.6 1.5 1.0 1.2 
No charge 0.2 0.2 0.2 0.2 0.1 0.2 
Other 2.7 1.2 2.1 2.2 0.9 1.6 
Median Household Income 
(Percentile), % 
      
0-25th 26.0 28.0 26.9 28.9 30.0 29.4 
26-50th 25.7 26.1 25.9 25.4 26.0 25.7 
51-75th 24.4 24.2 24.3 23.7 23.6 23.7 
76-100th 23.8 21.7 22.9 21.9 20.3 21.2 
Cardiac Arrest, % 4.4 4.0 4.2 4.2 4.3 4.3 
Ventricular Tachycardia, 
% 9.2 5.2 7.5 11.7 6.4 9.3 
Ventricular Fibrillation, % 4.4 2.9 3.7 4.1 2.8 3.5 
Comorbidities, %       
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Dyslipidaemia 55.5 50.4 53.3 53.0 48.9 51.2 
Smoking 29.9 17.8 24.8 28.8 17.8 24.0 
Atrial Fibrillation 36.3 39.8 37.8 43.6 49.4 46.1 
Thrombocytopenia 5.1 3.6 4.4 6.1 4.6 5.4 
Previous AMI 15.2 7.5 12.0 16.4 9.5 13.3 
History of IHD 54.9 34.4 46.2 61.5 43.5 53.6 
Previous PCI 13.7 7.7 11.2 14.2 9.5 12.1 
Previous CABG 16.9 6.4 12.5 18.0 8.3 13.7 
Previous CVA 7.2 8.2 7.6 8.4 9.5 8.9 
Family history of CAD 4.2 3.8 4.0 3.1 2.6 2.9 
AIDS 0.1 0.0 0.0 0.1 0.0 0.1 
Alcohol abuse 3.3 0.8 2.3 3.8 0.9 2.5 
Deficiency anaemias 12.7 16.4 14.3 21.2 25.2 23.0 
Chronic Blood loss anaemia 1.5 3.8 2.4 1.8 4.7 3.1 
RA/collagen vascular 
diseases 0.4 0.6 0.5 0.8 1.1 0.9 
Heart Failure 41.5 35.0 38.8 56.1 49.8 53.3 
Chronic pulmonary disease 18.0 18.4 18.2 25.9 26.0 26.0 
Coagulopathy 6.6 4.9 5.9 8.6 6.7 7.8 
Depression 5.5 9.9 7.4 7.4 12.2 9.5 
Diabetes 27.2 24.3 26.0 30.8 28.9 30.0 
Diabetes with complications 5.3 4.6 5.0 8.7 7.7 8.2 
Drug abuse 1.4 0.8 1.2 2.0 1.2 1.6 
Hypertension 71.0 73.5 72.1 72.4 75.0 73.6 
Hypothyroidism 9.2 23.3 15.1 10.7 24.1 16.6 
Liver disease 1.4 1.1 1.3 2.3 1.6 2.0 
Lymphomas 0.7 0.6 0.7 1.1 0.9 1.0 
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Fluid and electrolyte 
disturbances 18.4 23.4 20.5 26.7 32.0 29.0 
Metastatic cancer 0.4 0.4 0.4 0.8 0.7 0.7 
Other neurological disorders 6.3 7.5 6.8 8.1 9.4 8.7 
Obesity 12.1 12.9 12.4 12.7 14.7 13.6 
Paralysis 1.6 1.7 1.6 2.5 2.6 2.6 
Peripheral vascular disease 10.4 8.0 9.4 14.9 11.5 13.4 
Psychoses 1.9 2.5 2.1 2.9 3.6 3.2 
Pulmonary circulation 
disorder 0.6 0.9 0.8 1.2 1.9 1.5 
Renal failure (chronic) 20.0 17.0 18.8 32.5 27.3 30.2 
Solid tumour without 
metastases 1.5 0.9 1.2 2.2 1.3 1.8 
Valvular heart disease 1.4 1.9 1.6 2.5 3.0 2.7 
Weight loss 2.2 2.6 2.3 3.9 4.4 4.1 
Dementia 1.6 2.2 1.9 2.1 2.7 2.4 
Hospital bed size, %       
Small 8.2 9.0 8.5 7.3 8.1 7.6 
Medium 20.9 22.0 21.4 20.4 21.7 21.0 





There were several differences in patient characteristics during the index admission 
between those who were subsequently readmitted within 30 days and those who were not. 
(Table 9.2) Overall, patients who were readmitted were older (median 76 vs. 75 years) and 
more likely to have been admitted over a weekend. Furthermore, patients who were later 
readmitted had a higher prevalence of VT, AF, chronic and deficiency anaemias, 
thrombocytopaenia, history of IHD (AMI, PCI, CABG) or CVA, heart failure, chronic 
pulmonary disease, PVD, renal failure and fluid and electrolyte disorders.  Within the sex 
groups, women were older and had a higher prevalence of AF, anaemia (chronic and iron 
deficiency), previous CVA, hypertension, fluid and electrolyte disorders, and valvular heart 
disease. In contrast, men had a higher prevalence of heart failure, previous coronary-related 
disease and previous IHD (AMI, PCI and CABG), and diabetes. 
Causes of readmission 
30-day readmissions were more commonly due to non-cardiac than cardiac causes 
(8.4% and 5.6%, respectively), and both were higher in females than males. The rate of 30-
day readmissions due to cardiac and non-cardiac causes have declined over the study period 
in the overall cohort as well as in both sexes. (Figure 9.2) Despite adjustment for the 
aforementioned differences in patient characteristics, females were more likely to be 
readmitted for cardiac causes at 30 days (OR 1.22 95% CI 1.20, 1.24, Figure 9.3) and these 
odds were consistently higher in females compared with males throughout the study period. 
(Figure 9.4) 
Although the majority of 30-day readmissions were due to non-cardiac causes, there 
were differences in the proportions of cardiac and non-cardiac readmissions between 
individual CIED groups. The PPM group had the lowest proportion of cardiac readmissions 
(35.7%) while the CRT-D and ICD groups had significantly higher proportions of cardiac 
readmission (49.1% and 48.7%, respectively). (Figure 9.5) Within the sex subgroups, the 
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proportion of cardiac readmission was higher in females than males in the PPM and CRT-
P groups but not the CRT-D groups where there were no differences in rates between sexes. 
In contrast, the proportion of cardiac readmission was lower in females than males who 
underwent ICD implantation.  






* all predictors generated from a single multivariate regression model; § non-
significant; † p<0.01; ‡ p<0.001 
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Figure 9.4. Temporal trend of odds ratio (OR) of 30-day readmissions due to A) 
cardiac causes and B) device-related complications in women compared to men
 
*2015: January to August only 
 
 
Figure 9.5. Proportion of cardiac (vs. non-cardiac) readmissions according to 










The top non-cardiac causes of readmission included infectious (10.7%), respiratory 
(5.6%), PVD (3.5%), renal (3.2%), gastrointestinal (4.8%) and stroke/TIA diagnoses 
(2.8%). (Table 9.3) Females had higher rates of readmission for respiratory and 
gastrointestinal causes but lower rates of renal and PVD-related readmissions. No 
difference in readmissions for infection and stroke/TIA were observed between sexes. 
Table 9.3. Causes of 30-day readmission 
Cause/% of readmissions Male Female Total p-value 
Non-cardiac causes, %     
Infectious 10.7 10.8 10.7 0.538 
Respiratory 5.1 6.2 5.6 <0.001 
Bleeding 2.2 2.1 2.2 0.360 
Peripheral Vascular Disease 3.8 3.3 3.5 <0.001 
Renal 3.4 2.9 3.2 <0.001 
Genitourinary 2.2 2.2 2.2 0.596 
Gastrointestinal 4.6 5.0 4.8 <0.001 
TIA/Stroke 2.7 2.8 2.8 0.137 
Trauma 1.7 2.3 2.0 <0.001 
Endocrine/Metabolic 1.5 1.7 1.6 0.002 
Neuropsychiatric 2.9 2.6 2.7 <0.001 
Haematology-Oncology 2.3 2.1 2.2 0.006 
Rheumatology 0.2 0.1 0.1 <0.001 
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Cause/% of readmissions Male Female Total p-value 
ENT 0.3 0.4 0.3 0.261 
Dermatological 0.2 0.1 0.1 0.049 
Poisoning 0.2 0.3 0.3 0.237 
Syncope 1.5 1.4 1.5 0.121 
Other non-cardiac 17.1 16.8 17.0 0.156 
Cardiac Causes, %     
Device-related complications 3.0 3.5 3.2 <0.001 
Arrhythmia 8.5 9.1 8.8 <0.001 
Heart failure 17.8 17.6 17.7 0.242 
Chest pain 2.2 2.3 2.3 0.161 
Conduction disorders 0.3 0.3 0.3 0.873 
Valve disorders 0.6 0.6 0.6 0.982 
Circulatory disorder (hypo- or 
hypertension) 2.0 2.1 2.0 
0.751 
Pericarditis 1.3 1.5 1.4 <0.001 
Coronary artery disease (including 
angina) 2.6 1.5 2.1 
<0.001 
Acute myocardial infarction 1.9 1.8 1.9 0.010 
 
 Heart failure was the most common cardiac cause of readmission (17.7%), and this 
was similar between sexes (p=0.242). (Table 9.3, Figure 9.6) Arrhythmias and device-
related complications were the next most common cardiac causes of readmission and were 
both higher in females than males (9.1% vs. 8.5% and 3.5% vs. 3.0%, respectively, p<0.001 
for both) in the total CIED cohort. In multivariable analysis, females were associated with 
increased odds of readmission for device-related complications (OR 1.26 95% CI 1.19, 
1.33) compared with males. However, the rate of device-related complications declined 
over in the overall cohort as well as in both sexes throughout the pandemic. (Figure 9.2) 
The causes of cardiac readmission are presented according to device group in Table 
9.4 and further stratified by sex in Table 9.5. Within the individual CIED groups, 
arrhythmias were more common in the ICD group while heart failure cause of admission 
was highest in the CRT-P and CRT-D groups. (Table 9.4) The highest rates of readmissions 










Table 9.4. Cardiac causes of readmission according to device type 
Group (% within 
category) 
PPM CRT-P CRT-D ICD p-value 
Device-related 
complications 
3.1 2.3 3.5 3.5 <0.001 
Arrhythmia 8.0 6.1 9.1 11.4 <0.001 
Heart failure 14.0 24.6 26.1 23.2 <0.001 
Chest pain 2.3 1.6 2.0 2.5 <0.001 
Conduction disorders 0.2 0.3 0.3 0.3 <0.001 




1.9 2.0 2.7 2.2 0.071 




2.1 1.3 2.0 2.4 <0.001 
Acute myocardial 
infarction 
1.9 1.5 1.7 1.7 0.013 
 
When stratified by sex, the rates of device-related complications were higher in 
females off all CIED groups other than CRT-P where no difference was observed between 
sexes. (Table 9.5) The rates of heart failure admission were higher in females in the PPM 
























Table 9.5. Cardiac causes of readmission according to device type and sex  
 PPM CRT-P CRT-D ICD 
























2.7 3.4 <0.001 2.3 2.4 0.647 3.2 4.2 <0.001 3.3 3.8 0.028 
Arrhythmia 6.6 9.2 <0.001 5.7 6.7 0.136 9.4 8.3 0.008 12.1 9.7 <0.001 
Heart failure 12.4 15.4 <0.001 23.8 25.6 0.126 26.2 26.0 0.743 23.2 23.2 0.975 
Chest pain 2.3 2.3 0.826 1.2 2.1 0.016 1.7 2.6 <0.001 2.6 2.4 0.456 
Conduction disorders 0.2 0.2 0.899 0.3 0.1 0.135 0.3 0.5 0.001 0.3 0.4 0.119 




1.7 2.0 <0.001 2.2 1.8 0.320 2.8 2.5 0.262 2.3 1.9 0.004 




2.9 1.4 <0.001 1.6 1.0 0.056 2.3 1.2 <0.001 2.5 2.0 0.001 
Acute myocardial 
infarction 









Predictors of 30-day cardiac readmission 
Other than female sex, several other patient and device-related factors during the index 
admission were found to be associated with greater odds of 30-day cardiac readmission 
(Table 9.6, Figure 9.3) All complex types of CIED were associated with increased odds 
of cardiac readmission compared with PPM, with CRT-D and ICD groups being associated 
with the highest odds (OR CRT-P: 1.19 95% CI 1.13 - 1.25, CRT-D: 1.46 95% CI 1.42 - 
1.50, ICD: 1.46 95% CI 1.43 - 1.50). In-hospital complications during the index admission 
(AKI, acute stroke, thoracic and cardiac complications and post-procedural haemorrhage) 
were all associated with increased odds of cardiac readmission, especially cardiac 
complications (OR 1.42 95% CI 1.24 - 1.62) and AKI (OR 1.29 95% CI 1.26 - 1.32). Other 
patient-related comorbidities associated with increased odds of cardiac readmission were 
history of HF, VT, AF, deficiency anaemias, chronic pulmonary disease, coagulopathies 
and lymphoma. 
Table 9.6. Predictors of 30-day readmission due to cardiac causes*  
Variable OR [95% CI] p-value 
Female 1.22 [1.20, 1.24] <0.001 
Index admission related variables:   
PPM (reference) - - 
CRT-P 1.19 [1.13, 1.25] <0.001 
CRT-D 1.46 [1.42, 1.50] <0.001 
ICD 1.46 [1.43, 1.50] <0.001 
Acute kidney injury 1.29 [1.26, 1.32] <0.001 
Post-procedural haemorrhage 1.05 [1.01, 1.10] 0.014 
Cardiac complications 1.42 [1.24, 1.62] <0.001 
Thoracic complications 1.18 [1.13, 1.23] <0.001 
Baseline predictors:   
Age in years at admission 0.99 [0.99, 1.00] 0.173 
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Elective admission 0.80 [0.79, 0.82] <0.001 
Weekend admission 1.06 [1.04, 1.08] <0.001 
VT 1.26 [1.22, 1.29] <0.001 
Dyslipidaemia 0.93 [0.91, 0.95] <0.001 
Smoking 0.98 [0.97, 1.00] <0.001 
AF 1.42 [1.40, 1.44] <0.001 
History of ischemic heart disease 1.31 [1.28, 1.34] <0.001 
Previous percutaneous coronary intervention 1.04 [1.02, 1.07] <0.001 
Acquired immune deficiency syndrome 1.63 [1.26, 2.11] <0.001 
Deficiency anaemia 1.17 [1.15, 1.20] <0.001 
Chronic blood loss anaemia 1.01 [0.97, 1.06] 0.587 
Rheumatoid arthritis/collagen vascular diseases 0.95 [0.86, 1.04] 0.244 
Heart failure 0.96 [0.94, 1.00] 0.360 
Chronic pulmonary disease 1.25 [1.23, 1.28] <0.001 
Coagulopathy 1.18 [1.12, 1.25] <0.001 
Depression 1.03 [1.00, 1.06] 0.080 
Diabetes, uncomplicated 1.07 [1.05, 1.09] 0.000 
Diabetes with chronic complications 1.09 [1.05, 1.12] 0.000 
Hypertension 0.99 [0.97, 1.01] 0.136 
Hypothyroidism 1.01 [0.99, 1.04] 0.223 
Liver disease 1.05 [0.99, 1.12] 0.088 
Lymphoma 1.30 [1.20, 1.41] <0.001 
Fluid and electrolyte disorders 1.20 [1.18, 1.23] <0.001 
Other neurological disorders 0.92 [0.89, 0.96] <0.001 
Obesity 1.02 [0.99, 1.04] 0.15 
Peripheral vascular disorders 1.07 [1.04, 1.09] <0.001 
Psychoses 1.02 [0.97, 1.07] 0.457 
Pulmonary circulation disorders 1.02 [0.95, 1.10] 0.607 
Chronic renal failure 1.39 [1.36, 1.42] <0.001 
Solid tumour without metastasis 1.00 [0.93, 1.07] 0.922 
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Peptic ulcer disease excluding bleeding 1.00 [0.62, 1.59] 0.984 
Valvular disease 0.95 [0.90, 1.01] 0.072 
*All predictors are derived from index admission records. 
5.  Discussion 
My study is the first to systematically examine the rates, causes and predictors of 
cardiac readmission after de novo CIED implantation across all types of cardiac devices 
with a comparison between sexes in a national procedural cohort from the US. My findings 
show a decline in all-cause and 30-day readmissions over a six-year period, a finding that 
was observed in both females and males. I also find that, throughout the study period, 
females were more likely than males to be readmitted within 30 days for cardiac, non-
cardiac as well as and device-related causes. I also highlight differences in the cause of 
admission between CIED types and identify important patient and device-related factors in 
the index hospitalisation that are predictive of 30-day readmission.  
Hospital readmissions have significant implications to patients and healthcare 
institutions and, therefore, as are viewed as a surrogate of the care provided for patients. 
174, 175 Some previous studies have looked at the rates and causes of 30-day readmissions 
after CIED implantation, however, these were limited by several factors such as the focus 
on overall readmissions without the analysis of specific cardiac causes, especially in their 
analysis of predictors, and the lack of stratification by type of CIED. 84-88 The focus on 
cardiac causes of readmission and their predictors is of vast importance as these could be 
potentially avoidable in this population, unlike non-cardiac causes. Moreover, no study has 
examined de novo procedures exclusively, which carry a different risk of complications 
compared with upgrade/replacement procedures. It is also unclear whether sex differences 
exist in the rates and causes of 30-day cardiac readmission after CIED implantation. 
Furthermore, there have been significant limitations in the analytical approach of the 
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studies that have examined all-cause 30-day readmissions from the NRD database, which 
are likely due to the means they have coded and identified readmissions. For example, a 
study Ahmad et al. from the NRD database looking at 30-day readmissions after CIED 
implantation in 2013 identified 290,420 index procedures at a national level. 84 However, 
another study by Patel et al. for the year 2014 from the same database only identified 70,223 
index procedures in the US, which is significantly lower and almost definitely explained 
by an issue with their analysis.87 
My analysis shows that 14% of all patients undergoing de novo CIED implantation 
are readmitted within 30 days for any cause, but this has declined over the study period. 
This is in keeping with findings from previous reports. 84-88 While 30-day readmissions 
were mainly due to non-cardiac causes, which represented 60% of all readmissions, the rate 
of cardiac readmissions was significant and ranged between 35-49% depending on the type 
of CIED, the highest being in the CRT-D and ICD groups. Heart failure was the most 
common cause of cardiac readmission across all device groups, albeit more common in the 
CRT and ICD groups as expected, followed by arrhythmias and device-related 
complications, which were higher in the ICD and CRT-D groups. However, these 
differences are likely related to the complexity of these devices, which are more likely to 
result in complications, as well as patients’ underlying conditions for which they received 
these devices in the first place. For example, patients with severe left ventricular 
dysfunction as those who qualify for CRT and ICD devices and, therefore, are the ones 
more likely to readmitted with heart failure exacerbation.  
A positive finding in my study is the decline in 30-day readmissions for cardiac and 
device-related complications over the study period, which was observed in both females 
and males. This is likely due to advances in implantation techniques, the overall quality of 
care provided for patients, the awareness of risk factors for complications and better follow-
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up on discharge. 42, 53, 81, 118, 119, 176 However, a finding of concern was the persistently higher 
cardiac readmission rates of females throughout the study period, including for device-
related complications. While the rates of readmission for heart failure, the most common 
cardiac cause, were similar between sexes, other common cardiac causes such as 
arrhythmias and device-related complications were more common in females. Despite 
adjustment for baseline differences in patient characteristics and type of device received 
between sexes, females were 22% more likely to be readmitted for cardiac causes and 26% 
more likely to be readmitted for device-related complications compared with males. This 
is likely due to the higher rate of complications in females during the index admission as 
demonstrated in my previous work as well as other studies. 91, 112 While some previous 
studies have shown that females are more likely to be readmitted within 30 days after 
implantation, they only looked at all all-cause readmission. For example, Patel et al. 
showed a 9% increase in odds of 30-day readmission in females (OR 1.09 95% CI 1.04, 
1.14, p=0.001) in their analysis of 70,223 CIED procedures in the US. 87 However, these 
findings do not provide insight with regards to cardiac-specific readmissions that may be 
more avoidable in those undergoing CIED.  
My findings regarding the higher rate of readmissions for device-related 
complications in females differ from those in a study by Moore et al., which analysed 
~80,000 CIED implantations in Australia and New Zealand and reported no difference 
between sexes in hospitalizations for device-related complications as part of their 
secondary outcomes (women: 3.4% vs. men: 3.5%, OR 1.05 [0.97, 1.13]).91 However, their 
cohort was much smaller and included a lower proportion of women (37.9% vs. 43.1%) 
and those undergoing complex device implantation (CRT and ICD: 24.2% vs. 36.6%). 
Therefore, their study may have been underpowered to detect differences between sexes. 
Several factors place females at a higher risk of procedure-related complications after CIED 
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implantation including their smaller thoracic cavity and smaller vessel diameters, making 
them more likely to experience thoracic and vascular complications during implantation, 
as well as their thinner right ventricular walls that may be more prone perforation.53, 118-120  
I identify several important predictors of 30-day cardiac readmission from the index 
admission in my analysis, including certain patient and admission-related variables other 
than sex. Device complexity was an important predictor of cardiac readmission, with the 
odds increasing as high as 46% with CRT-D and ICD devices, compared with PPM. 
Similarly, complications experienced during the index admission (e.g., cardiac and 
thoracic, as well as AKI) were associated with increased odds of 30-day cardiac 
readmission. Certain strategies could be employed to minimise the risk of complications in 
those undergoing CIED implantation and, in turn, reduce their rates of readmission for 
device-related complications. The use of ultrasound guidance for vascular access, routine 
cephalic vein cut down, as well as true septal (vs. apical) implantation of RV leads could 
all minimise procedure-related complications, especially in females. Other comorbidities 
such as heart failure, arrhythmias (VT and AF), and chronic pulmonary disease were also 
associated with increased likelihood of cardiac readmission. Knowledge on the role of these 
patient-related predictors as important predictors of cardiac readmission could help 
physicians identify high-risk groups who may benefit from further optimisation during their 
index admission as well as closer follow-up after discharge, which may have an impact on 
their readmission rates.  
Limitations 
Several limitations of my study related to the nature of the dataset from which it 
was conducted. Diagnoses and procedures in the NRD are coded according to the ICD-9 
coding system by administrators and healthcare professionals. Therefore, coding 
inaccuracies are possible. However, the use of ICD codes has been previously shown to 
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reliably capture complications in CIED studies upon comparison with patients’ chart and 
medical notes. 110 Furthermore, information on the indication for CIED, operator 
experience, as well as pharmacological information (e.g., heart failure secondary 
preventative therapy) is not captured in NRD and so these variables were not adjusted for 
between the study groups. However, the implantation of complex devices such as CRT, 
which was the group with the highest rate of heart failure readmissions in my analysis, is 
usually contingent on the trial of optimal pharmacological therapy first for at least 3 
months. 8 Therefore, it is unlikely that significant differences were observed between 
patients who received these devices. Finally, my dataset did not include post-discharge 
mortality which is a competing risk for readmission.  
6.  Summary 
My study of a national cohort of CIED implantations over a six-year period shows 
that 30-day readmissions are common, with a significant proportion being for cardiac 
causes, including device-related complications, in both sexes. While the rate of 
readmissions has declined over the study period, there is potential for further work to 
reduce the rate of cardiac readmissions especially in females are at a higher risk of 
readmission due to cardiac and device-related causes compared with males. My analysis 
identifies important patient and procedure-related predictors of cardiac readmission that 
should be considered in the risk-assessment of patients prior to discharge and when 
planning follow-up to improve readmission rates. Furthermore, my work emphasises the 
need for further strategies to minimise complications during the index admission given 




Chapter 10. Discussion 
While there is ample evidence on the impact of several patient-related factors on procedural 
outcomes of CIED implantation, this is often based on findings from randomised controlled 
trials (RCT’s) that recruit highly selected and often healthier patient groups. 34-37 As such, 
there is limited data on procedural outcomes of high-risk patients who are often under-
represented or excluded from clinical trials such as females, patients with significant 
comorbidities, frailty or limited life expectancy, as well as those with cancers.  
Furthermore, patients enrolled into trials often receive more optimised management which 
is frequently associated with better outcomes.  
This drives the need for ‘real-world’ studies that would focus on patients who are 
less likely to be represented in RCT’s, particularly from large national datasets that are 
representative of the wider target population as opposed to single-centre studies or 
individual registries from large tertiary centres where there are more experienced operators 
with higher procedural volumes. 
The present thesis utilised two large datasets from the United States to study the 
association between patient-related characteristics and the management as well as 
outcomes of patients undergoing de novo CIED implantation, including hospital 
readmissions that are classed as a measure of the quality of care provided to patients 
undergoing CIED implantation. 
1. Key Messages 
Several key messages can be concluded from my thesis regarding its three main 
objectives. First, patient factors such as age, sex and history of ischaemic heart disease 
influence the choice of cardiac resynchronisation therapy (CRT) type offered to patients 
who are eligible for this intervention.  
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Second, I demonstrate the impact of several patient-related factors on in-hospital 
procedure-related outcomes after de novo CIED implantation: i) in my study on sex 
differences in procedural outcomes, I showed that female sex was an independent predictor 
of mortality and procedure-related complications and that this higher risk in females 
persisted for more than a decade of procedures; ii) my study on frailty and CIED procedural 
outcomes showed an incremental rise in the risk of in-hospital adverse outcomes including 
mortality and procedure-related complications with increasing frailty risk, a finding that 
was consistent across all CIED types; iii) in my study of cancer patients undergoing CIED 
implantation I reported no increased risk of post-procedure adverse outcomes in those with 
previous cancer while patients with active cancer were associated with significantly higher 
rates of mortality and adverse outcomes after CIED implantation. My work has also shown 
that the risk of adverse outcomes differed according to the type of cancer and highlighted 
further differences according to the type of CIED implanted; iv) my study focusing on the 
influence of comorbidity burden on procedural outcomes showed that severe comorbidity 
burden was associated with increased likelihood of in-hospital mortality and stroke, 
irrespective of the type of comorbidity. However, I found that comorbidity burden was not 
associated with an increased risk of procedure-related complications (thoracic, cardiac and 
bleeding).   
Finally, my work demonstrates that hospital readmissions with 30 days after CIED 
implantation are common, with up to 1 in 7 patients readmitted for any cause. While the 
majority of 30-day readmissions were due to non-cardiac causes, the rate of cardiac 
readmission was significant, including that for device-related complications. My study 
highlighted important differences in causes of readmissions between sexes and CIED types 
and identified important predictors of 30-day cardiac readmission. 
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2. Interpretation of findings and clinical implications 
a) What patient-related factors influence the choice of CRT device?   
In view of the limited recommendations on which patient groups should receive 
CRT with pacemaker (CRT-P) or CRT with defibrillator (CRT-D) devices in those eligible 
for this intervention, Chapter 4 of my thesis investigated patient-related factors favouring 
the receipt of CRT-P in a national procedural cohort in the United States (US). My study 
concluded that females, elderly patients (>60 years) and those with malignancies and 
chronic renal failure were more likely to receive CRT-P than CRT-D while males, previous 
ischaemic heart disease and a history of ventricular arrhythmias favoured the received of 
CRT-D. Sex, in particular, was a strong predictor of CRT type, with female patients much 
less likely to receive CRT-D than over CRT-P an 11-year period. This disparity between 
sexes could be explained by several factors as discussed in the relevant chapter. However, 
it is unclear whether this has an impact on the long-term outcomes of females. Another 
important factor favouring CRT-P is age, which is often synonymous with patients’ overall 
health condition and the burden of their comorbidities, and this could explain the reluctance 
of some cardiologists to implant CRT-D devices in elderly individuals given their higher 
cost and also the requirement of their deactivation towards the end of life. Perversely, the 
risk of fatal arrhythmias also increases in with age, increasing the need for defibrillator use 
in these patients. These findings warrant an individualised assessment of the benefits and 
risks of each type of device when counselling patients prior to device implantation. 
b) Identifying patient groups at risk of adverse outcomes after CIED implantation 
 In Chapters 5 to 8 of my thesis I studied the association between several patient 
characteristics and in-hospital outcomes of de novo CIED implantation, with comparisons 
between different CIED types. In Chapter 5 I reported an increased risk of in-hospital 
procedure-related complications (thoracic, cardiac and cardiac) but not mortality in females 
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irrespective of the type of CIED implanted. Furthermore, this risk persisted over the whole 
11-year study period.   
Similarly, my study on CIED outcomes in cancer patients (Chapter 6) showed that 
patients with an active (current) cancer malignancy were at an increased risk of in-hospital 
mortality and procedure-related complications, whose prevalence increased amongst all 
CIED implantations over 11 years, while those with a history of cancer were not associated 
with an increased risk of either event. Further differences were observed when I stratified 
my analysis by cancer type with lung malignancies being associated with the highest risk 
of mortality and thoracic complications, and prostate and colon cancers with the highest 
odds of procedure-related bleeding. 
In Chapter 7, I objectively measured frailty-risk amongst those undergoing de novo 
CIED implantation using a validated score (the Hospital Frailty Risk Score) and found the 
prevalence of CIED procedures performed on frail individuals has significantly risen over 
a decade with up to one in three patients classed as intermediate or high-risk frail in 2015. 
My work demonstrates a correlation between frailty risk and procedure-related outcomes 
as well as mortality. Specifically, high-risk frailty was associated with almost a two-fold 
increase in procedure-related complications and as high as 9-fold increase in mortality 
compared with low-risk frailty. 
 Chapter 8 of my thesis focused on the impact of comorbidity burden, as measured 
by the CCI score, on procedural outcomes after de novo CIED implantation. Patients 
classed as having severe comorbidity burden represented at least 40% of those undergoing 
CIED implantation. While comorbidity burden was shown to correlate with in-hospital 




 Together, these findings provide cardiologists with insights about important 
patient-related factors that require assessment prior to CIED implantation to identify high-
risk patients who may benefit from certain strategies to reduce their risk of procedure-
related complications or even a different type of CIED. For example, patients found to be 
at high risk of frailty could be offered a simple PPM or subcutaneous ICD in order to reduce 
their risk of thoracic complications. Similarly, routine use of ultrasound-guided venous 
access in females could lead to lower rates of thoracic complications and vascular injury.  
c) Hospital readmissions after CIED implantation 
My work in Chapter 9 shows that 30-day readmissions after CIED implantation are 
common, with a significant proportion being for cardiac causes (up to 40%) including 
device-related complications. Heart failure was the most common cause of cardiac 
readmission irrespective of patient sex and the type of device implanted. Over a period of 
six years females were more likely to be readmitted for cardiac and device-related causes 
than males, but cardiac readmissions declined overall in both sexes over that time. Other 
than females, patients with a greater propensity for cardiac readmissions within 30 days 
were those with HF, VT, AF, anaemia, chronic pulmonary disease, coagulopathies and 
lymphoma. Information on the rates of 30-day cardiac readmission from a national 
perspective provides a benchmark for individual hospitals to compare with their local 
practice and identify room for improvement. Furthermore, an insight into the common 
causes as well as predictors of cardiac readmission after CIED implantation could help 
cardiologists and other stakeholders identify patients with a high likelihood for readmission 
for whom interventions could be devised to reduce their rates of readmission. These could 
include a more rigorous assessment prior to discharge, more intensified education on 
warning signs and symptoms that should prompt them to seek medical attention and closer 




a) Quality of data 
The two datasets used in my thesis, the National Inpatient Sample (NIS) and 
Nationwide Readmissions Database (NRD), are administrative datasets coded using the 
International Classification of Diseases (ICD) manual. These are based on discharge 
summaries from the hospitalisation episodes prepared by clinicians and may have not 
undergone a full review by clinical coders. Furthermore, many discharge summaries are 
completed by junior clinicians who may have not had sufficient contact with the patient, if 
at all, and are tasked with their completion under time pressures, making the omission of 
certain comorbidities a possibility. While major conditions and procedures are likely to 
have been coded appropriately, it is possible that less important conditions or procedures 
were not included if they did not have a major role in the financial claims process through 
insurance companies.  
b) Variables studied 
 All acute diagnoses and procedures as well as patient comorbidities in the NIS and 
NRD datasets are coded according to the ICD system. While ICD-9 and ICD-10 coding 
systems have been previously validated in multiple cardiovascular cohorts in studies 
comparing ICD codes with patients’ medical records and inpatient charts, coding 
inaccuracies are possible due to human error. Furthermore, many variables identified 
through the ICD coding system do not reflect severity of a patients’ given condition. For 
example, heart failure is a spectrum that ranges from mild to severe, each of these stages 
conferring different prognoses. The severity of certain conditions such as anaemia or 
thrombocytopaenia is measured based on laboratory values, which were not captured in my 
datasets. Similarly, pharmacological information including anti-arrhythmic and anti-
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thrombotic medications are not captured in both NIS and NRD and, therefore, were not 
adjusted for in my analyses. Although these are unlikely to have significantly influenced 
in-hospital outcomes of CIED implantation, differences in the use of anti-thrombotic 
medications may have explained the higher bleeding rates in certain groups.  
c) Indication for CIED implantation 
One of the limitations in my studies is the lack of capture of indication for CIED 
implantation. While the indications for CRT therapy are clear due to the presence of well-
recognised eligibility criteria, there are many indications for PPM and ICD devices. 
Knowledge of the indication for implantation is of particular importance in patients offered 
ICD devices, who may be receiving this device to prevent fatal arrhythmias from happening 
from for the first time (primary prevention) or after a cardiac arrest (secondary prevention), 
with the latter conferring a higher overall patient risk profile and, in turn, worse in-hospital 
mortality and adverse outcomes.  
4. Future Work 
a) Sex disparities in the choice of CRT device 
 My study on the choice of CRT device, as well as previous studies, showed lower 
utilisation of CRT-D (vs. CRT-P) in females, elderly patients, and those with malignancies. 
However, further prospective work is warranted to study factors that contribute to such 
decisions by clinicians. It is possible that physician behaviour is influenced by confounders 
that were not captured in my study such as patient comorbidities affecting their survival as 
well as patients’ own wishes or their body habitus, and thereby favouring CRT-P. 
Furthermore, there may be other clinical criteria that led physicians to believe that females 
will be more superior responders to CRT therapy in terms of improvement of their left 
ventricular function and, therefore, less likely to experience ventricular arrhythmias that 
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will require defibrillation. Another important area of future work is the long-term follow 
up of patients in receipt of either device type to assess the appropriateness of therapy. For 
example, if females are less likely to receive CRT-D than males but have a similar survival 
at one or three years this would demonstrate that an appropriate choice of device was used 
at the time of implantation.  
b) Risk scores 
While there are established risk scoring systems for adverse outcomes and 
readmissions for cardiovascular procedures such as percutaneous coronary intervention and 
coronary artery bypass grafting, there are limited risk stratification tools for patients 
undergoing CIED implantation. 66-70 For example, the PADIT risk score has been recently 
described for the prediction of device-related infection after CIED implantation and was 
further validated in a US insurance claims database. 177, 178 While my thesis has described 
several patient-related factors that are associated with higher risk of procedure-related 
complications and hospital readmissions due to cardiac causes, further work is required 
from dedicated cardiac device registries that contain more granular procedural information 
(e.g. site of lead placement, procedure time, use of ultrasound guidance, etc) to establish 
and validate a scoring system that predicts these events, which have been shown to be quite 
common in my studies. A scoring system would help clinicians risk stratify patients at risk 
of adverse outcomes that are amenable to interventions to further reduce the incidence of 
such events. Furthermore, risk scoring systems help predict procedure risk and, in turn, 
procedural outcomes which are considered performance indicators for operators, 
institutions and the wider healthcare system. This is particularly relevant in the current era 
where there is a trend towards national reporting of outcomes, and such outcomes need to 
be weighed according to the individual procedural risk. For example, higher volume centres 
are more likely to perform more complex cases for higher-risk patients and without 
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objective measurement of the procedural risk they will appear to have worse overall 
outcomes compared with smaller centres.  
c) Alternative devices for high-risk patients  
The role of newer CIED technologies such as intracardiac (leadless) pacemakers 
and subcutaneous ICD devices should be prospectively studies in patient groups identified 
as high-risk for procedure-related complications of traditional (transvenous) CIED 
implantation. While these devices have gained popularity in recent years, they are more 
expensive and are not routinely offered in all cardiac centres. Furthermore, there have been 
limited studies comparing their long-term outcomes to traditional PPM and ICD devices in 
high-risk patient groups. 179-183 Exploring real-world outcomes of these devices in high-risk 
patients such as those with significant frailty or active malignancy would provide CIED 
implanters with important insights about their utility as reliable alternatives to those at high-
risk of procedure-related complications after traditional CIED implantation.  
5. Conclusions 
 In conclusion, my thesis investigated the role of several patient-related 
characteristics in the management and in-hospital outcomes of de novo CIED implantation. 
Differences in the choice of CRT device type were observed in females, elderly patients, 
and those with certain comorbidities. Several patient-related factors conferred worse 
procedural outcomes after CIED implantation, including mortality, in-hospital procedure-
related complications and post-discharge cardiac readmissions (including for device-
related complications). Factors such as sex, active malignancy, high-frailty risk, severe 
overall comorbidity burden are all predictors of these adverse outcomes. These findings 
emphasise the need for an individualised approach to the risk stratification of patients 
taking these factors in to consideration in order to identify patients who require further 
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optimisation prior to their procedure and post-procedure and those who would benefit from 
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